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I. General introduction 
Protein drugs are an integral part of today´s spectrum of active pharmaceutical ingredients 
and take up a market size of several billion dollars in total each year [1, 2]. Protein drugs are 
highly active drugs that selectively target the site of action by the inherent key-lock principle 
and specific interactions. Proteins are built from a sequence of amino acids (primary 
structure) and arrange themselves in a specific three-dimensional order forming, for 
example, so-called β-sheet or α-helical structures (secondary structure). These structures 
again form a tertiary structure which is defined by the relative arrangment of secondary 
structure components. Compared to small molecular drugs, the highly ordered three-
dimensional structure of proteins is prone to degradation upon inappropriate handling [3, 4]. 
A variety of chemical and physical degradation pathways have been investigated, and 
pharmaceutical companies screen for the best possible formulations for protein drug 
products to prevent aggregation and denaturation of the active during manufacturing, 
shipping, long-term storage and/or application to the patient [5-8]. 
In general, protein drugs need to be administered parenterally as the oral route is restricted 
by harsh pH conditions in the stomach, and a plethora of enzymes and surface active 
substances in the gastrointestinal tract which are detrimental to proteins [9-11]. Additionally, 
absorption of proteins from the gastrointestinal tract is per se limited due to their high 
molecular mass and the ionic structure of some amino acids. Buccal or dermal delivery of 
protein drugs generally fails due to the large amount of protein needed for systemic 
administration. In addition, the short plasma half-lives of proteins results in frequent 
applications of high doses which is hardly feasible for these delivery routes [11]. Pulmonary 
application of proteins was possible for inhalative insulin (Exubera®) which was marketed in 
2006 but withdrawn in 2007 due to economic inefficiency. In addition, increased rates of anti-
insulin antibody formation and a greater decline in pulmonary function under Exubera® 
treatment were reported [2, 12], which was a major drawback for the development of 
inhalative protein drug products. Thus until today parenteral application of protein drugs by 
injection or infusion is still the conventional route of administration. 
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Sustained delivery of protein drugs was investigated with the interest to reduce application 
frequency and systemic burden for the patients. As poly-lactic acid (PLA) and poly-lactic-co-
glycolic acid (PLGA) implants and microparticles had already been approved by regulatory 
agencies, PLA/PLGA became first choice for the development of sustained release protein 
drug devices. Peptides like leuproreline and goserelin were successfully loaded onto and 
delivered from such systems [13-15], however, today no protein drug formulated in an 
implant or microparticulate device is on the market. 
Besides other materials like hydroxyethylmethacrylate, ethylene-vinyl-acetate copolymer or 
polyvinyl alcohol [16, 17], using lipidic substances as matrix materials has attracted the 
interest of researchers for more than twenty years [18-20]. 
Lipids are natural substances that exhibit excellent biocompatibility and are in general 
biodegradable by lipases or body fluids [18, 21, 22]. Besides other lipid based sustained 
release formulations compressed triglyceride based implants have attracted much attention 
due to the easy preparation process and long term release of (protein) drugs from these 
devices [23-27]. Additionally, it has been reported that the fragile structure of a lyophilized 
protein, recombinant human interferonα-2a (IFNα), was conserved during long-term storage 
and release [27, 28], when incorporated into triglyceride matrices.  
Recently, Herrmann et al. demonstrated that the addition of PEG to the triglyceride implant 
matrix can be used to control the rate of IFNα release from compressed triglyceride implants 
by in-situ precipitation of the protein (IFNα) [24, 29, 30]. In-vivo delivery of IFNα in rabbits 
was also successful and no adverse tissue reaction with respect to the lipid formulation was 
observed [31]. 
A change of the manufacturing strategy from compression to twin-screw extrusion (tsc-
extrusion) allowed the production of rod-shaped and thus easily applicable implants. 
Moreover, the tsc-extrusion process seemed to affect the release profile of the implant and 
caused a more sustained protein drug release [32]. In-vitro degradation studies also showed 
that twin-screw extrudates were more prone to lipase induced degradation than compressed 
implants [33]. The sum of all features of twin-screw extrudates makes them a very promising 
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delivery platform for protein drugs. However, little is known about the underlying mechanism 
of sustained protein drug release from tsc-extrudates and the degradation properties of this 
type of implant and this will form the basis for this thesis. 
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1. Controlled release systems for pharmaceutical peptides and 
proteins  
1.1. Definition of ´controlled release` 
´Controlled drug delivery systems` have been described in literature since the 1970th when 
Alejandro Zaffaroni founded ALZA Corporation. ALZA’s inventions and patents include many 
so called ´therapeutic systems` that allow to control the rate of drug release over time 
periods ranging from days to years [34]. Controlled release systems include systems for 
localized drug delivery (e.g. in the eye: Ocusert® [35]), sustained drug release (e.g. sustained 
release tablets: OROS® [34]) or transdermal drug delivery (e.g. therapeutic patches, 
transdermal therapeutic systems (TTS) [34, 36]). Today ´controlled release` is a major factor 
in developing and marketing of new drug products as well as for the extension of patents of 
already marketed active pharmaceutical ingredients. 
Controlled drug delivery systems can be designed for local as well as for systemic drug 
administration, and various routes of application including oral, dermal, transdermal, vaginal, 
buccal, nasal, parenteral and pulmonary administration have been investigated [10, 37]. 
Sustained drug delivery devices can be divided in three major groups according to their 
control mechanism for the rate of drug release: matrix based systems, membrane based 
systems and chemically controlled systems [38]. 
In matrix based systems the drug is dissolved or dispersed in a matrix and released from the 
matrix either by diffusion through pores of the matrix (dispersed drug) or by diffusion within 
the matrix material itself (dissolved drug) [39, 40]. Membrane based systems control the drug 
release rate by an inert membrane which acts as a diffusional barrier [34]. Chemically 
controlled systems control the release rate either by matrix erosion (e.g. cleavage of ester 
bonds), by matrix swelling or cleavage of chemical bonds between the drug and a carrier 
system [36-38, 41, 42]. Release mechanisms will be discussed in detail later (see chapter I - 
0).  
Drug products for parenteral release include microspheres [43], implants [13], liposomes 
[44], gels [45], suspensions [46, 47], in-situ forming implants [48, 49], lipophilic solutions [50, 
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51] and solid lipid nanoparticles [52-54] and have been extensively reviewed by various 
authors [10, 37, 55]. 
 
1.2. Currently marketed peptide and protein depot formulations 
Usually the oral route is the easiest way to administer drugs in form of liquids, tablets or 
capsules. However, some active pharmaceutical ingredients like proteins or peptides cannot 
easily be administered orally due their instability in the gastrointestinal tract and/or 
bioavailability limitations. In order to circumvent these problems, parenteral application of 
protein drugs which includes subcutaneous injection and intravenous infusion is necessary. 
As already mentioned, most protein drugs posses only short half lives and thus frequent 
dosing is required, leading to poor patients’ compliance and high therapy costs. Therefore, 
therapeutic systems have been developed for parenteral application which should minimize 
dosing frequencies (e.g. one injection/application lasts for months/years), resulting in better 
patients’ compliance. 
One of the first therapeutic systems one the market containing a peptide drug was Zoladex® 
(1990). It is available as a one-month or three-months depot formulation and its 
biodegradable matrix consists of poly-lactic-co-glycolic acid (PLGA) and poly-lactic acid PLA 
(1:1). It comprises Goserelin acetate – a gonadotropin releasing hormone (GnRH) super 
agonist – and is indicated for the treatment of prostate cancer and breast cancer [15]. 
Lupron-Depot® was released in 1993 and is composed of a microparticulate system (PLA 
and leuprorelin acetate) that is indicated for the treatment of prostate cancer [13, 14]. Profact 
Depot® also contains a peptide drug (buserelin acetate – LHRH analog – prostate cancer) 
and is formulated in PLA-PLGA 1:3. An in-situ forming implant system against prostate 
cancer is Eligard® which contains leuprorelin acetate as active ingredient and is formulated in 
PLGA and N-methyl-2-pyrrolidon (NMP). The only marketed depot device that contained a 
protein drug was Nutropin Depot®, which was an injectable suspension of PLGA 
microparticles loaded with recombinant human growth hormone (rhGH - somatropin) as the 
active ingredient. Nutropin Depot® was designed to release somatropin over a period of one 
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month and was marketed in 1998, but withdrawn in 2004 which was explained by ´significant 
resources required by both companies (Alkmers Inc. and Genentech Inc.) to continue 
manufacturing and commercializing the product` [56].  
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2. Matrix materials for the preparation of protein containing 
sustained release devices 
Protein drugs are usually administered by subcutaneous injection or intravenous infusion 
because of their inherent instability in the gastrointestinal tract [10, 14, 57, 58]. However, the 
exploration of alternative delivery routes like parenteral, nasal or buccal delivery led to an 
increased interested in matrix materials which are able to maintain peptide/protein stability 
during manufacturing and allow ´controlled` protein release [9, 10, 59]. Since Langer et al. 
studied the release of proteins from polymers [16], a broad variety of substances has been 
under investigation for their suitability as matrix material for sustained protein drug release 
[57, 59, 60].  
In the 1980ies inert matrix materials studied by Langer and Siegel included 
hydroxyethylmethacrylate (HEMA), ethylene-vinyl-acetate copolymer (EVAc) and polyvinyl 
alcohol (PVA) [16, 17]. Model proteins (soybean trypsin inhibitor, lysozyme, alkaline 
phosphates, catalase and bovine serum albumin) were embedded into the matrix by a 
solvent evaporation method. The matrix materials were simply dissolved in an appropriate 
organic solvent or water, mixed with the protein and cast into moulds. After evaporation of 
the solvent under mild vacuum, the implants were additionally coated with identical matrix 
material by dipping and drying. In-vitro release from these polymer based implants lasted up 
to 100 days. However, these matrix materials were not bio-degradable and did not show any 
sign of erosion in-vitro and in-vivo. Thus the search for alternative carrier materials started. 
Poly-lactic acid (PLA) and poly-lactic-co-glycolic acid (PLGA) had already been successfully 
used to prepare biodegradable systems (microparticles, implants) for small molecular drugs 
and had been approved by regulatory agencies. Thus, a plethora of researchers used 
PLA/PLGA as matrix materials for protein and peptide loaded microparticles and/or implants 
[43, 61-66]. The preparation of PLA/PLGA implants was performed by emulsion, suspension 
or dissolution methods where the matrix material was dissolved in organic solvent and the 
protein was emulsified, suspended or dissolved in the organic phase. Unfortunately, the use 
of organic solvent was shown to be problematic with respect to protein stability as proteins 
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tend to unfold and aggregate in hydrophobic environments and at interfaces [3, 67, 68]. 
Additionally, after protein loading and preparation of microparticles or implants the organic 
solvent had to be removed from the system by a drying step. Interestingly, drying was not 
reported to induce significant protein degradation in PLGA matrices [64]. However, implant 
erosion during release was reported to have a detrimental effect on protein stability. 
Degradation of PLA and/or PLGA resulted in lactic and glycolic acids and induced a pH drop 
in the core of the delivery systems [64, 69, 70]. This pH shift was reported to start and to 
accelerate protein aggregation, deamidation [64], and acylation [71]. Additionally, an 
increase in osmotic pressure was detected inside biodegradable microspheres as a 
consequence of matrix erosion [69]. In order to overcome these shortcomings various 
approaches to prevent protein degradation were conducted. Protein aggregation during 
preparation was limited if interface-active excipients like PEG, gelatin, human serum albumin 
[72], HP-β-CD [73] or phosphatidylcholine [74] were used or anhydrous preparation methods 
were applied (solid-in-oil-in-oil dispersion) [75]. Preparation by suspension methods was 
generally more gentle for protein drugs as unfolding and aggregation processes were 
hindered. The conformation of the dry and solid protein was kinetically trapped in organic 
solvents [76]. Protein stability during release was increased by the addition of basic salts 
(e.g. Zn2+) which neutralize the acid degradation products of PLGA [62, 77, 78]. Alternatively, 
high protein loadings acted as buffer solutions and counteracted a pH drop [79]. The addition 
of surface active substances like Pluronic™ or BSA increased the rate of release and 
prevented aggregation of proteins probably by adsorption of surfactant molecules or BSA to 
the hydrophobic PLGA matrix [77]. Many therapeutic proteins have been embedded into 
PLGA based systems including recombinant human growth hormone [80], insulin [77], 
human epidermal growth factor [81], interferon α [82-85], interferon γ [86], interleukin-1α [74] 
and basic fibroblast growth factor [78]. Despite all these attempts, no protein drug containing 
product using PLA/PLGA is currently on the market. 
As an alternative to PLA/PLGA, other material were studied as matrix material for protein 
drugs. Polyanhydrides consist of dimers of fatty acids and/or sebacic acid and offer better 
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control over polymer properties and erosion behavior than PLGA. Additionally, degradation 
products of polyanhydrides have a neutral pH and no acidic primary hydrolysis products are 
produced. Polyanhydrides have been used to successfully deliver a LHRH analogue over 
time periods of one month [87]. 
Biomaterials like chitosan have been used to prepare protein loaded nanoparticles or 
microparticles [88, 89]. Chitosan is a mucopolysaccharide which is generated by the 
deacetylation of chitin, the major compound of the exoskeletons in crustaceans. Various 
methods for nano- or microparticle preparation have been described in literature [88, 89]. 
Insulin [90], xylanase, lipase and protease [91] as well as an anti-TNFα antibody [92] have 
been incorporated in chitosan based delivery systems. However, chitosan is not approved by 
regulatory agencies for parenteral applications.  
Collagen has been used for the delivery of recombinant human bone morphogenetic protein 
(rhBMP-2) from absorbable collagen sponges for bone regeneration [93, 94]. RhBMP-2 was 
loaded onto the sponges by simple soaking of the sponges with an rhBMP-2 containing 
solution. Additionally, collagen sponges were loaded with growths factors for e.g. dermal 
wound healing by dispersion and drying of protein containing solutions onto the matrices 
[95]. Collagen films were loaded with human growth hormone and growths factors [94]. 
Cylindrical collagen implants were used to delivery interferon in-vitro and in-vivo in a mouse 
model [96]. Collagen minipellets were loaded with interleukin-2 and pharmacokinetic studies 
in mice revealed that a single subcutaneous injection of a minipellet could prolong IL-2 
retention. Recently, Chan et al. produced nano-fibrous collagen microspheres loaded with 
various proteins including nerve growth factor (NGF) by an emulsification process [97]. 
Besides these substances, alginate [98], hyaluronic acids [99, 100], starch, tricalcium 
phosphate, and synthetic polymers (polyester, polyiminocarbonates, polycaprolactones and 
polyphosphazenes) were investigated for controlled protein and peptide drug delivery [9, 57]. 
Alternatively, in-situ forming implants were extensively studied [45, 49, 101, 102]. They 
consist of biodegradable polymers dissolved in a biocompatible carrier. Upon contact with 
body fluids or at body temperature the polymer solidifies and forms solid implants. For 
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example, Jin et al. produced injectable, thermoreversible gels, comprised of chondroitin-6-
sulfate, gelatin type A, methylcellulose and ammonium sulfate. The thermoreversible gels 
were formed from methylcellulose in the presence of the salting out agent ammonium sulfate. 
A complex coazervate of oppositely charged chondroitin-6-sulfate and positively charged 
high-molecular weight gelatin type A was embedded into the pre-formulated gel. FITC-BSA, 
which was simply admixed to the pre-formulated gel, was released over a period of 25 days 
in-vitro [45]. Thermoreversible hydrogels have also been described by Zentner et al. [103]. 
PLGA-PEG-PLGA triblock polymers (ReGel®) were used in this study and Zn-insulin, porcine 
growth hormone, G-CSF or recombinant hepatitis B surface antigen were incorporated into 
the gels. In-vitro and in-vivo studies indicated sustained release of the macromolecules after 
single-injections over a period 7-14 days and analysis showed equal biological effects 
compared to daily injections. Singh et al. demonstrated release of lysozyme from 
thermoreversible triblock copolymer implants over two to eight weeks [104]. Kang et al. 
utilized the Atrigel® system with incorporated insulin and found sustained protein release over 
up to 15 days [105]. The Atrigel® system consists of PLGA and lactic/caprolactone 
copolymers which are dissolved in an organic solvent (e.g. N-methyl-2-pyrrolidon (NMP), 
dimethyl sulfoxide (DMSO) or tetraglycol). Upon injection, the organic solvent dissipates and 
a phase separation step forms a depot at the site of injection [102].  
Lipidic substances (lipids) have also been investigated as parenteral, sustained release 
dosage form and will be discussed in the next chapter. 
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3. Lipids as matrix materials for the preparation of protein 
containing sustained release devices  
3.1. Lipid based drug delivery systems 
Lipids have been defined as ´biological substances that are generally hydrophobic in nature 
and in many cases soluble in organic solvents` [106] or as ´chemically heterogeneous group 
of substances, having in common the property of insolubility in water, but solubility in non-
polar solvents` [107]. Thus, lipids are generally defined by their hydrophobic nature but not 
by a special chemical structure. Fahy et al. divided ´lipids` into eight categories according to 
their chemical composition: fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, 
sterol lipids, prenol lipids, saccharolipids and polyketides [106].  
In order to enhance the oral bioavailability of small molecular drugs, they are often 
formulated in ´lipid` formulations [108]. This became more and more important during the last 
decades as novel high throughput screening methods resulted in an increased number of 
sparingly soluble lipophilic drug candidates which have a generally lower bioavailability after 
oral application compared to more hydrophilic drugs due to dissolution problems [109]. Thus 
numerous attempts for the development of ´lipid` based drug delivery devices are described 
in literature for small molecular drugs including self-micro-emulsifying drug delivery systems 
(SMEDDSs) [110], self-nano-emulsifying drug delivery systems (SNEDDSs), solid or waxy 
lipid powders, granules or pellets and colloidal drug carrier systems like liposomes and solid 
lipid nanoparticles (SLN) [108, 111]. Preparation methods for lipid based drug delivery 
systems are e.g. spray-cooling, spray-drying, melt-granulation, melt-extrusion, supercritical-
fluid based methods and high pressure homogenization [107, 109]. Most of these 
formulations aim for the improvement of the oral bioavailability of lipophilic drugs. 
As already stated above, oral application of protein drugs is in most cases not feasible due to 
the inherent instability of proteins in the gastrointestinal tract. Therefore researchers aim for 
parenteral, transdermal or pulmonary application routes [10] and a broad variety of lipids 
were used to create such delivery systems for proteinaceous drugs [21, 112]. 
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3.1.1. Lipid microparticles 
Protein loaded lipid microparticles can be prepared by a variety of methods including spray-
drying, spray-cooling, coazervation, w/o/w double emulsion techniques and supercritical fluid 
based techniques [113-115].  
In 1988 Steber et al. patented a method for the preparation of bovine growth hormone loaded 
microspheres for subcutaneous (s.c.) injection. The microparticles consisted of glycerol 
tristearate and glycerol distearate and were prepared by spray-cooling [116].  
Reithmeier et al. prepared thymocartin [117], insulin [117] and somatostatin [118] loaded 
microparticles by a modified solvent evaporation method as well as by a melt-dispersion 
method and used glycerol tripalmitate as matrix material. In-vivo studies showed that the 
microparticles were well tolerated by NMRI-mice and comparable to PLGA microparticles. 
Drug loading efficacy and release kinetics were dependent on the type of incorporated drug 
and the preparation method. Release from the microparticles lasted for up to 10 days, 
however, only incomplete release of the incorporated drug was achieved. Furthermore the 
melt dispersion technique resulted in the formation of the unstable α-modification of the 
triglyceride crystals which led to a in decreased storage stability as a consequence of 
polymorphic transformations. 
Del Curto et al. [119] prepared gonadotropin release hormone antagonist (Antide®) loaded 
lipid microparticles for subcutaneous administration based on monoglycerides (glycerol 
monobehenate and glycerol monostearate) by a cryogenic micronization process. Before 
cryo-milling within the flux of liquid nitrogen, the peptide was loaded onto the lipid matrix 
material by co-melting or solvent evaporation at 80-95 °C. Results from in-vitro release tests 
correlated well with in-vivo (rats) studies and Antide® plasma levels were present for 30 days 
after dosing in the animals. However, high temperatures were necessary to load the matrix 
which might be detrimental for the stability of protein drugs. 
A supercritical fluid based process was used to coat bovine serum albumin (BSA) particles 
with glycerol trimyristate and Gelucire® 50/02 [120, 121]. The method operated with 
supercritical carbon dioxide (CO2) in which the lipids were dissolved. Subsequently the solid 
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protein powder was dispersed into the supercritical fluid and by adjustment of the process 
parameters (pressure/temperature) the solubility of the lipid in the supercritical fluid was 
decreased and the lipid accumulated on the surface of the protein particles. Solubility studies 
including a variety of lipids (waxes, triglycerides and mixtures of glycerides and fatty acid 
esters) indicated that the process was strongly influenced by the solubility of the lipid 
components in supercritical CO2 [122]. In-vitro release tests indicated rapid BSA release from 
glycerol trimyristate microparticles but a sustained release over 24 hours from Gelucire® 
50/02 microparticles. This was explained by the varying porosity values of the microparticles. 
The supercritical fluid based process was found to be a gentle preparation method without 
the use of organic solvents or elevated process temperatures (13 °C - 52 °C) and no BSA 
degradation was detected after processing. However, the release lasted for only 24 hours, 
which is too short for most applications. 
Spray drying was used to prepare human IgG loaded PulmoSpheres™ (hollow porous 
microspheres) for pulmonary delivery. Therefore an emulsion of phosphatidylcholine and 
perflubron in water was mixed with a solution comprising an human IgG antibody and 
hydroxyethylstarch and immediately spray dried with an standard spray dryer. The 
microparticles consisted mainly of phosphatidylcholine and antibody loading was 
approximately 20%. The microparticles were administered into the lung of BALB/c mice by 
instillation of a stable suspension in perflubron and the IgG antibody reached systemic 
circulation. Antibody bioavailability was only 27% after intratracheal instillation of 
PulmoSpheres™ but reached up to 40% after instillation of IgG solution in saline. The 
advantage of the administration of IgG in PulmoSpheres™ was a strongly increased immune 
response to the human antibody, which was explained by the incorporation of the antibody 
into the drug carrier (PulmoSpheres™). The microparticles showed an increased cellular 
uptake by macrophages and a sustained release of the antibody [123]. A similar formulation 
comprising an inactivated form of influenza virus and a Fc receptor ligand was used to 
induce an immune response in BALB/c mice by receptor mediated targeting of phagocytes 
[124]. However, only short release periods were achieved (80% release within 6 hours). 
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Nevertheless, the feasibility of lipids for the preparation of a controlled release device by 
spray drying was shown. 
Spray congealing was used to prepare insulin loaded microparticles based on glycerol 
tripalmitate. Crystalline insulin was suspended in molten lipid at 70 °C with an ultraturrax and 
atomized at 70 °C and 4-6 bar spraying pressure. The atomized lipid particles were rapidly 
cooled in a stream of cold air (- 20 °C) and subsequently freeze dried to remove adherent 
water. Yields of encapsulation of 78-95% were reached and the protein was not affected by 
the spray congealing process. However, upon incubation deamidated insulin species as well 
as protein aggregates were detected within the matrix of the microparticles. In-vitro cell 
culture tests revealed that the protein was still biologically active and was only slowly 
released from the microparticles. After preparation the lipid crystallized in the unstable 
α-modification, and this was found to influence the release kinetics. The authors 
recommended an additional tempering step at elevated temperatures to transform the lipids 
into the stable β-modification [125]. Protein release (fluorescence labeled BSA) from 
Softisan® 154 microparticles prepared by the same spray congealing method was found to 
be controlled by water intrusion velocity into the microparticles [126] and the size and shape 
of the incorporated protein particles. Smaller protein particles with a more uniform distribution 
throughout the microparticles and less direct contact to each other resulted in a more 
sustained protein release. Spray congealing was also used by Richard et al. to prepare 
human growth hormone loaded microparticles for subcutaneous or intramuscular injection. In 
a first step, human growth hormone was spray dried with in a bulking agent (e.g. sucrose) 
and surfactant (Poloxamer 188), and the resulting particles were then dispersed into a lipid 
melt consisting of fatty acids, mono-, di- or triglycerides or phospholipids and mixtures 
thereof. Microparticles were prepared by spray-congealing of the lipid dispersion and the 
diameters of the particles were less than 100 µm [127]. 
Special types of lipid microparticles are lipospheres. They consist of a solid hydrophobic fat 
core stabilized by a monolayer of phospholipids and were firstly described by Domb et al. 
[128, 129]. The drug is usually dissolved or dispersed within the lipid core, which consists of 
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triglycerides or fatty acids. BSA (as an antigen) [128], somatostatin [118] and thymocartin 
[117] have been incorporated into such systems and their release behavior has been 
characterized [130]. 
 
3.1.2. Solid lipid nanoparticles (SLNs) for peptide and protein 
delivery 
Since the beginning of the 1990s solid lipid nanoparticles (SLN) have been investigated as 
drug delivery devices for topical, oral, pulmonary and parental applications [53]. The 
preparation of SLNs can be performed by (I) high pressure homogenization, by (II) a 
microemulsion technique from a ´critical solution` or by (III) a precipitation technique. (I) Hot 
temperature high pressure homogenization is performed with emulsion of triglycerides in 
water stabilized with lecithin or surfactants and polymers. The lipid is molten and the drug is 
dissolved in the hydrophobic phase. This pre-emulsion is homogenized and cooled down 
whereupon the lipid re-crystallizes and forms SLNs. Cold homogenization can be applied to 
protect temperature sensitive drugs or hydrophilic drugs, which would dissolve in water. The 
drug containing lipid melt is ground and microparticles are prepared and dispersed in a pre-
suspension comprising water, lipid and surfactants. Homogenization and preparation of 
SLNs is performed within water or a liquid with low solubility for the drug (e.g. PEG 600 or 
oils) and at temperatures well below the melting point of the lipid (10-20 K). The 
microemulsion technique (II) works with ´critical solutions` which are prepared from molten 
lipids in aqueous solutions containing surfactants and at temperatures above the melting 
point of the lipids (fatty acids and/or glycerides). This ´critical solution` is then dispersed into 
a cold aqueous medium wherein the lipid crystallizes and form nanoparticles. The 
precipitation technique (III) uses organic solvents in which the drug and the lipid are 
dissolved and emulsified in water. After preparation of a very fine emulsion the organic 
solvent is removed leaving back SLNs. However, the application of organic solvents renders 
this preparation method unsuitable for many applications [52, 53, 131, 132].  
I. - GENERAL INTRODUCTION 
18 
Protein and peptide loaded SLNs have been described by various authors [132]. For 
example Li et al. loaded yak interferon alpha by a double emulsion solvent evaporation 
method (w/o/w) into SLN [133]. In-vitro release tests showed antiviral activity of the 
preparation by a Madin-Darby bovine kidney (MDBK) cell assay for 16 days. Insulin and 
thymopentin release for gel-core SLNs was reported by Yang et al. [134, 135], who also used 
double emulsion solvent evaporation method. Release lasted for only 24 hours; however, 
oral bioavailability of insulin was reported in a rat model. Lysozyme [136], BSA [137], human 
recombinant epidermal growth factor [138] were embedded into SLN. Almeida el al. reported 
the incorporation of peptides like cyclosporine A, insulin and calcitonin into SLNs [139].  
 
3.1.3. Liposomes 
Since the introduction of liposomes as drug delivery devices by Bangham el al. [140] many 
groups prepared and described liposomal based drug delivery devices and in 2003 more 
than 2000 papers and 150 reviews have been published on this topic [141]. Liposomes are 
described as "spherical, self-closed structures formed by one or several concentric lipid 
bilayers with an aqueous phase inside and between the lipid bilayers" [141]. They show 
enhanced circulation times in the blood stream, can be used to passively (enhanced 
permeability and retention effect - EPR effect) or actively (immunoliposomes) target cells or 
organs and are well tolerated by the human body. PEGylated liposomes are described as 
"stealth" liposomes which are protected from opsonisation and clearance by the flexible PEG 
chains. Liposomes can be further divided into multilamellar vesicles (MLV), small unilamellar 
vesicles (SUV) and large unilamellar vesicles (LUV). Furthermore liposomes can be surface-
modified by chemical conjugation of proteins, peptides, polymers or other molecules. A 
common approach is antibody-mediated liposome targeting of cancer cells e.g. anti-HER2 
liposomes for the targeting of HER2 over expressing tumors [142]. In addition, liposomes 
were also prepared as carriers for protein and peptide drugs which were incorporated into 
the aqueous liposome core.  
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Liposomes were prepared to increase the circulation times of e.g. vasopressin [143] or 
interleukin-2 [144]. Locoregional treatment of head and neck tumors was possible by 
sustained release of interleukin-2 from liposomes at the site of action which reduced negative 
side effects [145]. Liposomal insulin was shown to effectively lower blood glucose levels over 
increased periods of time in diabetic rats [146] and even oral bioavailability of liposomal 
insulin in rats was described [147]. Recombinant human epidermal growth factor [148], 
human tumor necrosis factor [149] and other proteins or peptides were also successfully 
incorporated into liposomal formulations for the treatment of various diseases [132]. 
 
3.1.4. DepoFoam™ formulations 
Special forms of liposomes are so called multivesicular liposomes (MVLs, tradename: 
DepoFoam™) which are not designed for intra-vascular but parenteral application. MVLs are 
composed of one neutral lipid (e.g. triglyceride) and at least one membrane forming lipid (e.g. 
phospholipids) which form non-concentric multiple lipid layers. As a consequence the drug is 
only released from the outermost membranes of the MVLs but redistributes after release 
from internal vesicles. Therefore, the drug is released very slowly. A second advantage of 
this system is the high volume to lipid ratio which allows the encapsulation of high drug 
loadings. The preparation of DepoFoam™ formulations is performed in a two-step 
emulsification process. At first, a water-in-oil emulsion is prepared under the input of 
mechanical energy. The drug is dissolved in the aqueous phase which is subsequently 
emulsified in an organic solvent in which the lipids were dissolved. By the addition of an 
immiscible aqueous component, a second emulsion is prepared and the solvent spherules 
are dispersed in the aqueous component. The organic solvent is evaporated under reduced 
pressure and the solvent is completely removed leaving behind MVLs [150]. 
Marketed products like DepoCyt™ (cytarabine) and DepoDur™ (morphine) comprise small 
molecular drugs but also protein and peptide drugs have been incorporated into 
DepoFoam™ formulations. Qiu et al. prepared interferon α-2b containing MVLs which slowly 
released the protein after subcutaneous injection into mice. In-vitro release lasted for up to 7 
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days and increased serum half-lives were detected by ELISA assays compared to 
subcutaneous injection of unencapsulated interferon α-2b [151]. DepoFoam™ technology 
was used to prepare insulin-like growth factor loaded MVL which released the protein over a 
period of 7 days in-vitro and in-vivo. The protein was stable during the manufacturing 
process and biological activity was conserved [152]. Leridistim (chimeric growth factor 
containing interleukin-3 (IL-3) and granulocyte colony stimulating factor (G-CSF)) showed a 
sustained release from a DepoFoam™ formulation in-vivo in rats which resulted in elevated 
neutrophil counts for ten days in contrast to only two days for unencapsulated Leridistim 
[153]. Additionally, recombinant human insulin and peptides such as leuprolide, enkephalin 
and octreotide have been formulated into MVLs [154]. 
 
3.1.5. Vesicular phospholipid gels (VPGs) 
Recent developments in lipid based drug delivery are so called vesicular phospholipid gels 
(VPG) in which lipophilic, amphiphilic or hydrophilic drugs can be incorporated. VPG consist 
of 30-60% phospholipids which form a viscous gel-like structure by numerous densely 
packed vesicles [155, 156]. VPGs can be dispersed in water and form small unilamellar 
liposomes and can therefore be prepared as storage-stable intermediates for liposomes. For 
the preparation of VPG two manufacturing strategies are described in literature: high 
pressure homogenization and dual asymmetric centrifugation. 
High pressure homogenization is a one-step preparation method without the use of an 
organic solvent. At first, the phospholipids are mixed with water and drug and are allowed to 
swell for a certain period of time. Afterwards, the dispersion is processed by a high-pressure 
homogenizer for several times resulting in a uniform size distribution of the phospholipid 
vesicles.  
Dual asymmetric centrifugation is a technique by which the sample is rotated around a 
central axis and also around a second axis in the centre of the sample container [157] 
(Figure 1). As a consequence, shear forces are generated which allow the mixing of highly 
viscous substances and lead to the formation of VPGs. The method is very easy and straight 
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forward and can be applied without further preparation steps by simple mixing of drugs and 
excipients. In contrast to high pressure homogenization, the method is more gentle (lower 
temperatures and less shear forces) and can therefore be used for the preparation of peptide 
and protein loaded VPGs. Tian et al. successfully loaded granulocyte colony stimulating 
factor (G-CSF), recombinant human erythropoietin (rhEPO) and an IgG1 antibody into VPGs 
and described the sustained release of these macromolecules in in-vitro studies [158, 159]. 
EPO was released over 17 days, and no additional aggregated or fragmented protein 
species was detected after manufacturing or release. G-CSF was also linearly released from 
VPG over several days; however a protein loss was detected which was explained by the 
inherent instability of G-CSF in the release buffer. Release of IgG1 antibody from VPGs 
lasted up to 40 days and showed close to zero-order release kinetics. For all experiments 
VPG erosion was found to be the major driving factor for protein drug release [160].  
 
 
Figure 1: Schematic drawing of the principal of asymmetric dual centrifugation. Taken from Massing et al. 
[157]. 
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3.1.6. Cubic phase gels as protein delivery systems 
Cubic phase gels spontaneously form as liquid crystalline phases if polar amphiphilic lipids 
(like glyceryl monooleate) are placed in an aqueous environment. They consist of ´curved 
bicontinuous lipid bilayer(s) in three dimensions, separating two congruent networks of water 
channels` [161] (see Figure 2). Lipidic substances for the preparation of cubic phase gels 
include glyceryl monooleat, monoelaidin, phosphatidylethanolamine, phospholipids and 
PEGylated phospholipids. Successful incorporation into cubic phase gels and sustained 
release of proteins from cubic phase gels was described by Leslie et al. (hemoglobin) [162], 
Ericson et al. (lysozyme) [163] and Sadhale et al. (insulin) [164, 165]. The biological activity 
and the secondary and tertiary structure of the proteins were preserved in the lipid systems 
and insulin was even protected from agitation induced aggregation [164]. In-vitro protein 
release lasted for up to 1 week and in-situ forming placebo implant were well tolerated in in-
vivo studies after intravaginal or periodontal application. Cubic phase gels can be dispersed 
into surfactant containing low-viscosity solutions whilst retaining their internal nanostructure. 
These dispersions contain so called ´cubosomes` (USPTO registered trademark of GS 
Development AB Corp., Sweden) which are discrete, sub-micron, nano-structured particles 
of bicontinuous cubic liquid crystalline phase [166]. Cubosomes were prepared for the 
delivery of protein vaccines (ovalbumin) by Rizwan et al. [167, 168] and exhibited high 
entrapment rates and slow release profiles. 
 
 
Figure 2: Structure of glyceryl monooleate-water cubic phase gel in three dimension. Taken from Shah et 
al. [161]. 
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Figure 3: Cryo-transmission electron micrograph of dispersed particles of cubic phase gels or 
´cubosomes`. The cubosomes are approximately 150 nm in diameter. Taken from Spicer et al. [166]. 
 
3.1.7. Compressed lipid implants for peptide or protein drug 
delivery 
Compression has always been the first choice for the preparation of lipid based implant 
systems. The manufacturing by compression is very easy, cheap and can be performed 
without organic solvents and at low temperatures. A broad variety of solid lipids were used to 
prepare compressed implants and several authors used this technique to embed proteins or 
peptides into lipid matrixes [19, 27, 31, 169-172].  
Already in 1984 Kent et al. embedded bovine growth hormone and insulin into cholesterol 
matrixes together with a binder and a lubrication agent. The patent claimed that 
macromolecules like growth hormones would show diffusion controlled release from the inert 
matrix and the rate of release could be adjusted by controlling the porosity of the implant 
[20].  
Wang et al. released insulin from matrices consisting of cholesterol [173], various fatty acids, 
anhydrides of fatty acids and triglycerides [19]. The implants were prepared by simple 
admixture of the lipids and bovine insulin (Zn-salt) and compressed using a hydraulic press. 
Blood glucose level of diabetic Wistar rats could be controlled over 1 month after 
subcutaneous injection of lipid implants. Additionally implants consisting of palmitic acid were 
shown to start erosion during in-vivo release [171].  
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Compression was used by Khan et al. for the preparation of BSA loaded biodegradable lipid 
pellets. Cholesterol was used as matrix materials either alone or after a co-precipitation step 
and in a mixture with lecithin. BSA powder was mixed to the sieved lipid powders and 
compressed to 30 mg pellets. Subcutaneous implantation in mice resulted in measurable 
formation of anti-BSA antibodies after 40 days [174] and 10 months [175]. Increasing amount 
of lecithin resulted in an increased erosion rate and release rate. However, release lasted for 
only 10 days and no data about biocompatibility of such devices in-vivo were shown. 
Walduck et al. [22] used the same method and materials for the manufacturing of antigen 
loaded implants and successfully immunized sheep in a single immunization step. 
In 2006, Guse et al. published data about the ´Biocompatibility and erosion of implants made 
of triglycerides and blends with cholesterol and phospholipids` [23]. They found that the 
matrix materials glycerol tripalmitate and cholesterol showed good biocompatibility after 
subcutaneous implantation on NMRI-mice. Increasing amounts of lecithin, however, resulted 
in increased inflammatory reactions at the site of administration. The erosion of the implants 
was higher if mixtures of lecithin and glycerol tripalmitate were used (implants comprising 
50% lecithin collapsed at day 6) compared to pure glycerol tripalmitate or mixtures of 
cholesterol with glycerol tripalmitate. The latter implants stayed intact for up to 35 days and 
no sign of erosion or swelling was observed.  
Release of tetramethylrhodamine (TAMRA) labeled bovine serum albumin (TAMRA-BSA) 
and hyaluronidase from compressed glycerol trimyristate matrices was investigated by 
Vogelhuber et al. [172]. High burst release during the first day of incubation and incomplete 
protein release was detected after in-vitro release tests. Incomplete release was explained 
by insufficient amounts of pore-forming agents. However, protein integrity was maintained 
during manufacturing and storage in the triglyceride matrix. Subcutaneous implantation into 
NMRI mice and subsequent recovery of the matrices revealed that the implant did not show 
any sign of erosion during 15 days of incubation. 
Compressed implants consisting of glycerol tripalmitate were loaded with insulin and used for 
in-vitro cartilage engineering [169]. It was shown that insulin was released in a sustained 
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manner in its biologically active form from the triglyceride matrices and led to a weight 
increase in cartilaginous cell-polymer constructs. Implant manufacturing was performed by a 
wetting-compression method. In a first step, insulin was dissolved in water and appropriate 
amounts of the solution were added to mortars filled with the triglyceride powder. The 
mixtures were freeze-dried, manually homogenized in the mortar and subsequently 
compressed to cylindrical matrices. No aggregation or loss of activity was encountered 
during manufacturing or extraction from the matrices by chloroform. Matrices were loaded 
with 0.2%, 1.0% and 2.0% insulin and released 100%, 90% and 67% of the incorporated 
drug [169]. 
Compression was also used to prepare interleukin-18 (IL-18) loaded glycerol tripalmitate 
based implants. These implants were prepared to deliver IL-18 into rat-brains. The 
manufacturing process existed of two steps. At first a modified co-lyophilization process by 
which the protein was lyophilized together with PEG 6000 [176] was applied. The lyophilized 
powder was dispersed into tetrahydrofurane (THF) and PEG was selectively dissolved 
leaving back fine protein microparticles. This dispersion was mixed with dissolved glycerol 
tripalmitate by ultrasonication and frozen in liquid nitrogen. The organic solvent was 
completely removed by application of vacuum and the remaining powder formulation was 
subsequently ground and compressed. The authors claimed that a very homogeneous 
protein distribution was achieved by this procedure. Additionally, PEG acted as a 
cryoprotectant during freezing and as pore-forming agent and protein stabilizer during in-vitro 
release. Incomplete release (< 35%) of IL-18 from the matrices was explained by insufficient 
amounts of pore-forming agents and the very fine distribution of the drug within the lipid 
matrix [25].  
A comparison between four different manufacturing strategies for protein loaded compressed 
lipid implants was published by Könnings et al. [177]. In a first attempt, lyophilized lysozyme 
was directly mixed with lipid powder and compressed to implant matrices. As an alternative, 
a solid-in-oil dispersion of lyophilized lysozyme in THF was mixed with a solution of the 
triglyceride. Thirdly, a water-in-oil (w/o) emulsion was prepared wherein the protein was 
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dissolved in the aqueous phase and the lipid in dichlormethane. At last, the protein was co-
lyophilized with PEG 6000 and processed as already described above. Implants which were 
prepared from the pure powder mixture released the protein very rapidly (70%, 1 day) 
whereas manufacturing from the solid-in-oil dispersion led to incomplete drug release (25% 
total release). The w/o emulsion technique as well as the co-lyophilization technique 
released the protein more slowly over a period of 60 days. However, the w/o emulsion 
technique induced higher levels of aggregated protein species. Therefore the co-
lyophilization technique was found to be the most appropriate technique to for the 
preparation of slow releasing triglyceride implants. In continuative studies brain derived 
neurotropic factor (BNDF) was embedded into triglyceride matrices by this technique and in-
vitro release studies were performed. The protein was continuously released for more than 
one month and the manufacturing process did not induce the formation of aggregated protein 
species. 
Mohl et al. prepared recombinant human IFNα 2a (IFNα) loaded compressed implants from 
glycerol tristearin, PEG 6000 and lyophilized IFNα powder (lyophilized with HP-β-CD or 
trehalose in a protein-excipient ratio of 1:3). More than 90% of the incorporated protein was 
released over a period of one month and the release rate was controlled by the amount of 
PEG 6000 which acted as porogen [27]. Long-term storage studies (6 months) revealed that 
the lyophilized protein was stable in the lipid matrix if lyophilized with HP-β-CD as excipient. 
The use of trehalose as excipient resulted in increased levels of aggregated and oxidized 
IFNα species after storage and release [28].  
Further investigation were performed by Herrmann et al. and Mohl et al. and revealed that 
PEG 6000 did not only act as porogen but was able to precipitated IFNα from solution and 
thereby modulate the release behavior [24, 27, 29]. Protein precipitation by PEG 6000 did 
not affect the stability of IFNα during release. 
In-vivo IFNα release studies from compressed implants in rabbits were performed by Schwab 
et al. [31]. Sustained protein release was monitored by ELISA assays for nine days. 
Afterwards anti-drug antibodies were produced and eliminated IFNα from the rabbits` 
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bloodstream and thus IFN release could not be measured anymore. However, after 28 days 
of in-vivo incubation no adverse body reaction on the implant besides a minimal fibrous 
encapsulation was detected. 
 
3.1.8. Twin-screw extruded lipid implants 
Recently, twin-screw extrusion (tsc-extrusion) was introduced as a new manufacturing 
technique for the preparation of triglyceride based lipid implants by the group of Prof. Winter: 
[32, 33, 178]. Hereby, implants are prepared from powder mixtures comprising a protein drug 
powder, a release modifier, a high-melting and a low-melting lipid. A Haake MiniLab® Micro 
Rheology Compounder (Figure 4) is used for implant manufacturing which allows for the 
extrusion of low volumes.  
The lipid composition facilitates twin-screw extrusion of the powders at gentle temperatures 
which are set slightly above the melting point of the low melting lipid. Due to lipid melting in 
the extruder barrel, the powder mixture softens and can be pressed through the extruder 
outlet die resulting in rod-shaped lipid implants. Advantages of the implant preparation by 
twin-screw extrusion are obvious: 
 Implants can be prepared in a continuous mode with changing batch sizes without 
changing the extruder setup. 
 Up-scaling of the process is easily possible. 
 Resulting implant are rod-shaped and thus subcutaneous administration via a trochar 
is easy (Figure 6). 
 Implant diameters can be easily varied (1.9 mm, 1.5 mm, 1.0 mm, 0.5 mm) by fixing 
different mouthpieces in front of the extruder outlet die (Figure 5 + Figure 6). 
 Thorough mixing within the extruder barrel is provided by the rotating screws which 
leads to a very homogeneous distribution of drug within the matrix material. 
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Figure 4: Haake MiniLab
®
 Micro Rheology Compounder, Thermo Haake, Germany. A – twin-screw 
extruder and control unit. B – Close-up of the extruder barrel with screws and closed by-pass channel. 
 
 
Figure 5: Extruder outlet die. A – standard outlet die (Ø = 1.9 mm); B – outlet die with fixed mouthpiece (Ø 
= 1.0 mm). 
 
Schulze et al. prepared tsc-extrudates comprising IFNα and found sustained protein drug 
release which lasted for up to 40 days. Integrity of IFNα was not affected by the preparation 
process as shown by FTIR and SDS-PAGE studies [32]. Additionally, twin-screw extrusion 
was shown to result in a very homogenous distribution of a hydrophilic model compound 
methylene blue [179]. 
Schwab et al. performed an lipase based in-vitro degradation assay and found that tsc-
extrudates were better degradable compared to compressed implants [33]. 
 
A B 
A B 
A 
bypass channel screws 
outlet die 
control unit 
I. – GENERAL INTRODUCTION 
29 
  
Figure 6: (A) Rod shaped tsc-extrudates. Diameters from left to right: 1.9 mm, 1.5 mm, 1.0 mm and 
0.5 mm. (B) Model device for the application (trochar) of tsc-extrudates by subcutaneous injection. 
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4. Mechanism of release from implant matrices  
Mechanism of drug release from implant systems can be divided into 3 major groups: 
 diffusion controlled systems, 
 solvent activated systems (swelling controlled, osmotically driven) and 
 erosion controlled release [42, 180]. 
Diffusion controlled systems can be further divided into matrix and membrane systems where 
diffusion occurs either within the implant matrix material or through a membrane. Diffusion 
represents the rate limiting step for drug release. A concentration gradient of the drug 
between the implant core and the implant surface allows drug release which follows Fick´s 
second law of diffusion (Equation 1) which describes the dependency of the diffusion rate 
with respect to position and time of the diffusion borderline [181].  
 
Equation 1   
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For membrane or matrix systems zero-order release can be achieved as long as a constant 
diffusion gradient is established. This is the case if perfect sink conditions are prevailing and 
the concentration of the available drug is constant all the time. Membrane systems fulfill 
these requirements as long as the concentration of the drug in the core is much higher than 
the concentration which is able to diffuse through the membrane. As a consequence, the 
membrane is always saturated with the drug and constant amounts are released at the outer 
side of the membrane. Hereby, the solubility of the drug in the membrane is the rate limiting 
step for release and is controlling the rate of release. In the case of matrix systems, drug 
concentrations in the core are ´constant` if the system allows a dissolution of dispersed or 
precipitated drug, which is embedded into the matrix. Hereby, the released amount of the 
drug is compensated for by dissolution of formerly non-available drug material. This creates 
a constant starting concentration for release. It is important to note that the dissolution 
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velocity of the embedded drug is the rate limiting step for release. If dissolution is too fast, 
release will not be governed by the dissolution velocity but by drug diffusion according to the 
Higuchi equation (Equation 2). In matrix systems, the drug can be either dissolved in the 
matrix material (monolithic system) or is dispersed in the matrix and is dissolved upon 
contact in the release medium. In the former case, the drug diffuses through the matrix 
material and in the latter case, the drug is released through a porous network embedded into 
the matrix material and created upon dissolution of pore forming agent and/or drug (porous 
systems).  
The most prominent way to described drug release from inert systems is, as already 
mentioned, the Higuchi equation (Equation 2) where Q is the amount of drug released at time 
t per unit area, D is the diffusion coefficient and C0  an CS are initial drug concentration and 
solubility of the drug, respectively : 
 
Equation 2   tCCCDQ SS  )2( 0 ,   for C0  >> CS  
 
The Higuchi equation is assuming that diffusion is only one dimensional, D is constant 
throughout the experiment, perfect sink conditions are present and C0 >> CS. For this case, 
drug release is proportional to square root of time [39, 40]. 
Solvent activated systems can be swelling controlled as in the case of hydrogels [182] or 
osmotically driven as in the case of the Duros™ system [183]. In both cases, the permeation 
of the release medium into the implant device allows release of the active [184]. In swelling 
controlled systems a reordering of the implant polymer structures is responsible for drug 
release, whereas in osmotically driven systems the increased osmotic pressure releases the 
drug from the device. 
The last class of drug release system is the erosion driven system. Implant erosion is mainly 
a chemical process where for example ester bonds between lactic acid and glycolic acids are 
cleaved. Thereby, the chain lengths of the polymers decrease finally leading to the formation 
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of small and water soluble molecules and a matrix breakdown. Implant erosion can be 
divided into bulk erosion and surface erosion, which can however not be strictly separated 
[185]. Surface erosion leads to degradation of the implant starting from the implants surface 
and a more or less constant implant weight loss can be measured. On the contrary, bulk 
erosion leads to a chemical degradation of the implant over the complete implant matrix and 
ends in a rapid breakdown of the implant matrix after a certain lag time. Factors like water 
penetration velocity, chemical stability of the matrix material and (auto-)catalysis of 
degradation strongly influence the degradation rate of such systems and tailor made 
polymers (mostly PLGA) have been produced to exactly control the rate of implant 
degradation [61, 69, 185]. Drug release from eroding implant is difficult to describe by 
mathematical models due to the large number of influencing factors such as water entry 
velocity, degradation rate, osmotic pressure, pH within the implant, size of the implant and so 
on. Calculation of drug release utilizes Monte Carlo models to simulate the influence of 
polymer cleavage rate and diffusion models based on the Higuchi equation [186]. 
In general, an exact assignment to which system a drug delivery device belongs is often 
difficult as all mentioned processes can occur simultaneously. 
 
4.1. Mechanism of release from triglyceride based implants 
For triglyceride based implants diffusion controlled release from inert matrices has been 
shown and protein release was explained by drug diffusion in water filled implant pores within 
the implant matrix. Mathematical models were successfully used to describe protein release 
from such systems [24, 29, 30, 179]. Factors like the wettability of the triglyceride matrix 
[170], drug particle size [187] or implant homogeneity [177] were shown to strongly influence 
drug release from triglyceride based systems. 
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4.2. Mechanism of release from compressed and tsc-extruded 
implants 
Protein release from compressed implants was shown to be dominated by diffusion and 
sustained protein release from compressed devices was observed [27, 170, 188]. More 
sustained protein release from compressed triglyceride based implants was achieved by 
Herrmann et. al by an in-situ protein precipitation an re-dissolution process of the 
incorporated protein drug IFNα [24, 29]. In this system the drug (IFNα) and the pore-forming 
agent (PEG 6000) dissolved in the incubation medium and created a highly concentrated 
solution of both substances within the implant pores. Due to the high PEG concentration, the 
protein drug precipitates within in implant pores and was not immediately released. After an 
inital burst release of IFNα, a phase of sustained protein release started which was explained 
by the rate limiting re-dissolution of precipitated IFNα. This release mechanism was proven 
by mathematical modeling [30] and it was shown that excipients (HP-β-CD) and the 
precipitating agent (PEG 6000) were released faster than IFNα which was released linearly 
over 14 days (Figure 7). 
 
 
Figure 7: IFNα release from compressed lipid implants consisting of 10% IFNα lyophilisate, 10% PEG 6000 
and glycerol tristearin in PBS buffer pH 7.4. Taken from [29].  
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Interestingly, by changing the preparation method from compression to tsc-extrusion an even 
more sustained release of IFNα was achieved. Compared to compressed implants, the 
matrix of tsc-extrudates only differed in the triglyceride composition but tsc-extrudates also 
comprised 10% PEG 6000 and 10% IFNα lyophilisate. Furthermore a higher surface to 
volume ratio was found for tsc-extrudates which usually facilitates faster drug release. In 
addition to the more sustained IFNα release from tsc-extrudates, the release profile changed 
and a triphasic release was observed. After a burst release, a lag-phase was observed which 
lasted for up to day 20 and merged into a linear release phase (Figure 8). Protein integrity 
was neither disturbed during precipitation and re-dissolution nor by tsc-extrusion [32]. The 
striking difference between compressed implants and tsc-extrudates needs to be further 
investigated as the manufacturing process itself obviously resulted in a more sustained 
release of IFNα. 
 
 
Figure 8: Release of IFNα from tsc-extrudates comprising 20% (open circles) and 10% (closed circles) 
PEG 6000 and 10% lyophilized IFNα. Taken from [32]. 
 
 
 
Burst release 
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II. Aim of the thesis 
Extensive studies about the suitability of lipids as matrix materials for implants were 
performed during the last decades. With the emergence of protein pharmaceuticals and the 
concerns about protein stability in the currently used PLA/PLGA materials, lipids got back 
into the focus of researchers as material for long term delivery of drugs. 
In previous work, it was shown that triglycerides – besides other lipidic materials – were able 
to maintain the stability of embedded lyophilized proteins during storage and release [24, 27, 
28, 32]. Furthermore, triglyceride based implants proved to facilitate sustained release and 
allowed easy production of implants by simple compression [18, 24-26, 28, 172, 179, 189]. In 
continuative work it was even possible to tailor protein release e.g. by choice of implant 
geometry [32] or by admixing of protein precipitating agents (PEG) [24, 29]. 
Recently, a novel method for the preparation of lipid based (triglyceride based) implants was 
described: twin-screw extrusion (tsc-extrusion) [178]. Hereby a low-melting and a high-
melting lipid were admixed and extruded with a commercially available twin-screw extruder. 
Similar to other triglyceride based implant systems, tsc-extrudates exhibited a sustained 
release profile [32, 179] and were shown to be degradable by in-vitro incubation with lipase 
[33]. However, compared to compressed implants, tsc-extrudates allowed slower release 
profiles and were much better degradable by lipases. 
The exact reason for the beneficial release properties and the improved in-vitro degradability 
of tsc-extrudates was not yet fully understood. In this thesis mechanistic studies were 
conducted to explain the sustained protein release from tsc-extrudates. Besides long-term 
release experiments, protein release was also investigated on a molecular level by 
microscopic single-molecule tracking experiments. The superior in-vitro degradability of tsc-
extrudates in the lipase degradation assay [33] was the starting point for further in-vitro 
studies and formed the platform for an in-vivo degradation study in rabbits. Further work 
included the tailoring of protein release by the application of a protein precipitation and re-
dissolution mechanism already described by Herrmann et al. [24, 29]. We attempted to 
II. – AIM OF THE THESIS 
38 
transferred the mechanism from recombinant human interferon α to other molecules to prove 
the general applicability of the described system.  
 
Consequently the goal of the current thesis was to further develop and describe the 
properties of tsc-extrudates in order to facilitate the manufacturing of protein loaded 
triglyceride based implants for in-vivo application. 
 
A summary of the goals of this thesis is given here: 
 The general applicability of the precipitation and re-dissolution mechanism described 
for recombinant human interferon α2a to other proteinaceous molecules was studied. 
 The mechanism for sustained protein release from tsc-extrudates was investigated 
with special interest on the influence of the manufacturing strategy and the implant 
matrix composition. 
 The release mechanism of proteins from tsc-extrudates was analyzed on a molecular 
level by a microscopic approach. Our aim was to track single protein molecules inside 
triglyceride based implants by fluorescence microscopy and to elucidate the 
pathways via which the molecules were released from the implants. 
 Finally, investigations about the in-vitro and in-vivo degradability of tsc-extrudates 
were carried out. Therefore the effects of lipase addition to the implant matrix for the 
enhancement of implant degradation were studied and an animal study in rabbit was 
conducted.  
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III. Twin-screw extrudates for the sustained release of a 
therapeutic antibody 
1. Introduction 
Antibodies are usually administered intravenously and large doses are required (up to 1 g / 
70 kg patient) for systemic distribution. Multiple dosing is necessary as antibodies are 
cleared from the plasma after intravenous infusion in first-order kinetics exhibiting half-lives 
of a few days [190]. Additionally, due to painfully application procedures by injection, 
patients’ compliance is often poor. From the point of view of a pharmaceutical company, 
systemic administration of an antibody is comparatively costly due to the high amounts of the 
protein drug required. Thus, a local sustained delivery system for antibodies would have the 
advantageous of direct delivery of the drug to the site of action, a reduction of systemic 
exposure and potential toxicity [191]. Furthermore, multiple injections could be avoided, if a 
delivery system released the antibody in a sustained (at best zero-order) way over prolonged 
time periods. 
The local delivery of pooled human polyclonal antibodies was reported in mice for the 
prophylactic treatment of gram-positive and gram-negative abdominal infections [192]. 
Hereby, the antibody was loaded into a carboxymethylcellulose gel and antibody serum 
levels were detectable over a longer period of time compared to intravenous injection. The 
administration of the antibody showed a synergistic effect with antibiotics, and the mortality of 
the mice was drastically reduced. Similar results were reported by Felts et al. in two studies 
investigating burn wound models in mice [193, 194]. Parkhurst et al. reported antibody 
release from poly(ethylene-co-vinyl acetate) (PEVac) disc devices to neutralize leukocyte 
adhesion molecules. These devices were inserted into the vaginal canals of mice as 
prophylaxis against sexually transmitted diseases [195]. Other groups investigated the local 
delivery of an antibody by Pluronic™ based gels [196] or by the application of antibody 
comprising PLGA based microspheres [197]. 
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Besides that, the topical application to mucosal surfaces, the cornea or the skin as well as 
pulmonary and respiratory antibody delivery has been reported [190]. For example antibody 
containing lipid-based hollow-porous microparticles (PulmoSpheres™) were produced by 
spray-drying of dipalmitoylphosphatidylcholine (DPPC) and were investigated for the ability to 
trigger or modulate immune responses in BALB/c mice after inhalation [124].  
Of course implantable devices of various geometries (slabs, films, gels, cylinders) have also 
been under investigation [27, 32, 190, 192] to fit to the needs for local delivery.  
A wide range of matrix materials was successfully used for the preparation of antibody 
releasing drug devices. Materials used were e.g. PLGA, PEVAc [198], tricalcium phosphate, 
carboxymethylcellulose [190], chitosan [92], hyaluronic acid [100] , SiO2 [199] and silk [200].  
Thus, we identified a need for a controlled local delivery system for antibodies and 
triglyceride based twin-screw extrudates may exhibit an excellent delivery platform therefore. 
Zero-order release of a protein from triglyceride based implants was already achieved for 
IFNα by in-situ precipitation of drug in the presence of PEG 6000 [24, 29, 32]. 
Antibodies are also described to show reversible precipitation in the presence of PEG [201-
203]. As reported in the literature, protein precipitation by PEGs can be used to gain highly 
concentrated protein solutions or to purify proteins [201, 204-207]. Additionally, 
subcutaneous delivery of crystalline monoclonal antibodies was performed after precipitation 
of antibodies with PEG. Hereby highly concentrated suspensions (200 mg/mL) of crystalline 
antibody in PEG/ethanol mixtures were obtained which were injected subcutaneously into 
BALB/c mice (0.1 mL) where the antibody crystals dissolved within 12 h [208]. 
Thus a transfer of the strategy of in-situ protein precipitation within lipid based implants from 
the IFNα/PEG system [24, 29] to a IgG1/PEG system might be promising.  
In order to proof the applicability of tsc-extruded lipid based implants for the controlled 
sustained delivery of a therapeutic antibody we performed antibody solubility studies and in-
vitro release tests of an IgG1 antibody from tsc-extruded lipid implants. 
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2. Materials and methods 
2.1. Materials 
MabB is a monoclonal IgG1 antibody. It is formulated in 10.5 mM phosphate buffer pH 6.4 
with a concentration of 17.0 mg/mL. It comprises 2 heavy and 2 light chains and has a 
molecular weight of about 150 kDa. Hydroxpropy-β-cyclodextrin (HP-β-CD) was a gift of 
Wacker Chemie AG (Burghausen, Germany). Carboxymethylcellulose 90,000 D.S 0.7 and 
Kollidon® 25 were purchase from Sigma-Aldrich (Steinheim, Germany), dextran 35,000 was 
from Biomedicals Lab (Aurora, Ohio, USA) and PEG 6000 was donated from Clariant 
(Wiesbaden, Germany). All salts were of analytical grade and purchased from Merck 
(Darmstadt, Germany). 
 
2.2. Quantification of mabB 
Antibody quantification was performed UV-metrically (280 nm) after separation by SE-HPLC 
(Dionex Ultimate 3000, Dionex, Idstein, Germany). The flow rate was 0.5 mL/min and 100 µL 
of each sample were injected onto two in-line Superose 12 (10/300 GL) size-exclusion 
columns (GE Healthcare, Uppsala, Sweden). The running buffer consisted of 200 mM 
potassium phosphate with 150 mM potassium chloride and was adjusted to pH 6.9 with 0.1 N 
solutions of potassium hydroxide and/or hydrochloric acid. 
 
2.3. Precipitation and re-dissolution studies 
Preliminary solubility studies with mabB were performed with various excipients including 
carboxymethylcellulose 90,000 D.S 0.7, Kollidon® 25 (polyvinyl pyrrolidone), dextran 35,000, 
PEG 6000, sodium chloride, sodium sulfate and ammonium sulfate. Equal volumes of mabB 
(5 mg/mL) and highly concentrated solutions of the agents in PBS buffer pH 7.4 were 
admixed, shortly vortexed and incubated for 2 hours at 37 °C. Afterwards, samples were 
centrifuge (4K15, Sigma, Osterode, Germany), 20,000 RZB, 37 °C) for 10 minutes and 
visually assessed for protein precipitation (= formation of a pellet).  
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For re-dissolution studies, 50 µL of mabB stock solution (10 mg/mL, pH 7.4) and 50 µL of 
PEG 6000 stock solution (20% and 50% in PBS pH 7.4) or control (PBS buffer pH 7.4) were 
admixed and the protein was precipitated in samples containing PEG 6000. After incubation 
on a shaker (40 rpm) at 37 °C for 1, 2, 3, 6, 9, 14 and 20 days, the samples were diluted 15-
fold with PBS pH 7.4 and assessed by SDS-PAGE and SE-HPLC. Total protein recovery and 
monomer content were determined UV-metrically (280 nm) after SE-HPLC separation.  
 
2.4. Antibody solubility studies in the presence of PEG 6000  
Solubility of mabB in the presence of various amounts of PEG was determined by admixing 
equal volumes of antibody solution (5 mg/mL or 10 mg/mL) with solutions of PEG 6000. 
Therefore, PEG solutions with concentrations ranging between 2% and 50% (w/v) were 
prepared by dissolution of PEG 6000 in PBS buffer pH 7.4. 
In order to proof an influence of the pH on the precipitation capacity of PEG 6000, antibody 
solutions and PEG solutions were adjusted to pH 4.0, 6.0, 7.4, 9.0 and 11.0 with hydrochloric 
acid and sodium hydroxide prior to mixing.  
After pipetting solutions were quickly vortexed (10 sec) and incubated at 37 °C on a 
horizontal shaker (40 rpm) for 2 hours. Afterwards, the solutions were centrifuged at 20,000 
RZB for 10 minutes, the supernatant was drawn and diluted 4-fold and the antibody 
concentration was measured UV-metrically at 280 nm with the Fluostar Omega Platereader 
(BMG LABTECH GmbH, Offenburg, Germany). Linearity of UV measurements was 
established over a concentration range from 0.010 mg/mL to 1.0 mg/mL. 
 
2.5. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Non-reducing denaturizing SDS-PAGE was used to monitor the aggregation and 
fragmentation of the antibody after precipitation and re-dissolution. Analysis was performed 
using an XCell II Mini cell system (Novex, San Diego, CA, USA). Samples were diluted to a 
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final concentration of 0.05 mg/mL in a pH 6.8 Tris-buffer containing 2 % SDS and 2 % 
glycerine. The samples were denatured at 95 °C for 20 minutes and then 10 μL of the 
solutions were loaded to the gel wells.  
Electrophoresis was performed using NuPAGE® Pre-Cast 7% Tris-Acetate gels 
1 mm x 10 wells and NuPAGE® Tris-Acetate running buffer. Separation was accomplished 
with a constant current of 40 mA and running time was approximately 45 min. 
Gels were stained with the SilverXPress© Silver Staining Kit (Invitrogen, Karlsruhe, 
Germany) or the Colloidal Blue Staining Kit (Invitrogen, Karlsruhe, Germany). To check the 
performance of the system a standard was analyzed on each gel. To determine the 
molecular weight of the detected bands a molecular weight standard was analyzed on each 
gel as well (Mark 12 Unstained Standard, Invitrogen, Karlsruhe, Germany). 
 
2.6. Lyophilization of mabB 
Lyophilization of mabB was performed according to the schema in Table 1 in a ε12G freeze-
dryer (Christ, Osterode, Germany). 
Table 1: Lyophilization schema for mabB and PEG 6000 
step temperature 
time per step or 
heating/cooling rate 
pressure 
Cooling/freezing step 
to - 45 °C 1.6 K/min atmosphere pressure 
- 45 °C 90 min atmosphere pressure 
primary drying 
to - 20 °C 0.1 K/min to 10
-2
 mbar 
- 20 °C 35 hours 10
-2
 mbar 
secondary drying 
to + 20 °C 0.1 K/min to 10
-3
 mbar
 
+ 20 °C 20 hours 10
-3
 mbar 
sealing of vials 
The pressure chamber was filled with nitrogen to a pressure of 800 mbar 
and the vials were sealed with rubber stoppers. 
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2.7. Lyophilization of PEG 6000 
Lyophilization of PEG was performed according to the method of Ketan et al. [209]. In brief, 
PEG 6000 was dissolved in ultrapure water to give a final concentration of 10% (m/m) and 
aliquots of 1 mL were pipetted into 2R vials. Lyophilization was performed according to the 
cycle in Table 1 with a ε12G freeze-dryer (Christ, Osterode, Germany). 
 
2.8. Coulometric Karl-Fischer headspace titration 
The residual moisture of the samples was determined with a coulometric Karl Fischer titration 
using the Aqua 40.00 titrator (Analytik Jena AG, Halle, Germany) equipped with a headspace 
oven. Standard samples (Apura® water standard 1.0, Merck, Darmstadt, Germany) were 
analyzed to control the accuracy of the system. For measurements, samples were heated at 
90 °C in the headspace oven and the evaporated water was transferred into the titration 
solution were the amount of water was determined. All samples were measured in triplicate. 
 
2.9. Preparation of lipid implants by tsc-extrusion 
Triglyceride based tsc-extrudates were prepared from a powder mixture comprising 56% 
D118, 24% H12, 10% lyophilized PEG 6000 and 10% lyophilized mabB (mabB:HP-β-CD 1:3) 
(Figure 9). The composition was chosen according to Schulze et al. [24, 29]. 
D118, and H12 were a gift from Sasol (Witten, Germany) and the chemical composition of 
the triglycerides as well as their melting ranges are depicted in Table 2. Lyophilized antibody 
and PEG powder cakes were ground in agate mortars before use. Equal masses of H12, 
lyophilized PEG 6000 and lyophilized mabB were weighed into an agate mortar and a 
uniform powder mixture was created. Afterwards, the rest of H12 and D118 were admixed in 
three single steps to ensure an even distribution of the components. 
Tsc-extrusion was performed with a MiniLab® Micro Rheology Compounder (Thermo Haake 
GmbH Karlsruhe, Germany) as described by Schulze et al. [32]. In brief, the powder mixture 
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was fed into the barrel of the extruder and extrusion was performed with closed bypass 
channel at 41 °C through the extruder outlet die (Ø = 1.9 mm, rotation speed: 40 rpm).  
Table 2: Triglyceride composition and melting ranges of H12 and D118. 
 Stearic acid Palmitic acid Myristic acid Lauric acid Melting range 
D118 100% - - - 70-72 °C 
H12 - 71% 27% 2% 37-40 °C 
 
 
Figure 9: Composition of mabB comprising lipid tsc-extrudates. 
 
2.10. Antibody release tests from tsc-extrudates 
For antibody release tests, rod-shaped extrudates were cut at a length of approximately 
2.0 cm and weighed on an analytical balance before and after in-vitro release. Extrudates 
(n = 5) were placed in 2.0 mL Eppendorf tubes and release tests were performed at 37 °C in 
a horizontal shaker (40 rpm) in 1.9 mL PBS buffer pH 7.4 and pH 4.0. At predetermined 
points of time samples were drawn by complete exchange of the incubation buffer. Protein 
content was analyzed after separation by SE-HPLC as described above (III.2.2). 
D118, 56% 
H12, 24% 
PEG 
6000, 
10% 
mabB lyo, 
10% 
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2.11. Scanning electron microscopy 
After release, implants were washed three times with distilled water and vacuum dried to 
constant weight in a vacuum dryer (Memmert, Schwabach, Germany) at 25 °C and 11 mbar. 
Lipid implants were assessed with a scanning electron microscope 6500F (Jeol GmbH, 
Eching, Germany) without applying any coating procedure.  
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3. Results and discussion 
3.1. Preliminary precipitation studies 
Precipitation studies with highly concentrated solutions of various precipitants and mabB 
(5 mg/mL) were performed to find a suitable precipitating agent. Results are displayed in 
Table 3. The antibody was rapidly precipitated after the addition of PEG 6000 and 
ammonium sulfate. This was not surprising as antibody precipitation with polyethylene glycol 
is well described in literature and established in downstream processing of pharmaceutical 
products [201, 210]. Ammonium sulfate precipitation of various proteins is also well 
described in literature and often used to purify proteins. 
Carboxymethylcellulose (CMC), Kollidon® 25, dextran 35,000, sodium sulfate (NaSO4), and 
sodium chloride (NaCl) did not lead to a rapid precipitation of the antibody from solution and 
were thus not further investigated as pore-forming/precipitating agent.  
Table 3: MabB precipitation in isotonic PBS buffer pH 7.4 
Precipitant Precipitant concentration [% - w/v] Precipitation [yes/no] 
CMC 90,000, D.S. 0.7 0.5 no 
Kollidon® 25 15 no 
Dextran 35,000 20 no 
PEG 6000 25 YES 
NaCl 15 (2.56 M) no 
NaSO4 8 (0.56 M) no 
(NH4)2SO4 14 (1.04 M) YES 
 
3.2. Antibody solubility studies in the presence of various amounts 
of PEG 6000 
Solubility of mabB was found to decrease with increasing amounts of PEG 6000 (Figure 10). 
A minimum of 10% PEG 6000 (w/v) was necessary to completely precipitate the protein from 
solution. MabB solubility in the presence of PEG was also found to be dependent on the pH 
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of the incubation medium. At pH 4.0 no precipitation was observed in a 20% (w/v) PEG 
solution. However, between pH 6 to 11 antibody precipitation occurred (Figure 11).  
 
Figure 10: Solubility of mabB in the presence of increasing amounts of PEG 6000 
 
 
Figure 11: Influence of pH on the solubility of mabB (5 mg/mL) in solutions of (A) 10% PEG 6000 and (B) 
20% PEG 6000 in PBS buffer. 
Interestingly, a 10% solution of PEG did not lead to antibody precipitation at pH 11 but a 20% 
PEG solution precipitated the protein. Thus antibody precipitation is dependent on the pH 
and on PEG concentration and these two factors have synergistic effects. Antibody 
precipitation was found to be fully reversible after dilution (1:10) and 2 hours incubation in 
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PBS buffer pH 7.4 and only minor changes in monomer content were found compared to the 
stock solution (Figure 12). 
 
Figure 12: Recovery of mabB after precipitation with various amounts of PEG 6000 and re-dissolution by 
10-fold dilution with PBS buffer pH 7.4. A: total recovery of mabB after re-dissolution, 100% = 0.5 mg/mL; 
B: monomer content of mabB after re-dissolution.  
 
3.3. MabB precipitation and re-dissolution after long-term 
incubation 
MabB was precipitated from solution by mixing with PEG 6000 (pH 7.4 in PBS buffer) to give 
final concentrations of 5 mg/mL of protein and 10% or 25% of PEG 6000. Samples were 
incubated for up to 20 days at 37 °C and 40 rpm and subsequently re-dissolved by 1:10 
dilution with PBS pH 7.4. Total protein recovery and monomer content after re-dissolution of 
precipitated mabB samples were analyzed by SE-HPLC and UV-detection. MabB was 
completely recovered after incubation from all samples and did not significantly differ 
between samples containing varying amounts of PEG and different incubation times (Figure 
13). However, monomer recovery showed a decrease in monomer content with increasing 
incubation times and PEG content (Figure 14). 
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Figure 13: Total recovery of mabB after precipitation with PEG 6000 and incubation at 37 °C. Samples 
were taken after 2 hours and after 1, 3, 6, 9, 14 and 20 days as displayed. 
 
 
Figure 14: Recovery of mabB monomer after precipitation with PEG 6000 and incubation at 37 °C. 
Samples were taken after 2 hours and after 1, 3, 6, 9, 14 and 20 days as displayed. 
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3.3.1. Non-reducing SDS-PAGE of re-dissolved samples 
Precipitation and re-dissolution of incubated samples after 2 hours incubation time did not 
show a difference between control samples (standard, 0% PEG) and re-dissolved samples 
(10%, 25% PEG – Figure 15) by SDS-PAGE.  
 
 
Figure 15: SDS-PAGE of re-dissolved mabB: Samples were precipitated by PEG (10% or 25%) or treated 
with control buffer (PBS pH 7.4), incubated for 2 hours at 37 °C on a shaker (40 rpm) and re-dissolved by 
15-fold dilution with PBS buffer pH 7.4. 
 
However, samples taken after 20 days of incubation showed increasing amounts of dimers, if 
incubated with higher amounts of PEG 6000 (10%, 25% PEG; Figure 16). Dimer formation 
might be a result of chemical reactions especially disulfide crosslinking, which is described in 
literature [211]. This aggregation pathway works via autooxidation of PEG by light and heat 
and leads to crosslinking of cystein residues. However, SDS-PAGE under reducing 
conditions was not performed with these samples and therefore no final answer regarding 
the origin of the increased dimer concentrations can be given. 
Marker   Standard   0%       10%      25%       0%      10%      25%       0%       10% PEG 
dimer (300 kDa) 
 
 
monomere (150 kDa) 
 
fragment (~ 66 kDa) 
 
fragment (~ 50 kDa) 
 
 
fragment(~ 21 kDa) 
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The overall results were consistent with the findings after SE-HPLC analysis, where also 
increased amounts of dimers were detected. 
Although a monomer loss of mabB was detected by SDS-PAGE and SE-HPLC, the system 
strongly resembled the IFNα/PEG systems described by Herrmann et al. [24, 29]. Therefore 
we decided to manufacture, mabB comprising tsc-extrudates and to investigate the release 
behavior of the antibody from these implants in-vitro. Total protein release was quantified by 
SE-HPLC analysis (280 nm), which allowed to detect and quantify the amount of aggregated 
mabB species. 
 
 
Figure 16: SDS-PAGE of re-dissolved mabB Samples were precipitated by PEG (10% or 25%) or treated 
with control buffer (PBS pH 7.4), incubated for 20 days at 37 °C on a shaker (40 rpm) and re-dissolved by 
15-fold dilution with PBS buffer pH 7.4. 
 
3.4. Production of lyophilized of mabB powder 
For the production of mabB containing lipid implants, a dry powder of mabB was prepared by 
lyophilization of mabB solutions according to Table 1. In order to find a suitable formulation 
for antibody lyophilization, various batches were prepared with either Trehalose, HP-β-CD or 
without any excipient as listed in Table 4. 
Marker             25%    10%     0%       St       St        0%     10%   25%      St.      St. 
dimer (300 kDa) 
 
 
monomere (150 kDa) 
fragment (~ 66 kDa) 
fragment (~ 50 kDa) 
 
 
fragment(~ 21 kDa) 
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Trehalose is widely described in literature as lyo- and cryoprotectant for protein drugs [212] 
and was used for the lyophilization of IFNα [28] or IgG1 antibody [213]. HP-β-CD was already 
used by Mohl et al. and Herrmann et al. for the preparation of triglyceride based implants and 
was shown to increase IFNα storage stability within the implants [24, 27, 28] compared to the 
application of sugars as matrix materials. Additionally HP-β-CD stabilized protein drugs like 
EPO during the production of PLG microcapsules by a W/O emulsion technique during 
vortexing or ultrasonication [214] and Brewster et al. noted enhanced stability of 
somatotropin and IL-2 in the presence of HP-β-CD [215]. Ressing et al. used HP-β-CD as 
lyoprotectant for IgG antibodies and found increased protein stability and activity compared 
to samples which were freeze dried with sucrose or dextran [216].  
After lyophilization of the antibody, total protein recovery and monomer content upon 
reconstitution were assessed by SE-HPLC and the water content of the lyophilisates was 
determined by Karl-Fischer titration.  
Table 4: Mixing ratios between antibody and excipients for mabB lyophilization. 
formulation excipient conc. excipient [mg/mL] conc. mabB [mg/mL] 
A - - 15 
B trehalose 45 15 
C HP-β-CD 45 15 
D trehalose 15 15 
E HP-β-CD 15 45 
F - - 30 
 
3.4.1. Total recovery of mabB after lyophilization 
Total recovery of mabB after reconstitution in incubation buffer (isotonic PBS pH 7.4) did not 
show differences between formulations and incubation at 37 °C for up to 14 days did not 
result in a loss of protein (Figure 17). Assessment of monomer content after reconstitution 
showed a decrease of the monomer content in samples A + F which were lyophilized without 
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the addition of an excipient (Figure 18). This was accompanied with an increase in dimers 
and oligomers as detected by SE-HPLC (data not shown). No differences between trehalose 
and HP-β-CD comprising formulations were detected and the antibody was stable in all 
formulations. The four formulations yielded about 95% of monomer and a total recovery of 
about 100%. In order to mimic the conditions during the release studies, samples were 
incubated at 37 °C for several days prior to analysis by SE-HPLC. Non-lyophilized mabB 
solution from bulk material was used as ´standard` and incubated at the same conditions. As 
can be seen in Figure 17 and Figure 18 no changes in monomer content and total protein 
content during the time of incubation (14 days) were observed. Thus, the protein was stable 
for at least up to 14 days in the incubation medium.  
 
 
Figure 17: Total recovery of mabB from lyophilized samples after reconstitution in PBS buffer. Samples 
were incubated upon reconstitution at 37 °C for 2 hours (t0), 24 hours (t24), 4 days (t96), 9 days (t216) and 
14 days (t336). Formulations: A – 15 mg/mL mabB without excipient, B – 15 mg/mL mabB with 45 mg/mL 
trehalose, C – 15 mg/mL mabB with 45 mg/mL HP-β-CD, D – 15 mg/mL mabB with 15 mg/mL trehalose, E – 
15 mg/mL mabB with 15 mg/mL HP-β-CD, F – 30 mg/mL mabB without excipient. 
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Figure 18: Monomer content of mabB from lyophilized samples after reconstitution in PBS buffer. 
Samples were incubated upon reconstitution at 37 °C for 2 hours (t0), 24 hours (t24), 4 days (t96), 9 days 
(t216) and 14 days (t336). Formulations: St – standard, A, B, C, D, E and F – identical to Figure 17. 
 
3.4.2. Water content of lyophilized samples 
It was shown, that water content differed strongly between formulations A-F. Samples which 
contained only the antibody but no excipient showed water content of 14.3% (m/m) and 5.6% 
(m/m) which is too high to guarantee protein stability during storage. Samples comprising 
45 mg/mL and 15 mg/mL trehalose showed residual moistures of 5.6% and 2.4% and 
formulation E which consisted of 15 mg/mL HP-β-CD showed a residual moisture content of 
3.9%. An adequate water content of 1.5% (m/m) was obtained for formulation C which 
consisted of HP-β-CD and the antibody in a ratio of 3:1 (45 mg/mL + 15 mg/mL). Although an 
optimization of the freeze-drying circle for the lowering of the residual moisture content would 
have been possible, it was decided to use formulation C for the preparation of tsc-extrudates 
for the following reasons. 
Mohl [28] and Herrmann [29] also used HP-β-CD in a ratio of 3:1 to formulated IFNα as a 
lyophilized powder and prepared triglyceride based implants thereof. Additionally, HP-β-CD 
was shown to better preserve IFNα integrity in triglyceride implants compared to trehalose 
[28] and to stabilize proteins against denaturation at interfaces [217]. This last point might be 
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of crucial importance for the delivery of protein drugs from lipid implants as the lipid matrix 
exhibit big hydrophobic surface areas and thus a large hydrophobic solid-liquid interface. 
Therefore we decided to use HP-β-CD as excipient for our mabB lyophilisate. 
 
3.5. MabB release studies from tsc-extruded lipid implants 
Release studies were carried at according to III.2.10 at two different pHs (7.4 + 4.0). This 
was done, to prove the influence of in-situ antibody precipitation within the lipid implant on 
in-vitro release kinetics. It was already shown in chapter III.3.1, that PEG was able to 
precipitated the antibody at concentrations higher than 10% at pH 7.4 but not at pH 4.0, and 
thus, these pHs were used to control the rate of release.  
 
3.5.1. Weight assessment and SEM measurement of tsc-
extrudates 
Tsc-extrudates were weighed before and after release tests on an analytical balance. 
Extrudates after release test were dried to constant weight prior to weighing as described in 
III.2.11. Weight assessment showed a decrease of implant weight of about 23% which was 
explained by dissolution and release of the water soluble parts of the implant matrix (PEG + 
HP-β-CD + mabB) (Figure 19). As only 20% of the implants consisted of water-soluble PEG 
or mabB lyophilisate an additional weight loss of about 3% was detected after in-vitro 
incubation. This weight loss was explained by a partial breakdown of the lipid matrix during 
the long in-vitro release test.  
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Figure 19: Remaining implant mass after in-vitro release tests at pH 4.0 and pH 7.4. Theoretical mass was 
calculated as total triglyceride mass (matrix). 
 
Figure 20: SEM measurement of lipid tsc-extrudates after in-vitro release test: A + B: surface of implants; 
C + D: longitudinal cross-sections of implants. Magnification: 35-fold (A + C) and 150-fold (B + D). 
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SEM measurements after release tests showed a highly porous implant matrix (Figure 20) 
with very small pores ranging in the lower µm size. The small pore size as well as the 
homogeneous distribution of the pores throughout the implant matrix was explained by the 
intensive mixing prior extrusion and during the extrusion process itself. Additionally, the 
lyophilized protein became a very fine powder after grinding and could be easily admixed to 
the lipid matrix material. Based on the SEM data and the assumption that the pores within 
the implants were created by dissolution of PEG and protein lyophilisate only, a particle size 
of the lyophilized product in the low µm range (1 - 20 µm) can be assumed. Homogenous 
drug distribution within implant matrices and small particle sizes have been successfully used 
by many authors [26, 177, 187] to achieve more sustained release profiles and are thus 
favorable for long-term release. 
 
3.5.2. MabB release from lipid tsc-extrudates 
Antibody release tests from tsc-extrudates were performed at pH 4.0 and pH 7.4. The pH of 
the incubation medium was found to have a significant effect on the precipitation capacity of 
PEG 6000 in-vitro as described in Figure 11. The antibody was easily precipitated at 
‘physiological’ conditions (isotonic PBS buffer pH 7.4) but not if the PBS buffer was adjusted 
to pH 4.0.  
MabB release from implants which were incubated at pH 4.0 was complete within 35 days 
(Figure 21 - A). The antibody was released in a sustained manner with very little initial burst 
release and a constant release phase between days 2 and 22. A total of 95% of the 
incorporated antibody mass was released. 
Protein release from tsc-extrudates at pH 7.4 was more sustained and lasted over 150 days. 
After a small burst release of 7% during the first 14 hours, the antibody was released with 
zero-order kinetics over 149 days (Figure 21). A total of 95% of the incorporated protein was 
released and samples which were analyzed by SE-HPLC revealed that the released antibody 
fractions were mainly monomeric (93-95%) which was identical to antibody bulk material 
(Figure 22). 
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Figure 21: mabB release from tsc-extrudates at pH 7.4 (open circles) and pH 4.0 (closed squares) 
comprising PEG 6000 as pore forming agent. A – release curve till complete release was achieved. B – 
close-up of release curve till day 22.  
 
Figure 22: Monomer content of release mabB as percentage of total peak areas. 
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The linear release behavior was explained by an in-situ protein precipitation step at pH 7.4 
which did not occur at pH 4.0. Upon contact with water, lyophilized PEG 6000 and mabB 
instantaneously dissolved and the protein was precipitated in a highly concentrated solution 
of PEG 6000. During release-tests PEG 6000 was diluted within the freshly formed implants 
pores and slowly washed out of the implant matrix. As a result, the PEG concentration within 
the implant pores decreased, mabB molecules re-dissolved and were finally released from 
the implant. 
Thus in analogy to IFNα [24, 29] another proteinaceous drug can be released in a linear 
manner from lipid implants due to a precipitation and re-dissolution process. However, 
comparison between the IFNα/PEG system and the mabB/PEG system reveal certain 
differences. 
 Release of mabB did not show a lag phase between burst release and the linear 
release phase which was observed in the IFNα/PEG system (Figure 23). This might 
be explained by the fact that a higher concentration of PEG is necessary to 
precipitate mabB (> 10%, Figure 10) than for the precipitation of IFNα (> 5%, [24]). 
Thus, a washing out of excessive PEG might take less time in the case of mabB re-
dissolution. 
 
Figure 23: Left: Release of IFNα from tsc-extrudates comprising 20% (open circles) and 10% (closed 
circles) PEG 6000 and 10% lyophilized IFNα. Taken from [32]. Right: Release of mabB from tsc-extrudates 
comprising 10% PEG 6000 and 10% lyophilized mabB. 
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 In-vitro release lasted for 150 days in the case of mabB but only 60 days in the 
IFNα/PEG system [32]. Thus a more sustained release profile was observed for 
mabB compared to IFNα. This is explained by two factors. Firstly, mabB has a higher 
molecular weight than IFNα (150 kDa versus 19 kDa) and thus diffuses more slowly 
within the pores of the implant. However, such a change should not result in such a 
drastic increase of the time for drug release. Secondly, we used lyophilized PEG 
6000 instead of PEG 6000 P (particle size: 60% > 200 µm, Figure 38) for the 
preparation of the mabB comprising tsc-extrudates and this resulted in an implant 
structure with very small and finely distributed pores (Figure 20). As already 
described, smaller (drug) particle sizes and a finer distribution of drug (and pore-
former) particles within the implant matrix result in a more sustained release profile 
from inert matrices [32, 177, 187].  
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4. Conclusion  
A sustained release dosage form for the delivery of a monoclonal antibody over a period of 
150 days was developed. The antibody was released mainly in its monomeric form 
throughout the incubation period and the linear release profile could clearly be attributed to a 
precipitation and re-dissolution step of the antibody.  
No additional degradation products were detected by SE-HPLC assessment and the ratio 
between monomers and dimers was identical to antibody bulk solution. This high stability of 
the antibody might be explained by the presence of HP-β-CD in the formulation which was 
shown to maintain protein stability in lipid matrices [27, 28]. 
Sustained release of the antibody was also observed at pH 4.0, where no precipitation and 
re-dissolution step was expected. Thus a major part of the sustained protein release can be 
clearly ascribed to the properties of the tsc-extrudate itself and makes them a very promising 
delivery platform to achieve long-term protein release.  
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IV. Influence of the manufacturing strategy on protein release 
kinetics from lipid based implants 
1. Introduction 
The preparation of triglyceride based implants is usually performed by compression of lipid 
powders blends which were admixed with drug and excipients [25, 27, 33, 169, 218]. In 
2007, Schulze et al. introduced a new preparation method for the manufacturing of 
triglyceride based lipid implant (tsc-extrusion [32]) which featured several advantages. The 
most important one, was a different release profile of IFNα from tsc-extrudates which was 
obviously more sustained compared to compressed implants. However, no direct comparison 
between tsc-extruded and compressed implants could be made as the matrix of tsc-
extrudates consisted of a triglyceride mixture whereas compressed implants were prepared 
from pure tristearin. The triglyceride mixture of tsc-extrudates is necessary to allow extrusion 
of the solid powder blend by tsc-extrusion and consists of two (or more) different lipids which 
are described as ‘low-melting’ and ‘high-melting’ lipid further on. The high melting lipid stays 
solid throughout the extrusion experiment whereas the low-melting lipid is (partially) molten 
during the process, leading to a softening of the powder blend and allows extrusion of the 
mixture through the extruder outlet die. 
In order to elucidate the differences between compressed and tsc-extruded implants and to 
verify a more sustained protein release from tsc-extrudates, we prepared triglyceride based 
lipid implants with equal matrix compositions by four different manufacturing processes and 
compared the release kinetics. Further on we characterized the different implants by 
scanning electron microscopy, differential scanning microscopy and X-ray diffraction 
measurements. Lysozyme was used as a model protein as it is well described in literature, 
very stable and does not precipitate in the presence of PEG which was used as pore-forming 
agent. Hereby the influence of protein precipitation on protein release from lipid implant was 
eliminated and the comparison between the different implants became easier. 
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2. Materials and methods 
2.1. Materials 
2.1.1. Lysozyme 
Hen egg white lysozyme (synonym: Muraminidase, lysozyme c) was purchased from Sigma 
as lyophilized powder (Product Number: L 6876). Lysozyme is expressed in egg white of 
chicken and is one of the best described proteins in literature. It is a single chain protein of 
129 amino acids and is cross linked by 4 disulfide bridges. Its secondary structure reveals 5 
α-helixes and 3 β-sheets. The protein shows enzymatic activity which hydrolyzes the 
peptidoglycan present in bacterial cell walls between N-acetyl-D-muraminic acid and N-
acetyl-D-glucosamine residues. The molecular weight of the protein is 14.3 kDa and its IP is 
11.4. 
 
2.1.2. Triglycerides 
Triglycerides D118 and H12 were donated from Sasol (Witten, Germany). D118 consists of 
glycerol tristearin and H12 is a mixed acid triglyceride consisting of palmitic, myristic and 
lauric acid (section III.2.9, Table 2). 
 
2.1.3. Buffer salts and chemical reagents 
PEG 6000 P was a gift from Clariant (Gensdorf, Germany). Di-sodium hydrogen phosphate 
dihydrate (Na2HPO4*2H2O), sodium dihydrogenphosphate di-hydrate (NaH2PO4*2H2O), 
potassium dihydrogen phosphate (KH2PO4), sodium chloride and potassium chloride were 
purchased from Merck (Darmstadt, Germany). Sodium azide was purchased from Acros 
Organics (Geel, Belgium). 
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2.2. Methods 
2.2.1. Lipid powder composition 
The powder mixture for the preparation of triglyceride based implants was identical for all 
manufacturing processes and consisted of D118 (tristearate – 56%), H12 (mixed acid – 
24%), PEG 6000 (17.5%) and chicken-egg white lysozyme (2.5%) (Figure 24). A single lipid 
blend was prepared for the manufacturing of all implants to guarantee identical matrix 
composition. 
 
 
Figure 24: Composition of lipid powder blend used for the preparation of lipid implants by four different 
manufacturing processes. 
 
2.2.2. Manufacturing strategies for lipid implants 
2.2.2.1. Compressed implants 
Preparation of compressed implants was performed using a hydraulic press (Maassen, 
Eningen, Germany). Template diameter was 5.0 mm and a compression force of 0.6 t was 
applied for 45 sec. About 50 mg of lipid blend was weighed into the template prior to 
compression. 
 
56.0% 
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2.2.2.2. RAM extruded implants 
RAM extrusion was performed using a purpose made extruder device. The lipid blend was 
directly extruded through the outlet dye (1.2 mm diameter) after application of sufficient 
pressure by a hydraulic press (Maassen, Eningen, Germany). RAM-extruded devices 
showed a diameter of 1.2 mm and an average length of 15 mm (Figure 25). Extrusion was 
performed at room temperature without the application of additional heat. 
 
  
Figure 25: (A) Hydraulic press for the preparation of compressed implants, RAM extrudates and 
´compressed tsc-extrudates`. (B) Purpose made RAM extruder devices with extruder rack and piston. (C) 
RAM extrudates. Pictures taken from [179]. 
 
2.2.2.3. Tsc-extruded implants 
Tsc-extrusion was performed on a MiniLab® Micro Rheology Compounder (Thermo Haake 
GmbH, Karlsruhe, Germany, Figure 4). Twin-screw extrusion was performed at a 
temperature of 41 °C through the extruder outlet die (diameter 1.9 mm). The rotation speed 
of the extruder screws was set to 40 rpm and the bypass channel was closed to inhibit 
material circulation within the extruder. 
 
A 
C 
B 
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2.2.2.4. ´Compressed tsc-extrudates` 
´Compressed tsc-extrudates` were produced by grinding of tsc-extrudates in an agate mortar 
and subsequent compression with a hydraulic press (Maassen, Eningen, Germany) as 
described for compressed lipid implants. Sample diameter was 5.0 mm and sample weight 
about 50 mg. ´Compressed tsc-extrudates` feature the geometry of compressed implants but 
the matrix material was treated in analogy to tsc-extruded implants. 
 
2.2.3. Lysozyme release studies 
Rod shaped tsc-extrudates were cut into pieces of about 20 mm length, weighed on an 
analytical balance (BP 61 S, Sartorius AG, Göttingen, Germany) and placed in 2.0 mL 
microcentrifuge tubes (VWR, Darmstadt, Germany). Compressed implants, RAM-extruded 
implants and ´compressed tsc-extrudates` were weighed and placed in 2 mL microcentrifuge 
tubes. All samples (n = 3) were incubated in 1.8 mL isotonic PBS buffer pH 7.4 containing 
0.05% sodium azide. Release studies were performed on a horizontal shaker at 37 °C 
(40 rpm, Certomat®IS, B. Braun Biotech International, Göttingen, Germany). On 
predetermined time points the incubation medium was completely removed and fresh buffer 
was filled into the tubes.  
 
2.2.4. Lysozyme concentration determination 
Samples were analyzed by SE-HPLC using a Superose column (Superose 12 10/300 GL; 
GE Healthcare, Uppsala, Sweden). The mobile phase consisted of 85.6 mmol sodium 
dihydrogenphosphate di-hydrate (NaH2PO4*2H2O) and 103.6 mmol di-sodium 
hydrogenphosphate di-hydrate (Na2HPO4*2H2O) which was adjusted to pH 6.8 by 
hydrochloric acid or sodium hydroxide. The flow rate was 0.62 mL/min and lysozyme was 
detected photometrically at 280 nm (Ultimate 3000, Variabel Wavelength Detector, Dionex 
Softron GmbH, Germering, Germany). 
IV. - INFLUENCE OF THE MANUFACTURING STRATEGY ON PROTEIN RELEASE KINETICS 
71 
 
2.2.5. X-ray diffraction measurements 
Wide angel X-ray diffraction measurements were performed on an X-ray diffractometer XRD 
3000 TTT (Seifert, Ahrensberg, Germany). Radiation was generated by a copper anode 
(40 kV, 30 mA, wavelength 0.154178 nm). Experiments were conducted at 0.05° (2 theta) 
within a 5° - 40° range. Lipid implants were ground prior to the measurements in an agate 
mortar to prepare powders from analysis. 
 
2.2.6. Differential scanning calorimetry (DSC) 
Samples were ground and about 10 mg were exactly weighed into aluminum crucibles. 
Sealed crucibles were analyzed with DSC 204 Phoenix (Netzsch, Selb, Germany). Heating 
and cooling rates were set to 5 K/min within a -20 °C to 100 °C temperature range. 
 
2.2.7. Scanning electron microscopy (SEM) measurements 
After the release tests, implants were vacuum-dried in a VO 200 vacuum chamber 
(Memmert, Schwabach, Germany) for 72 hours at 25 °C to remove all adhering water. 
Scanning electron microscopy was carried out without coating with a 6500F (Jeol GmbH, 
Eching, Germany). 
 
2.2.8. Helium pycnometry 
The volume of lipid implants was determined by helium pycnometry (He-pycnometry) with a 
accuPyc 1330 (Micromeritics, Mönchengladbach, Germany). Therefore, dry lipid implants 
were placed in a 1 mL measuring cell to make a final volume of about 500 µL (half cell 
volume) and measured after calibration of the instrument.  
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3. Results 
3.1. Lysozyme release from lipid based implants 
Lysozyme release from the different lipid implants is depicted in Figure 26. RAM-extruded 
devices showed a very high burst release and 100% of the incorporated protein was 
released within the first 24 h. Compared to this immediate delivery, implant manufacturing by 
compression resulted in a sustained release of lysozyme which lasted for 14 days until 
complete protein release was achieved. Tsc-extruded lipid implants showed a more 
sustained release over a period of 42 days. Released leveled out at about 93% indicating 
incomplete protein release. Slowest release rates were achieved from ´compressed tsc-
extrudates` (Figure 26). As implants were of different shape implant geometry and surface 
area were taken into account and a calculation of lysozyme release per surface area was 
performed. No difference between tsc-extruded implants and ´compressed tsc-extrudates` 
was found as protein release per implant surface area was identical for both formulations. 
Thus ´compressed tsc-extrudates` showed a more sustained lysozyme release only due to a 
smaller surface area compared to tsc-extrudates(Figure 27). 
Based on this observation it can be concluded that different manufacturing protocols per se 
lead to different release kinetics. Importantly, from the comparison between ´compressed 
tsc-extrudates` and tsc-extrudates it can be reasoned, that twin-screw extrusion is superior to 
compression with respect to more sustained release. Hereby, the applied heat during tsc-
extrusion might play a crucial role as RAM extrudates are produced without triglyceride 
melting and exhibit a much higher release rate than tsc-extrudates. 
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Figure 26: Lysozyme release from lipid implants which were prepared by four different manufacturing 
processes: compression, RAM extrusion, tsc-extrusion, and a combination of tsc-extrusion + 
compression (´compressed tsc-extrudates`). 
 
      
Figure 27: Cumulative lysozyme release per surface area [mg/mm
2
] from different lipid implant. (I) - 
dimensions of a tsc-extrudate. (II) - dimensions of a compressed implant. 
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3.2. Assessment of implant pore structure 
SEM measurements were performed to examine the pore structure of the different implants 
as porosity is a main factor in controlling the rate of release from inert matrices [26, 187, 219, 
220]. Obviously, RAM extrudates exhibited a very porous implant matrix even before release 
and thus rapid and complete lysozyme release can be explained easily. The surface of RAM-
extrudates was rough and the implant was very fragile and easily broke apart during handling 
(Figure 28 A).  
No pores were observed on the surface of compressed, tsc-extruded and 
´compressed+tsc-extruded` implants (Figure 28 B, C, D). All formulations showed smooth 
surfaces and a compact structure with without pores prior to incubation. Thus the different 
release kinetics between compressed and extruded implants did not result from unequal 
surface porosity of the implants.  
Implant porosity before incubation was calculated from true and apparent implant volume 
which was determined by He-pycnometry and a sliding rule, respectively. Porosities were 
calculated according to Equation 3 and showed higher values for RAM extrudates than for 
the other implants (Figure 29) which exhibited equal values. No difference in implant porosity 
or apparent implant density was detected between compressed devices and tsc-extrudates 
indicating similar matrix properties without void spaces. 
 
Equation 3    [%]1
eslidingrul
pyknometryHe
V
V 
  
ε = implant porosity [%]  
VHe-pycnometry = implant volume as determined by He-pycnometry  
Vslidingrule = implant volume as determined by sliding rule 
 
Although the fast release from RAM extrudates can be easily explained by the high porosity 
of these implants, porosities cannot be taken into account for the explanation of the different 
release profiles of the other formulations. Therefore X-ray diffraction measurements and 
DSC measurements were performed to further assess the lipid implants.  
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Figure 28: SEM pictures of the surfaces of RAM-extrudate, tsc-extrudate, compressed implant and 
´compressed tsc-extrudate` before incubation. 
 
 
Figure 29: Assessment of apparent densities (left graph) and porosities (right graph) of triglyceride based 
implants. 
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3.3. X-ray diffraction measurements 
Diffraction measurements were performed with triglyceride bulk materials, blends of bulk 
materials, ´supercooled melts` of bulk materials and with powders of ground implants (Table 
5). 
Diffraction pattern of D118 indicated the presence of β-modification with spacings at 
0.465 nm, 0.391 nm and 0.375 nm (Figure 30 – I). Diffraction pattern of H12 indicated the 
presence of β´-modification and exhibited strong spacings at 0.430 nm and 0.389 nm (Figure 
30 – II) [221]. 
 
Figure 30: X-ray diffraction pattern: D118 (I) and H12 (II) 
 
´Supercooled melts` of the bulk materials were prepared to create instable modifications of 
the triglyceride materials which could eventually be created during the melting step of the tsc-
extrusion process. Preparation of ´supercooled melts` were performed by completely melting 
of bulk materials and rapid ´supercooling` of the lipid melts by liquid nitrogen. ´Supercooling` 
of D118 resulted in a drastically changed diffraction pattern with one broad spacing at 
0.418 nm which indicated the metastable α-modification (Figure 31 – I). Interestingly, after 
´supercooling` of H12 spacings at 0.430 nm and 0.389 nm were still detectable, although an 
increase of metastable α-modification was obvious from the diffraction spectrum (Figure 31 – 
II). 
0
100
200
300
400
500
600
700
5 10 15 20 25 30 35 40
2 theta, [°]
c
p
s
0
100
200
300
400
500
600
700
5 10 15 20 25 30 35 40
2 theta, [°]
c
p
s
0.465 
0.391  
0.375 
0.430  
0.389  
* 0.418  
*  
I II 
IV. - INFLUENCE OF THE MANUFACTURING STRATEGY ON PROTEIN RELEASE KINETICS 
78 
Of course, the lipid powder blend containing H12 (24%), D118 (56%) and PEG 6000 (20%) 
(Blend A) showed a combination of the diffraction pattern of all bulk materials (Table 5). The 
identical diffraction pattern was also found in RAM-extruded and compressed implants, 
indicating no changes in lipid crystallinity due to implant manufacturing (Table 5) by 
compression or RAM extrusion.  
 
 
Figure 31: X-ray diffraction pattern: ´supercooled melt` of D118 (I) and ´supercooled melt` of H12 (II) 
 
The weak H12 spacing at 0.418 nm which was detected in H12 bulk material, and Blend A 
was lost in tsc-extruded lipid implants. Nevertheless, tsc-extrudates still exhibited high 
crystallinity (Table 5, Figure 32) and an almost perfect overlay with Blend A (Figure 32 + 
Figure 33). 
In order to mimic the extrusion process (H12 melting), Blend A was heated to 44 °C for 5 
minutes and a so called Blend B was created. Diffraction pattern of Blend B also lacked the 
spacing at 0.418 nm what was in analogy to the diffraction pattern of tsc-extruded implants 
(Figure 32 and Figure 33). The loss of the spacing at 0.418 nm in tsc-extrudates was thus 
explained by melting of the low melting lipid (H12) during the tsc-extrusion process.  
We concluded that tsc-extrusion led to a minor change (loss of spacing at 0.418 nm) in lipid 
phase properties due to the applied heat. However, crystallinity in tsc-extrudates was still 
high exhibiting a mixture of β- and β´-modification. No considerable amount of instable α-
modification was detected by X-ray diffraction measurements. 
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Figure 32: X-ray diffraction pattern of a tsc-extrudate 
 
Figure 33: Overlay of X-ray diffraction pattern of blend A (D118 + H12 (70-30%) (blue)) and blend B(D118 + 
H12 heated to 40 °C (red)). 
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Table 5: Diffraction pattern of bulk materials, lipid powder blends and lipid implants. Blend A and B 
consist of H12 (24%), D118 (56%) and PEG 6000 (20%). 
material spacings [nm] 
H12 bulk 0.462 0.430 0.418  0.389  
D118 bulk 0.465   0.406 0.391 0.374 
H12 ´supercooled` 0.445 0.429  0.406 0.389  
D118 ´supercooled`   0.418    
Blend A – 
non heated 
0.462 0.430 0.418 0.404 0.389 0.374 
Blend B – 
heated 
0.462 0.430 X 0.404 0.389 0.374 
tsc extrudate 0.465 0.430 X 0.406 0.391 0.374 
RAM-extrudate 0.465 0.430 0.420 0.406 0.391 0.374 
compressed implant 0.463 0.430 0.419 0.405 0.391 0.375 
 
3.4. DSC-measurements 
DSC measurements with ground lipid implants showed melting point depression for both 
D118 and H12 compared to the pure bulk materials (Table 6). D118 melting endotherm was 
lowered from 74.5 °C to 70.4 °C for all implants. H12 melting endotherm decreased from 
40.2 °C to 37.5 °C in RAM-extruded and compressed implants and to 35.5 °C in tsc-
extrudates or ‘compressed tsc-extrudates’. Interestingly, Blends A (non heated) and B 
(heated) performed similarly to implants prepared by RAM-extrusion/compression or tsc-
extrusion (Figure 34 and Table 6). 
A explanation for the lower melting point of H12 after tsc-extrusion is an interaction between 
H12 and D118 during tsc-extrusion (temp.: 41 °C) where the low melting lipid H12 melts or at 
least partially melts generating a eutectic with D118.  
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Table 6: Melting peaks of bulk material and lipid implants (1
st
 heating scan) 
samples melting endotherms 
H12 bulk (β´-modification) 40.2 °C   
PEG 6000  62.3 °C  
D118 (β-modification)   74.5 °C 
RAM-extrudate 37.5 °C 60 °C 70.4 °C 
compressed implant 37.5 °C 60 °C 70.4 °C 
tsc-extrudate 35.5 °C 60 °C 70.4 °C 
compressed tsc-extrudate 35.5 °C 60 °C 70.4 °C 
Blend A – non heated 38.1 °C 58.6 °C 70.4 °C 
Blend B – heated 34.6 °C 61.7 °C 70.4 °C 
 
 
Figure 34: DSC thermogram of lipid implants prepared by RAM-extrusion, compression and tsc-extrusion. 
First melting endotherm (35.5-37.5 °C) represents H12 melting, second endotherm (~ 60 °C) PEG 6000 
melting and third endotherm (70.4 °C) D118 melting. 
 
Lipid powder mixtures with different ratios between H12 and D118 (0%-100% with 10% 
increments) were prepared and DSC measurements were carried out (Figure 35) to 
investigate on the lipid phase behavior of this triglyceride mixture. 1st heating scans showed 
melting point depression of D118 from 74.6 °C (pure D118) to 58.8 °C (10% D118). No 
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significant change in melting behavior of H12 could be detected in the 1st heating scan, 
although a slight depression of the maximum of the melting endotherm from 39.7 °C to 
37.7 °C was observed (Figure 35). However, onset of H12 melting was identical in all 
triglyceride mixtures. Importantly, a 30/70 mixture of H12 and D118, which is identical to the 
lipid ratio used for implant preparation, exhibited the same melting points for H12 and D118 
as in RAM extruded and compressed implants. This indicates that the melting point 
depression observed in these devices did not result from the manufacturing process. 
 
Figure 35:DSC-measurements of a lipid powder blend containing H12 and D118 bulk material: 1
st
 heating 
scan. Lipids were step wisely mixed in ratios from 0-100% using 10% increments. Melting endotherm: 
37 °C = H12 melting; 70 °C = D118 melting. 
 
The 2nd heating scans of lipid powder mixtures showed a distinct melting point depression of 
H12 from 37.0 °C (pure H12) to 28.3 °C (10/90 - H12/D118 ) (Figure 36). The melting point 
depression of H12 in tsc-extrudates can be ascribed to the melting of H12 during tsc-
extrusion.  
The extrusion process was mimicked to confirm the assumption that the applied heat leads 
to a melting point depression of H12 in tsc-extrudates. Therefore a lipid powder mixture 
(Blend A) was placed inside the extruder barrel and heated to 44 °C for 5 min but not 
extrusion was performed (Blend B - heated). DSC melting peaks of Blend B were in good 
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agreement to the melting peaks obtained from tsc-extrudates. Thus, we concluded that the 
applied heat in the tsc-extrusion process leads to the changed melting profile of tsc-extruded 
implants (Figure 37). 
 
 
Figure 36: DSC-measurements of a lipid powder blend containing H12 and D118 bulk material: 2
nd
 heating 
scan. Lipids were step wisely mixed in ratios from 0-100% using 10% increments. Melting endotherm: 
30 °C = H12 melting; 70 °C = D118 melting. 
 
The 2nd heating scans of H12-D118 mixtures showed additional exothermic melting events 
indicating instable lipid modifications after complete melting of the lipid mixture (Figure 36). 
This is especially important, as the formation of instable modifications might lead to 
polymorphic transformation during long term storage and thus altering of release kinetics. 
Importantly no exothermic peaks were detected in tsc-extruded implants (Figure 34). From 
that, we concluded that no instable lipid modification is formed during tsc-extrusion. This is in 
good agreement with X-ray diffraction measurements, where also no instable α-modification 
was detected in tsc-extrudates. 
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Figure 37: DSC thermogram of two powder mixtures containing 24% H12, 56% D118 and 20% PEG 6000. 
Red line indicates untreated lipid powder mixture (Blend A), black line indicates the same mixture heated 
to 44 °C for 5 min (Blend B). Melting endotherms: 34.6 °C + 38.1 °C = H12 melting; 60 °C = PEG melting; 
70.4 °C = D118 melting.  
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4. Summary 
RAM-extrudates showed high initial burst release and complete lysozyme liberation within 
24 h. This release behavior was explained by the high porosity of RAM extruded devices as 
detected by SEM measurements. Compressed implants show sustained lysozyme release 
with continuous lysozyme delivery over 14 days. Tsc-extrudates and compressed tsc-
extrudates showed even more sustained lysozyme release compared to compressed 
implants. 
SEM pictures did not reveal a significant difference between compressed and tsc-extruded 
implants as both exhibit a smooth surfaces and a dense implant core.  
X-ray diffraction measurements as well as DSC measurement indicate minor changes in lipid 
crystallinity after twin-screw extrusion, which were not detected in RAM-extruded or 
compressed implants. Presumably these differences in the lipid phase properties derive from 
partial melting of the implant matrix during the manufacturing process and contribute to the 
more sustained lysozyme release from tsc-extrudates compared to compressed implants. 
Presumably, melting of matrix material led to a better coating or sealing of protein particles 
during the preparation process than simple compression. Although implant density was 
identical for compressed and tsc-extruded implants, melting might contribute to a ‘denser’ 
core by sealing of tiny channels and thus led to reduced water penetration velocity into the 
device. 
Most importantly, DSC and X-ray diffraction measurements showed the absence of instable 
lipid modifications after the extrusion process. This is of uppermost importance regarding 
long-term storage stability of the implant devices. The observed melting point depression 
simply derived from the formation of an eutectic by mixing of two triglycerides but not from 
modification changes. During tsc-extrusion, both triglycerides were thoroughly mixed and 
partially dissolve in each other, forming a stable triglyceride phase. 
Thus is was shown that tsc-extrusion per se led to a more sustained protein release and this 
effect was attributed to the melting of the low-melting lipid during the manufacturing process. 
 
 
 
  
V. – MECHANISTIC STUDIES ON LYSOZYME RELEASE FROM TSC-EXTRUDED LIPID IMPLANTS (I) 
87 
V. Mechanistic studies on the release of lysozyme from twin-
screw extruded lipid implants (I) – influence of pore-former 
and lipid composition 
1. Introduction 
In chapter 0 we showed that tsc-extrusion per se leads to a sustained release of proteins 
from triglyceride based implants and in chapter III we stated, that the release of an antibody 
or IFNα [24] can be modified by protein precipitation which allows an even more sustained 
release of the drug. However, no general work was performed so far, how release from tsc-
extrudates can be controlled. Kaewvichit et al. [187] found that protein release from 
compressed lipid implants was influenced by factors like e.g. drug particle size and drug 
loading. We decided to modify the currently used matrix composition with respect to 
triglyceride composition and properties of pore-forming agent and thereby try to modify 
protein release from tsc-extrudates. 
 
1.1. Material 
Hen egg white lysozyme was purchased from Sigma (Product Number: L 6876). Various 
grades of PEG were donated from Clariant, Wiesbaden, Germany. For our studies we used 
PEG 3350 P, PEG 4000 P/PF/PS, PEG 6000 P/PF/PS, PEG 8000 P, PEG 12000 P and 
PEG 20000 P (P = powder, PF = powder fine, PS = powder spray-dried). Salts were of 
analytical grade and purchased from Merck (Darmstadt, Germany). Sodium azide was 
purchase from Acros Organics (Geel, Belgium). Triglycerides were a gift from Sasol (Witten, 
Germany). 
 
1.2. Methods 
Methods used within these studies include the preparation of tsc-extrudates, in-vitro release 
test of lysozyme from tsc-extrudates, lysozyme quantification and SEM measurements and 
were already described in chapter IV.2.2.  
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2. Results of the influence of the pore-forming agent on 
lysozyme release 
According to the studies of Siegel [17, 222], Kaewvichit [187], Mohl [27], and Herrmann [29] 
a sufficient amount of water soluble ingredient (drug and/or pore-former) is necessary to 
allow complete drug release from inert matrices like triglyceride based implants. Upon 
hydration, the water soluble parts of the inert implant dissolve and create an interconnected 
pore network through which the active can be released.  
PEG was used by various groups [24, 179, 223-226] as pore former because it acts as a 
stabilizer and emulsifying agent and was shown to prevented aggregation and inactivation of 
proteins upon encapsulation in bioerodible polyester microspheres or stabilize BSA which 
was encapsulated in PLA-PEG microsphere blends [225, 227]. Additionally, PEG does not 
precipitated lysozyme (model protein in the study) nor does it have any adverse effects on 
lysozyme stability or integrity [228, 229]. We investigated the influence of PEG particle size, 
PEG viscosity and PEG dissolution velocity on lysozyme release from tsc-extrudates. 
 
2.1. Influence of PEG 4000 particle size on lysozyme release 
The particle size of the pore former is described to have a major influence on drug release 
profiles from inert matrixes. The larger the particle size the more likely will the particles touch 
the implant surface and the faster the drugs should be released [25, 177, 187]. A minimum 
concentration of hydrophilic component which can dissolve in water is however required to 
allow complete drug release from inert triglyceride based matrices [27, 28, 189]. By 
decreasing the porogen particle size, a finer distribution of the porogen within the implant is 
possible and the  surface area of the porogen increases. Thus a greater ratio of the 
incorporated protein drug is in direct contact with this hydrophilic component and thus a 
complete drug release is more easily to establish. However, by decreasing the particle size 
of hydrophilic components the interconnected network which has to be formed from these 
particle will also become finer and due to this a more sustained protein release can be 
achieved. This was already shown by Könnings et al. for the release of brain-derived 
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neurotrophic factor (BDNF) [177] from compressed implants. However, if particles are too 
fine it is not possible to build an interconnected network, because the particles are separated 
within the matrix which again leads to an incomplete drug release. 
In order to elucidate the effect of the size of the pore-forming agent on our system PEG 4000 
and PEG 6000 with various particles sizes were used as pore formers and extruded into lipid 
matrices. For all formulations 20% of pore former and 2.5% of lysozyme as model protein 
was used. The high concentration of pore forming agent was chosen in accordance to Mohl 
[223] und Herrmann [179]. They found that total protein release from inert compressed D118 
matrices was only possible at concentrations of more than 20% hydrophilic components. The 
triglyceride matrix of tsc-extrudates consisted of H12 and D118 in a ratio of 30/70 (m/m). 
Extrusion was performed at 40 rpm and 42 °C and in-vitro release tests were carried out. We 
used three batches of PEG 4000 and PEG 6000 powders with different particle sizes and 
determined the particle size by sieving. The size distributions for the 3 powders (´powder` = 
P, ´powder fine` = PF and ´powder fine < 45µm` = PF < 45 µm) are displayed in Figure 38. 
´Powder` and ´powder fine` were used a purchased from the supplier and ´powder fine < 
45µm` was prepared by sieving of ´powder fine`. 
 
Figure 38: Particle size distribution of various powders of PEG 4000/6000: P (powder), PF (powder fine) 
and PF < 45 µm (sieved fraction) 
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Protein releases kinetics did not differ between the formulations containing different particle 
sizes (Figure 39 + Figure 40). Lysozyme was completely released within 27 days from all six 
formulations and showed similar release behavior independent of the PEG particle size or 
PEG variety (4000 versus 6000) used. This was explained by the small implant diameter 
compared to compressed implants and by the high concentrations of the pore-forming agent. 
Nevertheless, release lasted for up to 15 days. As lower concentrations of pore-forming 
agent eventually lead to incomplete drug release, we found that adjustment of porogen 
particle size was not helpful to control the rate of protein release. 
In chapter I.1 we explained slow antibody release from tsc-extrudates with the small particle 
size of lyophilized PEG 6000. However no direct comparison between the lysozyme and 
antibody release is possible, as antibody precipitation in the presence of PEG changes the 
conditions for release drastically.  
No change between lysozyme release from implants comprising PEG 4000 or PEG 6000 
was observed in this study. The effect of different PEG qualities on protein release from tsc-
extrudates will be discussed in the next chapter. 
 
Figure 39: Lysozyme release from tsc-extrudates comprising 20% PEG 4000 of different particle sizes. 
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Figure 40: Lysozyme release from tsc-extrudates comprising 20% PEG 6000 of different particle sizes. 
 
2.2. Influence of viscosity within the implant pores 
As lysozyme release from tsc-extrudates was found to be diffusion controlled, factors like 
temperature and viscosity of the release medium within the implant pores play a crucial role 
for the release kinetics. According to the Boltzmann equation the diffusion coefficient strongly 
depends on temperature (T), hydrodynamic radius (rH) of the molecule and dynamic viscosity 
(η) of the solvent. Especially the viscosity of the fluid within the implant pores is of uppermost 
importance as it hinders water entry into and diffusion of protein molecules out of the implant. 
To investigate the influence of viscosity within the implant pores, we prepared implants 
containing various PEGs ranging from PEG 3350 to PEG 20000. With increasing molecular 
weight and increasing PEG concentration, the viscosities of PEG solutions increase. Figure 
41 depicts the viscosities of the varieties of PEG which were used for our study in a 50% 
aqueous solution at 20 °C. The maximal solubility for each PEG quality lies between 52% 
(PEG 20000) and 56% (m/m) (PEG 3350). A distinct difference between the PEG qualities 
can be observed with PEG 20000 being 30 times more viscose than PEG 3350. As all other 
crucial factors like the incubation temperature, PEG particle size (and thus pore size within 
the matrix) and the composition of the lipid matrix (H12-D118 – 30/70 (m/m)) were equal, a 
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difference in the lysozyme release profile would clearly result from a change of the viscosity 
within the implant pores. For all PEG species dissolution time did not differ significantly, if 
45% (m/m) solutions were prepared and ranged between 8 - 9 hours for complete PEG 
dissolution.  
No differences in lysozyme release rates between tsc-extrudates comprising different 
qualities of PEG were observed (Figure 42). Protein release rate was independent of the 
molecular weight of the applied PEG variety. Within 27 days lysozyme was completely 
released from all tsc-extrudates. 
Thus, viscosity of the aqueous PEG solution within the lipid implant pores has no major 
influence on the lysozyme release rate at 37 °C. Within the setup of the study the influence of 
viscosity on lysozyme release can be neglected and does not allow for an adjustment of the 
rate of release. 
 
Figure 41:Viscosities of 50% aqueous solutions of PEGs which were used for the production of tsc-
extrudates. (Data taken from certificate of analysis from supplier (Clariant, Wiesbaden, Germany).) 
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Figure 42: Lysozyme release from tsc-extruded lipid implants comprising different qualities of PEG 
ranging between PEG 3350 and PEG 20000. 
 
2.3. Influence of the dissolution rate of PEG 
In order to elucidate the influence of the dissolution rate of PEG on the lysozyme release 
kinetics from tsc-extrudates, we used fast dissolving lyophilized PEG 6000 as pore forming 
agent and compared the rate of release to PEG powder (< 45 µm). The lyophilized powder 
was ground in a mortar, sieved and the particle fraction between 0-45 µm was used to 
prepare tsc-extrudates. 
Dissolution rates of powdered PEG and lyophilized PEG were measured by dissolving 50 mg 
of each variety in 50 µL and 250 µL PBS buffer (resulting in concentrations of 50.0% (m/m) 
and 20.0% (m/m) PEG). For both concentrations, lyophilized PEG dissolved instantaneously 
(< 1 min) and the dissolution of PEG < 45 µm was clearly sustained for up to 7 hours for the 
50% solution (m/m) (Figure 43).  
However, dissolution rates of PEG 6000 were found to exhibit only a minimal influence on 
the release kinetics. During the first 2 days of in-vitro release, no difference between 
lysozyme release from tsc-extrudates containing lyophilized PEG and the powdered form of 
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PEG was found. After 9 days, protein release from tsc-extrudates containing the lyophilized 
PEG was slightly faster and complete release was achieved earlier compared to crystalline 
PEG (Figure 44). In conclusion, no major influence of the dissolution rate of the pore-forming 
agent on protein release kinetics was found.  
 
 
Figure 43: Dissolution rate of lyophilized PEG 6000 (2 vials on the left) and powdered PEG (2 vials on the 
right). A: before addition of PBS buffer pH 7.4. B: 60 seconds after addition of 50 µL (I + III) or 250 µL (II + 
IV) PBS buffer pH 7.4 
 
Figure 44: Lysozyme release from tsc-extrudates containing PEG 6000 PF < 45 µm (open squares) or 
lyophilized PEG 6000 (PEG lyo – black circles). 
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Changes in PEG particle size, PEG viscosity and PEG dissolution velocity did not 
significantly affect the rate of lysozyme release from tsc-extrudates. We therefore decided to 
further investigate the lipid matrix properties and try to adjust the rates of release by changes 
in triglyceride matrix composition. 
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3. Influence of lipid matrix composition 
3.1. Influence of the ratio between low and high melting lipid 
As described above, tsc-extrudates comprise a lipid matrix consisting of a high melting and a 
low melting lipid. To study the influence of ratio between low and high melting lipid on protein 
release, tsc-extrudates comprising lysozyme, PEG 6000 P (pore-forming agent), D118 as 
high melting lipid and H12 as low melting lipid were prepared as displayed in Table 7. The 
ratio of D118 to H12 was varied from 80-20% to 60-40%, as tsc-extrusion could be 
performed best within these limits. If higher rates of H12 were used no or only little material 
flow could be established because the lipid mixture became too soft within the extruder 
barrel. At lower ratios of H12, the torque within the extruder barrel increased and abrasion in 
the material led to blackening of the tsc-extrudates. Additionally material flow was very low at 
this conditions. 
Tsc-extrudates were prepared according to Table 7, subsequently cut into pieces and in-vitro 
release tests at pH 7.4 and 37 °C were performed. 
 
Table 7: Compositions and extrusion temperatures of tsc-extrudates. 
low melting 
lipid – H12 [%] 
high melting 
lipid – D118 [%] 
ratio 
D118:H12 
PEG 6000 
[%] 
lysozyme 
[%] 
extrusion 
temperature 
16% 64% 80-20 17.5% 2.5% 41 °C 
24% 56% 70-30 17.5% 2.5% 41 °C 
32% 48% 60-40 17.5% 2.5% 41 °C 
 
Interestingly, no influence of the amount of low melting point lipid was found at the first 
glance. Release from 80%-20% and 70%-30% D118-H122 implants were completely 
identical and 60%-40% D118-H12 was only slightly faster in the beginning of the experiment.  
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Figure 45: Lysozyme release from tsc-extrudates: influence of the ratio between low melting point and 
high melting point lipid. 
In general, our findings suggest that protein release is quite independent of the matrix 
composition between ratios of 80-20% to 70-30% (D118-H12) if a concentration of 20% of 
hydrophilic components was used. For higher amounts of H12 a slight change in the release 
profile was observed. In-vitro release from tsc-extruded implants showed to be quite robust 
concerning the composition of the lipid matrix. Grinding of tsc-extrudates and extraction of 
lysozyme showed that lysozyme was completely released from all implants. As a 
consequence, the 60-40% (D118-H12) implants did not show incomplete release but only a 
loading of 90% of the theoretical value. Thus lysozyme release from these implants was 
faster and leveled earlier than release from the other devices. A reason for the lower loading 
might lie in an incorrect weighing step or the extrusion step which was more complicated due 
to the high H12 content of these implants.  
However, protein release is clearly dominated by the highly porous implant structure which is 
created upon PEG dissolution and release.  
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3.2. Influence of the high melting lipid 
In order to study the influence of the type of high melting lipid on lysozyme release, implants 
comprising D120, D118 and D116 were prepared according to Table 8 and in-vitro release 
tests were performed in isotonic PBS pH 7.4 at 37 °C. 
As can clearly be seen in Figure 46 perfect overlays of the release profiles of the three 
different formulations were obtained. Thus no influence of the type of high-melting lipid was 
observed in this study. 
 
 
Figure 46: Lysozyme release form tsc-extrudates consisting of H12 and various high-melting lipids (D120: 
glycerol triarachin, D118: glycerol tristearin, D116: glycerol tripalmitin) 
 
Table 8: Compositions and extrusion temperatures of tsc-extrudates containing various high melting 
lipids. 
type of high 
melting point 
lipid 
high melting 
point lipid [%] 
low melting 
point lipid 
H12 [%] 
PEG 6000 
[%] 
lysozyme 
[%] 
extrusion 
temperature 
[°C] 
D120 56% 24% 17.5% 2.5% 42 °C 
D118 56% 24% 17.5% 2.5% 42 °C 
D116 56% 24% 17.5% 2.5% 42 °C
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3.3. Influence of the type of low-melting lipid 
Lipid tsc-extrudates with various low melting lipids were prepared according to Table 9. Low 
melting lipids differed in their chemical composition (mono-acid: D112 (glycerol trilaurin) + 
D114 (glycerol trimyristin); mixed-acid: E85 + H12 (lauric, myristic and palmitic acid)) and 
their melting ranges ( 
Table 10). 
Extrusion was easily possible for H12, E85 and D112 lipid powders but not for D114 
(trimyristate). No lipid tsc-extrudate could be obtained by simply loading the extruder but 
pressure was applied to the material feeding to enable extrusion.  
Table 9: Compositions and extrusion temperatures of tsc-extrudates containing various low melting point 
lipids  
type of low 
melting point 
lipid 
low melting 
point lipid 
[%] 
high melting 
point lipid – D118 
[%] 
PEG 6000 
[%] 
lysozyme 
[%] 
extrusion 
temperature 
[°C] 
H12 24% 56% 17.5% 2.5% 42 °C 
E85 24% 56% 17.5% 2.5% 45 °C 
D112 24% 56% 17.5% 2.5% 50 °C 
D114
*)
 24% 56% 17.5% 2.5% 56 °C
*) 
*)
 extrusion could hardly be performed 
 
Table 10: Endothermic DSC melting maximums and melting ranges of triglycerides as raw materials and 
within tsc-extruded lipid devices. 
 
melting peak of lipid powder 
[°C] 
melting ranges/peaks within tsc-extrudate 
[°C] 
H12 37.9 °C 29 °C – 39 °C; peak: 35.1 °C 
E85 45.8 °C 28 °C – 44 °C; peak: 42.8 °C 
D112 45.0 °C 34 °C – 46 °C; peak: 41.1 °C 
D114 58.6 °C 50 °C – XX °C
*)
; peak: 55.7 °C 
*)
 end of D114 melting peak in tsc-extrudates could not be determined due to overlap with D118 melting peak 
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Figure 47: Influence of the type of low melting point lipid on lysozyme release rate. 
As can clearly be seen from Figure 47, significant differences in the release rates between 
tsc-extrudates were found. Tsc-extrudates containing the mixed acid triglycerides H12 and 
E85 resemble each other and show identical release behaviors. However the use of the 
triglycerides D112 and D114 led to a faster release of lysozyme. This was explained by 
differences in the manufacturing process (temperatures). 
It was already state above that extrusion of the mixture comprising D114 was hardly 
possible. Finally, extrusion could only be performed at 56 °C by applying pressure onto the 
material feed and thus forcing the lipid matrix through the extruder out let die in a sort of 
RAM extrusion. Extrusion of D112 could be established easily, however, extrusion 
temperature had to be set to 49 °C. As can be observed from Figure 48 melting of PEG 6000 
starts at 46-48 °C and exhibits an endothermic melting peak at 62.2 °C. In consequence a 
melting of PEG 6000 can be expected for D114 containing extrudates during the production 
process and partial melting of PEG 6000 is expected in D112 comprising extrudates. To 
study the influence of a simultaneous melting of lipid and PEG, both substances were mixed 
and heated together to 60 °C. A phase separation was observed between both substances 
which was not surprising as triglycerides are hydrophobic per definition and PEGs are more 
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hydrophilic substances. A staining of PEG with methylene blue and of H12 with sudan red 
helped to visualize the phase separation (Figure 49). 
 
 
Figure 48: DSC thermogram of PEG 6000. Onset of melting: 47 °C; maximum of endothermic melting 
peak: 62.2 °C. Extrusion temperatures for D114 (56 °C - red) and D112 (50 °C - blue) comprising 
extrudates. 
 
 
 
Figure 49: Simultaneous melting of lipid (H12 – stained with sudan red (A)) and PEG 6000 (stained with 
methylene blue (B)) results in phase separation between both phases (C). 
It is very likely that the matrix structure of implants containing D114 and D112 differ strongly 
from the other extrudates as a melting of PEG and thus a phase separation step is involved 
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in the production. This phase separation would explain why lysozyme release from D114 
containing implants is complete within two days and implants comprising D112 show 
accelerated release rates compared to the other tsc-extrudates. As the preparation 
temperature for D112 comprising implants was lower than for D114 comprising implants, 
PEG melting is expected to be less pronounced and thus the phase separation less 
developed. SEM measurement of D114 implants before release indicate that the matrix of 
these implants differs in core structure to e.g. H12 implants (Figure 50). 
 
 
Figure 50: SEM micrographs of cross sections of tsc-extrudates. (A) D118-H12 extrudate + 20% PEG + 
2.5% lysozyme; (B): D118-D114 extrudate + 20% PEG + 2.5% lysozyme 
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4. Summary and outlook 
Lysozyme release studies from tsc-extrudates showed that tsc-extrudates were quite robust 
with respect to lysozyme release kinetics. Changes in the size of the pore-forming agent, 
increasing viscosities of the dissolving porogen or rapid dissolution of the porogen did not 
significantly affect release properties. However, high amounts of pore-forming agents were 
used in all experiments to ensure total protein release, which resulted in highly porous 
implant matrixes during the release studies and in consequence enhanced up release 
kinetics.. 
A change in the type of high melting lipid did not affect the release kinetics, which was not 
surprising due to the fact that the high melting lipid was not directly molten or affected during 
neither production nor release.  
On the contrary, a change in the type of low melting lipid from H12 to D112 or D114 resulted 
in faster protein release. This was explained by the manufacturing process of these implants 
from lipid-PEG mixtures during which a phase separation process happens between molten 
PEG and molten low melting lipid. Tsc-extrudates with the low-melting lipids H12 and E85 
exhibited identical and sustained lysozyme release rates. 
Melting (or partial melting) of the implants during manufacturing and release turned out to be 
of major importance to completely understand the system. Melting was shown to lead to 
subtle changes in implant structure after manufacturing (chapter 0) and resulted in phase 
separation between PEG and the low-melting lipids D112 or D114. Additionally, DSC 
measurements showed that implant melting can be expected during release tests at 37 °C. 
Therefore we decided to further investigate the influence of partial implant melting on protein 
release kinetics as described in chapter 0.  
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VI. Mechanistic studies on the release of lysozyme from twin-
screw extruded lipid implants (II) – influence of implant 
melting 
1. Introduction 
During the production of tsc-extrudates, the (partial) melting process of the low-melting lipid 
was found to be of major importance for the explanation of the long-term release of proteins 
from these implants. Melting (and tsc-extrusion) was found (I) to allow extrusion at gentle 
temperatures, (II) to increase implant density and to seal tiny pores, (III) to fuse the different 
triglyceride powder components and (IV) to lead to a very homogeneous distribution of the 
protein within the implants. DSC measurements of tsc-extrudates revealed that a phase of 
molten triglyceride must also be present during in-vitro release tests and might affect protein 
release rates. Therefore we conducted lysozyme release studies from different tsc-
extrudates at various temperature. Additionally, we changed the amount of pore-forming 
agent in order to identify a ´percolation threshold` for the newly developed triglyceride based 
implant system and to study the mechanism of protein release. 
 
 
 
 
  
VI. - MECHANISTIC STUDIES ON LYSOZYME RELEASE FROM TSC-EXTRUDED LIPID IMPLANTS (II) 
109 
2. Materials and methods 
2.1. Materials 
The monoacid lipid triglyceride glycerol-tristearin (Dynasan 118, micronized) as well as the 
mixed-acid lipid triglycerides H12 and E85 were kindly provided by Sasol GmbH (Witten, 
Germany). Mixed-acid lipid triglycerides Gelucire 33/01, Gelucire 39/01 and Gelucire 43/01 
were a gift from Gattefossé (Saint Priest, France). The composition of the triglycerides is 
summarized in Table 11. Polyethylene glycol 4000 PF (PEG 4000) and 6000 P (PEG 6000) 
were donated from Clariant (Gendorf, Germany). Chicken egg white lysozyme (L 6876) was 
purchase from Sigma-Aldrich as lyophilized powder. All salts used were of analytical grade 
and purchased from Merck (Darmstadt, Germany).  
Table 11: Composition of lipid triglycerides 
Triglyceride type D118 H12 E85 
Gelucire 
33/01 
Gelucire 
39/01 
Gelucire 
43/01 
C8 fatty acid, %  - - 9 2 2 
C10 fatty acid, %  - - 7 3 2 
C12 fatty acid, %  71 27 48 43 33 
C14 fatty acid, %  27 71 17 14 11 
C16 fatty acid, %  2 2 8 10 15 
C18 fatty acid, % 100 - - 9 27 37 
 
2.2. Preparation of lipid twin-screw extrudates (tsc-extrudates) 
Lipid twin-screw extrudates were prepared as described by Schulze et al. [32] with a Haake 
MiniLab® Micro Rheology Compounder (Thermo Haake GmbH, Karlsruhe, Germany). In 
brief, a lipid powder blend comprising D118 as high melting lipid and H12, E85, Gelucire 
33/01, Gelucire 39/01 or Gelucire 43/01 as low melting lipid was mixed with varying amounts 
of PEG (0-40%) and 2.5% of lysozyme as model protein. Extrusion temperature was set 
slightly above the melting maximum of the low melting lipid (Table 12) and extrusion of rod-
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shaped implants was performed through a 1.9 mm outlet die in steady-state mode with 
closed bypass. The compositions of the lipid tsc-extrudates are summarized in Table 13. 
 
Table 12: Melting temperatures of triglyceride bulk materials 
Triglyceride type 
onset of melting as 
determined by DSC, °C 
melting maximum as 
determined by DSC, °C 
H12 29 °C 39 °C 
E85 20 °C 41 °C 
Gelucire 33/01 8 °C 27 °C 
Gelucire 39/01 15 °C 39 °C 
Gelucire 43/01 21 °C 43 °C 
 
Table 13: Composition of lipid tsc-extrudates 
No. low melting lipid high melting lipid pore forming agent model protein 
1 H12 – 22.5% D118 – 52.5% PEG 6000 – 22.5% 
lysozyme 2.5% 
2 E85 – 22.5% D118 – 52.5% PEG 6000 – 22.5% 
3 Gelucire 33/01 – 22.5% D118 – 52.5% PEG 6000 – 22.5% 
4 Gelucire 39/01 – 22.5% D118 – 52.5% PEG 6000 – 22.5% 
5 Gelucire 43/01 – 22.5% D118 – 52.5% PEG 6000 – 22.5% 
6 H12 – 29.25% D118 – 68.25% PEG 4000 – 0% 
7 H12 – 27.75% D118 - 64.75% PEG 4000 – 5% 
8 H12 – 26.25% D118 – 61.25% PEG 4000 – 10% 
9 H12 – 24.75% D118 – 57.75% PEG 4000 – 15% 
10 H12 – 23.25% D118 – 54.25% PEG 4000 – 20% 
11 H12 – 17.25% D118 – 40.25% PEG 4000 – 40% 
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2.3. Differential scanning calorimetry (DSC) 
Twin-screw extrudates were ground in an agate mortar and approximately 10 mg were 
analyzed in sealed Al-crucibles. Measurements were performed with DSC 204 Phoenix 
(Netzsch, Selb, Germany) with heating and cooling rates of 10 K/min in a temperature range 
from 5 °C to 90 °C. 
 
2.4. Wide-angle X-ray scattering (WAXS) 
Wide-angle X-ray scattering (WAXS) was performed by an X-ray Diffraktometer XRD 3000 
TT (Seifert, Ahrensberg, Germany), equipped with a copper anode (40 kV, 30 mA 
wavelength 0.154178 nm). Experiments were conducted at 0.05° (2 theta) within a 5° - 40° 
range. 
 
2.5. In-vitro release tests 
Lipid implants were cut into pieces of approximately 2.5 cm length, placed into 2.0 mL safe 
lock reaction tubes (Eppendorf AG, Hamburg, Germany) and incubated in 1.9 mL 0.01 M 
isotonic phosphate buffered saline (PBS) pH 7.4 containing 0.05% NaN3 as preservative. 
Release tests at various temperatures were performed with implants consisting of D118, 
H12, PEG 6000 (22.5%) and lysozyme (2.5%) (Table 13). The tubes were placed in water 
baths at 20 °C, 25 °C, 33 °C, 35 °C, 37 °C and 40 °C (Julabo SW-20C, Julabo Labortechnik 
GmbH, Bad Seelbach, Germany) and temperature controls showed, that the temperature 
was constant within a range of +/- 0.3 K during the experiment. All other release experiments 
were performed in water baths at 37 °C. Samples were drawn by complete exchange of the 
incubation medium and centrifuged with a Sigma 4K15 centrifuge (Sigma, Osterode am 
Harz, Germany). The supernatant was assessed UV-photometrically at 280 nm with a 
FluoStar Omega plate reader (BMG Labtech GmbH, Offenburg, Germany).  
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2.6. Protein extraction from lipid implants 
Implants were ground in an agate mortar, incubated with PBS pH 7.4 and heated to 60 °C for 
5 min in a Thermomixer Comfort (Eppendorf, Germany) at 40 rpm. Afterwards, the samples 
were cooled down, centrifuged and the protein concentration in the aqueous phase was 
determined by UV measurements at 280 nm with a FluoStar Omega plate reader (BMG 
Labtech GmbH, Offenburg, Germany). Protein extraction from freshly prepared implants 
showed a recovery of 98.2% ± 1.3% (n = 6). 
 
2.7. Assessment of implant weight and weight loss 
After the protein release studies tsc-extrudates were dried to constant weight in a vacuum 
dryer (Memmert, Schwabach, Germany) at 20 °C and 50 mbar and weighed on an analytical 
balance (d = 0.1 mg, Sartorius BP 61S, Sartorius, Göttingen, Germany). Implant weight loss 
(WL) was calculated from the implant mass before (mbefore) and after incubation (mafter). 
Theoretical implant weight loss (theoWL) was calculated from theoretical amounts of water 
soluble components per implant (PEG 4000 and lysozyme). 
 
2.8. Scanning electron microscopy (SEM) 
After in-vitro release implants scanning electron microscopy was performed with a 6500F 
(Jeol GmbH, Eching, Germany) without further processing or a coating step.  
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3. Results 
3.1. Preparation of lipid twin-screw extrudates. 
Preparation of lipid tsc-extrudates was possible for all formulations. To allow preparation of 
smooth lipid extrudates the extrusion temperatures were set slightly above the melting 
temperature of the low melting lipid, which resulted in a softening of the lipid mass within the 
twin-screw extruder. If the extrusion temperature was set too high, no material flow could be 
established, because no torque was built up in the extruder barrel.  
 
3.2. Lysozyme release at various temperatures  
During in-vitro release tests with tsc-extrudates consisting of H12, D118, PEG 6000 (22.5%) 
and lysozyme (Table 13 – formulation 1) at various temperatures all implants stayed solid 
and kept their shape. A major impact of temperature on lysozyme release was detected 
(Figure 51). With increasing incubation temperature lysozyme was released faster from the 
tsc-extrudates. Complete lysozyme release was achieved for incubation temperatures 
between 33 °C and 40 °C within 20 days and the release kinetics resembled each other. 
However, at 20 °C or 25 °C the release rates were much lower and release lasted for up to 
200 days (data not shown), finally liberating only 80% of the incorporated protein. The 
borderline between fast (33 °C – 40 °C) and sustained (20 °C – 25 °C) lysozyme release was 
found at 29 °C where the lysozyme release rate was significantly higher than at 20/25 °C 
however lower than at 33/40 °C. Additionally, the protein was not completely released at 
29 °C but approximately 15% remained trapped in the matrix. From all samples the 
remaining lysozyme mass was quantified after extraction from the matrix and the missing 
protein (15-20%) could be recovered. 
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Figure 51: Lysozyme release from lipid tsc-extrudates at various temperatures. Extrudates consisted of 
52.5% D118, 22.5% H12, 22.5% PEG 6000 and 2.5% lysozyme (Table 13 – formulation 1). 
 
3.3. Lysozyme release from lipid implants comprising various low 
melting lipids 
Implants prepared according to Table 13 (formulation 1-5) did not show any difference in 
protein release at 37 °C. All implants released 100% of the incorporated lysozyme mass 
within 16 days (Figure 52). However, when the release tests were performed at 20 °C 
significant differences between the formulations were found. Extrudates comprising D118 
and Gelucire 33/01 or Gelucire 39/01 released the protein much faster than D118/H12 
containing implants (Figure 53).  
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Figure 52: Lysozyme release from lipid extrudates comprising D118, PEG 6000 (22.5%) and different low 
melting lipids at 37 °C. 
 
 
Figure 53: Lysozyme release from lipid extrudates comprising D118, PEG 6000 (22.5%) and different low 
melting lipids at 20 °C.  
3.4. Lysozyme release with various amounts of pore forming agent 
With increasing amounts of pore forming agent (PEG 4000) lysozyme was released faster 
from the implants at 37 °C (Figure 54). For samples comprising more than 15% of pore 
forming agent complete lysozyme release was achieved within 25 days of incubation. 
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Interestingly samples comprising only 5-15% PEG also released more than 90% of the 
embedded protein and even the samples which consisted of triglyceride, no PEG and 2.5% 
lysozyme, released 83% of lysozyme within 240 days. A reduction of the incubation 
temperature to 20 °C resulted in incomplete drug release from samples comprising no PEG 
4000 and about 90% of the protein remained trapped in the triglyceride matrix. 
 
 
Figure 54: Lysozyme release from lipid extrudates comprising D118, H12 and various amounts of PEG 
4000 at 20 °C (□) and 37 °C. (B) is a close-up of (A) depicting the first 30 days of release. 
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3.5. Scanning electron microscopy of tsc-extrudates after in-vitro 
release 
Scanning electron microscopy (SEM) images of H12-tsc-extrudates with 0%, 5% or 10% 
PEG showed a dense implant core after 240 days of incubation (Figure 55 – E, F, G). 
However, the sample surfaces were rough and broken (Figure 55 – A, B, C). Samples 
comprising 20% PEG showed a porous implant core (Figure 55 – H) and well defined pores 
embedded into a smooth implant surface after only 60 days of incubation and a ´mantel 
zone` surrounded the implant core. This mantel tended to break from the implant during in-
vitro release and could easily be scrapped off the implant after incubation.  
 
3.6. Result of DSC measurements 
DSC measurements of tsc-extrudates directly after preparation did not indicate unstable 
modifications which could be attributed to the preparation process (Figure 56). All samples 
showed melting endotherms at 70 °C and 60 °C which derived from D118 and PEG 6000 
melting respectively. Melting temperatures of high and low melting lipids showed a slight 
depression after extrusion compared to bulk materials (e.g. D118: 74 °C – 70 °C; H12: 39 °C 
– 35 °C). This can be explained by the formation of an ´eutectic system` or a ´monotectic 
partial solid solution` during the manufacturing process at which the low melting lipid was 
molten and re-crystallized in the presence of the high melting lipid [230].  
The mantel layer of long-term incubated implants (240 days) showed a depletion of H12 and 
only minimal amounts of the low melting lipid could be detected whereas the peak for the 
D118 melting endotherm was very prominent (Figure 56). 
After in-vitro release a distinct influence of the incubation temperature on the melting 
behavior of H12 in tsc-extrudates could be detected. At temperatures of 33 °C, 35 °C and 
37 °C different ratios of H12 within the implants were molten during the release tests which 
resulted in altered DSC thermograms of tsc-extrudates after the release-test (Figure 57). 
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Figure 55: SEM micrographs of surfaces and cross-sections of lipid extrudates after incubation. Samples 
A+E: 0% PEG – 250 days of incubation, B+F: 5% PEG – 250 days of incubation; C+G: 10% PEG – 250 days 
of incubation, D+H: 20% PEG – 60 days of incubation. Dotted line (E-G): borderline between fragile mantel 
layer and dense implant core. 
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Figure 56: DSC thermograms from bottom to top: bulk materials (Gelucire 33/01, Gelucire 39/01, Gelucire 
43/01, H12, E85 and D118); extrudates before incubation consisted of D118, PEG 6000 and different low-
melting lipids (Gelucire 33/01, Gelucire 39/01, Gelucire 43/01, H12 and E85); mantel layer of extrudates 
(D118/H12) after 240 days of incubation. 
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Figure 57: DSC thermograms of D118/H12/PEG 6000 extrudates from top to bottom: before release (60 °C 
- PEG melting, disappears upon incubation), after incubation/release at 37 °C, 35 °C and 33 °C. Squares 
(■) indicate the incubation temperatures during the release tests. 
 
3.7. Results of X-ray measurements 
X-ray measurements after preparation of tsc-extrudates indicated the presence of β- and β´-
modifications of the lipids (Figure 58). Reflections occurred at 2θ=19.45  d=0.46 nm, 
2θ=23.30  d=0.39 nm, 2θ=24.35  d=0.37 nm and reflections of lower intensities occurred at 
2θ=21.0  d=0.42 nm and 2θ=22.40  d=0.41 nm. The strong diffraction lines at 0.46 nm, 
0.39 nm and 0.37 nm indicated β-modification of the lipid extrudates whereas the weaker 
diffractions lines at 0.42 nm and 0.41 nm derived from minor amounts of β´-modifications 
[221, 230]. Pure D118 and pure H12 exhibited β- and β´-modifications respectively [32].  
After in-vitro release, a more distinct reflection pattern was observed from all samples (Figure 
59). The diffraction lines were sharper und narrower; however, the position of the diffraction 
lines did not alter. In addition, the β´-spacing at 0.41 nm was found to be more prominent in 
these samples than before the in-vitro release test. These findings indicate an increase in 
crystallinity of the remaining implant rods after the release test. 
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Figure 58: Diffraction pattern of tsc-extrudates directly after preparation. From top to bottom: extrudates 
comprising D118/H12, D118/E85, D118/Gelucire 43/01, D118/Gelucire 39/01 and D118/Gelucire 33/01. 
 
Figure 59: X-ray diffraction measurements of tsc-extrudates after in-vitro release. From top to bottom: 
extrudates comprising D118/H12, D118/E85. D118/Gelucire 43/01, D118/Gelucire 39/01 and D118/Gelucire 
33/01.  
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3.8. Assessment of implant weight 
Implant weight loss (WL) after incubation was compared with a theoretical weight loss 
(theoWL) as calculated from the total water soluble load. Weight losses in long-term 
incubated samples (240 days, 37 °C – grey bars. 0-15% PEG) were higher than the 
theoWLs. Incubation at 20 °C did not result in a mass loss of the tsc-extrudates (Figure 60).  
 
Figure 60: Checked bars: theoretical weight loss (theoWL); grey bars: weight loss (WL) after 240 days of 
incubation at 37 °C (0-15% PEG) and 20 °C (0% PEG); white bar: weight loss after 240 days of incubation 
(0% PEG) at 20 °C.  
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4. Discussion 
4.1. Lysozyme release at various temperatures 
Partial melting of the implant matrix during in-vitro release was expected at 37 °C and was 
confirmed by DSC measurements (Figure 56 + Figure 57) This partial implant melting was a 
consequence of the application of a ´low-melting` lipid during the preparation process (Table 
12).  
Lysozyme release tests from H12/D118 implants (Table 13: formulation 1-5) showed 
accelerated protein release with increasing incubation temperature. This was – in general – 
not surprising as faster dissolution times and higher diffusion coefficients of both PEG 6000 
and lysozyme correlate with increasing temperatures. A closer look at the data, however, 
showed a highly accelerated release, when the temperature was increased from 25 °C to 
29 °C. At temperatures at and above 29 °C nearly complete lysozyme release from the 
implants could be established whereas 20% of the protein mass remained trapped within the 
implant at 20 °C and 25 °C after 240 days of incubation (data not shown). At 29 °C an 
intermediate or borderline release profile was detected between slow/incomplete releasing 
implants at 20/25 °C and fast/complete releasing implants at 33/40 °C. Interestingly, 29 °C 
was determined to be the onset of melting of H12 within tsc-extrudates (Figure 56). Thus, at 
20/25 °C and without melting of the low melting lipid 15-20% of lysozyme were trapped within 
the lipid matrix und could not be released into the buffer medium. At 29 °C, the matrix started 
to soften leading to accelerated release profiles and a higher amount of totally released 
protein. At 33/40 °C increasing fractions of the low-melting lipid were molten which allowed 
complete drug release (Figure 57). The release was found to be very robust towards 
changes in incubation temperature if the temperature was set at or above the melting range 
of the low melting lipid. However, the high amount of water-soluble excipient (22.5% PEG 
6000) led to the rapid formation of highly porous implants and allowed fast protein release 
from the matrix. Thus only a minimal influence of partial implant melting on the release 
kinetics was detected if the incubation temperature was set at or above the melting 
endotherm of the low-melting lipid. 
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4.2. Lysozyme release from implants comprising various low 
melting lipids 
Release tests with implants comprising different low melting lipids (Gelucire 33/01, Gelucire 
39/01, Gelucire 43/01, E85, H12 - Table 13) were performed at 20 °C and at 37 °C, to further 
investigate the influence of melting on the release kinetics. The lipids show different onsets 
of melting as bulk materials and within the tsc-extruded implants. It turned out that all 
implants released the model protein with similar release kinetics at 37 °C (Figure 54) which 
was well above the onset of melting for all implants. Complete drug release was achieved for 
all formulations which can be explained by a sufficient amount of pore-forming agent (22.5%) 
as well as by the partial melting of the implants. The system was very robust towards an 
exchange of the low-melting lipid at an incubation temperature of 37 °C. 
On the contrary, at 20 °C the physical state of implants differed from each other. Onsets for 
melting as measured by DSC started below the incubation temperature (20 °C) for 
extrudates comprising Gelucire 33/01 and Gelucire 39/01 but no for D118/H12 extrudates 
(distinct onset: 29 °C, Figure 56). In-vitro release tests showed that lysozyme release from 
tsc-extrudates containing H12 was more sustained (> 200 days) and incomplete (78%) 
compared to implants containing Gelucire 33/01 or Gelucire 39/01 (Figure 55). These 
findings correlated well with the results from the temperature dependent release study and 
showed again, that melting enabled faster and more importantly total drug release.  
 
4.3. Lysozyme release from implants comprising various amounts 
of pore forming agent 
During the first experiments lysozyme release was influenced by the high porosity the matrix 
and the protein was probably released through an interconnected pore-network. Various 
authors have described a minimum amount of water soluble compounds also known as 
´percolation threshold` [26, 222, 231] or ´critical porosity value` [219] to be necessary for 
complete drug release from insoluble hydrophobic matrices. This percolation threshold 
depends on the size, shape, loading and physical properties of the implant or dosing form. 
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Percolation thresholds ranging between 5% and 40% have been described in literature for 
various applications. Herrmann et al. [29] found a minimum of 20% of hydrophilic 
components necessary to allow total release of recombinant human interferon α2a release 
from compressed tristearin based implants. Bonny and Leuenberger identified porosities of 
30% as sufficient for total drug release according to the percolation theory from tablets 
comprising hydrogenated castor oil [219]. Könnings et al. found that total lysozyme release 
from compressed implant was possible for lysozyme loads of only 5%, however, the implants 
were only 2 mm in diameter and 2.2 mm in height [26]. 
In order to determine a percolation threshold for tsc-extrudates (diameter: 2 mm length: 
2.5 cm) the amount of the pore former (PEG 4000 PF) was varied between 0% and 40% 
(w/w).  
Lysozyme release tests at 37 °C showed that increasing amounts of PEG 4000 PF led to 
accelerated protein release which can be explained by a more rapid formation of an 
interconnected pore-network throughout the implant (Figure 54). 
Interestingly, lysozyme was also almost completely released from implants comprising no or 
only low amounts of PEG (10%, 5% or 0%). Lipid implants released a total 90% of the 
incorporated protein mass if only 2.5% of the implant matrix consisted of hydrophilic 
components (lysozyme + 0% PEG). Total release was achieved by the addition of only 5% 
PEG to give a total of 7.5% hydrophilic components.  
All implants showed burst release within the first 12 hours of incubation liberating 5-10% of 
the incorporated protein mass which was probably in close proximity to the implant surface. 
After burst release implants comprising high amounts of PEG (40%-15%) showed “normal”, 
diffusion controlled release profiles until all lysozyme was released.  
On the contrary, diffusion controlled release was observed from implants with less pore 
former only during the first days of incubation. Afterwards, a linear release phase appeared 
which lasted for several weeks (Figure 54). Implants comprising no PEG showed a burst 
release of 10% followed by a quasi-linear release phase up to day 150. When release tests 
were performed at 20 °C, identical implants (0% PEG) only showed a burst release of about 
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10% and directly leveled into a plateau phase without further release of lysozyme. Thus, at 
20 °C and without partial implant melting, 90% of the protein remained trapped in the matrix. 
However, at 37 °C partial implant melting facilitates total drug release and led to a sustained 
release profile lasting for weeks. In 2009 Schulze et al. described a different method to 
achieve sustained release of rhIFNα2a from tsc-extrudates. They used a protein precipitating 
agent and accomplished linear protein release for up to 60 days [32]. However, no such 
protein precipitating agent is necessary to achieve sustained protein release from tsc-
extrudates at low-loadings. In addition, no pore-forming agent is necessary to facilitate nearly 
complete drug release. Thus the determination of a ´percolation threshold` is not possible as 
partial implant melting allows protein release from the matrix at 37 °C but not at 20 °C 
although the implant composition is identical. Moreover, lysozyme release from tsc-
extrudates follows a novel release mechanism which is based on the melting of the low 
melting lipid during release and does not necessarily need a percolation threshold to allow 
complete protein release. By application of a pore-forming agent a biphasic release can be 
achieved after the initial burst release. In the beginning dissolution and diffusion of PEG and 
protein control the release kinetics and after liberation of the pore-forming agent a melting 
associated release takes over. At PEG concentrations above 10%, no melting associated 
linear release phase could be detected in the release profile any more. 
The influence of melting on the lipid implant composition was also investigated by monitoring 
the weight loss of long-term incubated implants (240 days). A higher weight loss than 
expected from theoretical calculations was detected (assuming no chemical degradation of 
lipids in-vitro). Samples (0% PEG, 2.5% lysozyme) which were incubated at 20 °C for 240 
days (Figure 60) even showed less weight loss than expected, which was explained by 
incomplete protein drug release. It is very likely, that ´non-molten` low-melting lipid sealed 
lysozyme particles from contact with release medium and thereby inhibited release of the 
protein from the dense implant matrix. Thus an erosion of the triglyceride matrix was only 
detected after in-vitro incubation in PBS buffer for 240 days at an incubation temperature of 
37 °C. Interestingly, Schwab et al. showed that the lipid composition of tsc-extrudates 
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improved lipase induced degradability in-vitro compared to compressed implants of pure 
D118. They found that tsc-extrudates were well degradable by an lipase-assay [33] and 
ascribed it to the implant composition. Especially, the presence of the low-melting lipid 
rendered the implant better degradable due to (I) faster cleavage of fatty acids with shorter 
chain-length and (II) partial melting of the implant during incubation. From our data, we 
conclude, that partial melting of the implants might lead to better degradation of 
tsc-extrudates in-vitro and in-vivo and to allow protein release in-vitro. 
SEM measurements of long term incubated samples also showed erosion processes and 
more fragile implant structures of long-term incubated samples at 37 °C compared to 
samples which were incubated for 60 days only (Figure 55) or at 20 °C (data not shown). The 
formation of a ´mantel layer` around the implants was observed (Figure 55- E, F, G) and this 
fragile zone easily broke off and consisted mainly of D118 as confirmed by DSC 
measurements (Figure 56). Interestingly, it took a rather long time until a change in the 
matrix composition occurred and the formation of the mantel layer could be detected. We 
conclude that the depletion of H12 from this mantel layer rendered this zone more fragile and 
led to an increase in porosity of the implants. Implant porosity and thus the ability of water to 
intrude into the matrix was determined to be one of the most important factors for the release 
of drug substance [26, 170, 232] No change between the ratios of D118 and H12 was 
detected in the implant ´core`, which might explain the incomplete drug release (80%) from 
samples without PEG 4000. Samples which were incubated for 60 days only showed a 
porous implant structure which only derived from the dissolution and liberation of PEG and 
lysozyme (Figure 55 - H). However, after 240 days of incubation no such pores could be 
observed anymore in implants comprising 5% or 10% PEG (Figure 55 - F, G) which was 
explained by merging and rearrangement of lipid material due to melting.  
 
4.4. X-ray diffraction measurements 
X-ray diffraction measurements showed an increase in β- and β´-modification and higher 
crystallinity after in-vitro release. This can be explained by two complementary factors. First, 
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a tempering of the lipid during in-vitro release at 37 °C might have resulted in a reordering of 
the lipid chain structure thus an increase in the overall crystallinity of the implant. Similar 
effects were already described before to alter the drug release rates from lipid matrix 
systems [233-235]. Additionally, a loss of low-melting lipid as detected by DSC measurement 
from the mantel zone might have resulted in an increase of D118 concentration and thus a 
higher fraction of lipids with β-modification. Loss of H12 resulted in a more fragile and porous 
implant structure (Figure 55) which again resulted in accelerated protein release.  
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5. Conclusion 
The influence of lipid melting on the in-vitro release of lysozyme from twin-screw extruded 
triglyceride based implants was examined. It was found that partial melting of the matrix 
facilitated total protein release from the implant and led to erosion of the lipid matrix in-vitro. 
Higher incubation temperatures resulted in accelerated lysozyme release. However, the 
release kinetic was quite robust if the incubation temperature was above the melting range of 
the low melting lipid. Additionally, the release kinetic was found to be independent of the type 
of low-melting lipid when partial melting occurred. As minor temperature variability is a 
common incidence in-vivo, these findings are important regarding the in-vivo applicability of 
tsc-extrudates.  
The protein was released from the implant even without addition of a pore-forming agent, 
indicating a ´new` melting-induced release mechanism. Hereby, the triglyceride based 
implants softens - but does not instantaneously degrade – and allows long term protein 
release. If protein release was performed without partial implant melting, a ‘non-release’ of 
the protein (despite 5-10% burst release) was observed. 
DSC measurements indicated a depletion of H12 from the triglyceride matrix during long 
term incubation, and X-ray measurements showed an increase in the crystallinity of the 
triglycerides. Both findings were ascribed to the partial melting and tempering of the implant 
during incubation. The melting of the low melting lipid facilitated a nearly complete and linear 
release of lysozyme over more than 150 days.  
A mass loss of the matrix material after in-vitro long-term incubation was detected. This 
finding can be explained by depletion of molten H12 from the matrix which in consequence 
rendered the implant more fragile and prone to degradation and erosion.  
We concluded that partial melting of the implant facilitated complete drug release, allowed a 
linear release profile and will induce a better degradability of this system. We suggest that by 
choice of a suitable implant composition long-term protein drug release from tsc-extrudates 
with subsequent biodegradation of the triglyceride matrix material is feasible in-vivo.  
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VII. In-vivo biodegradability of lipid twin-screw extruded 
implants in rabbits 
1. Introduction 
A major obstacle in the development of a sustained release device is the choice of a suitable 
matrix material and an appropriate processing method. Usually, materials which are used for 
the manufacturing of implant matrices are processed at elevated temperatures (e.g. melt 
extrusion) and/or by the use of organic solvents [17, 236]. Both factors have a negative 
impact on protein stability during processing as they can lead to protein unfolding, 
denaturation and aggregation. Additionally, the matrix material should be biodegradable to 
avoid a surgical intervention for the removal of the implant after total/complete drug release. 
However, the commonly used biodegradable polymers poly-lactic acid (PLA) or poly-lactic-
co-glycolic acid (PLGA) are often not applicable. During matrix degradation lactic and glycolic 
acid is produced which in consequence leads to an increase in osmotic pressure and a pH 
drop within the matrix which may result in protein acylation, deamidation or aggregation [69, 
71, 237]. 
In order to overcome these limitations lipidic substances have been under investigation as 
implant matrix materials for protein drugs [18]. Lipids are natural substances and were shown 
to be biocompatible in various studies [31, 174, 177, 238]. For example, compressed 
tristearate implants (D118) were well biocompatible in-vivo over a period of 28 days in rabbits 
[31] and compressed tripalmitate implants (D116) over a period of 60 days in mice [23]. 
Additionally these substances (e.g. triglycerides, fatty acids) are inexpensive, easy to handle 
and have been shown to maintain the stability of proteins drugs during storage and release 
[18, 28, 32]. Different lipidic substances have been used for the preparation of sustained 
release dosage forms for protein drugs and multiple manufacturing methods have been 
proposed [18, 159, 177, 239, 240]. The preparation of solid implants is usually performed by 
compression of e.g. cholesterol [19, 23, 240], free fatty acids [19, 171] or triglycerides [25, 
27, 31, 172] and is the most commonly used method. However, neither compressed 
triglyceride based implants nor cholesterol based implants showed any sign of erosion after 
VII. – IN-VIVO BIODEGRADABILITY OF TWIN-SCREW EXTRUDED IMPLANTS IN RABBITS 
132 
in-vitro and in-vivo release studies in species such as rabbit, mice, and sheep, which renders 
the systems unfavorable [23, 27, 31, 240]. Additionally, the use of free fatty acids and 
phospholipids has been shown to induce inflammatory reactions in mice and these are thus 
not first class substances [23] for the preparation of solid implants. 
Recently, Schulze et al. described a new manufacturing technique for triglyceride-based 
protein loaded implants: tsc-extrusion (see I.3.1.8). This method features the advantage of a 
steady-state production process at moderate temperatures which secures the stability of the 
protein drug during manufacturing. 
Schwab et al. compared the degradability of compressed and tsc-extruded lipid implants with 
an in-vitro lipase assay and found that tsc-extrudates were better degradable [33]. The 
matrices of compressed implants were not affected by incubation in lipase solutions, 
however a breakdown of the matrices of tsc-extrudates was observed. This was explained by 
(I) the composition of the lipid matrix as well as by (II) the structure of lipid tsc-extrudates 
resulting from the extrusion process. The mixture of high and low melting lipid and the 
production process seem to render the implants biodegradable. Thus twin-screw extruded 
lipid implants are a very promising option as parenteral depot formulation as biodegradability 
is of great importance for patient´s compliance. Degradation products of triglycerides 
(glycerol and fatty acids) are natural substances thus no inflammatory reactions are expected 
at the site of implant erosion in-vivo. 
However, to proof the degradability of lipid tsc-extrudates an in-vivo study is necessary, as 
in-vivo conditions can hardly be simulated in-vitro.  
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2. Materials and Methods 
2.1. Materials 
Lipids D118 (glycerol tristearin), H12 (triglyceride consisting of lauric, myristic and palmitic 
acid, melting point: 37 °C) and E85 (triglyceride consisting of lauric, myristic palmitic acid, 
melting point: 42 °C) were kindly donated by Sasol (Witten, Germany). PEG 6000 was a gift 
from Clariant, Wiesbaden, Germany. 
 
2.2. Preparation of lipid implants 
Triglyceride based implants were prepared by twin-screw extrusion of mixtures of high 
melting lipid D118, a low melting lipid (H12 or E85)and a pore-forming agent (PEG 6000) 
according to Figure 61. Four formulations (A-D) were prepared which differed in the amount 
of pore forming agent (20%, 0% and 40% PEG 6000 – formulations A, B, C) and the type of 
low melting lipid (E85 instead of H12 – formulation D). Preparation of rod shaped implants 
was performed as described previously. Extrusion was performed using a Haake MiniLab® 
Micro Rheology Compounder with closed bypass channel and a rotation speed of 40 rpm 
(Thermo Haake GmbH, Karlsruhe, Germany). The resulting implants had a diameter of 1.9 
mm and were cut to a length of 17 mm resulting in an implant mass of approximately 55 mg. 
Lipid implant rods were sterilized by gamma-irradiation (total dose: 30.5 kGy, Gamma 
Service Produktbestrahlung GmbH, Radeberg, Germany) before in-vivo application. 
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Figure 61: Composition of triglyceride based tsc-extrudates. D118 = dark grey bars (formulation A-D), H12 
= black bars (formulations A-C), E85 = light grey bar (formulation D) and PEG 6000 = white bars 
(formulation A, C, D).  
Prior to extrusion, the near fluorescent carbocyanine dye 1,1´-dioctadecyl-3,3,3´,3´-
tetramethylindotricarbocyanine iodide (DiR) (excitation: 750 nm; emission: 782 nm) 
(Invitrogen, Karlsruhe, Germany) was dissolved in methylen chloride (2 mg/mL), and 
dissolved in melts of H12 and E85 to obtain final concentrations of 10-7 mol/mg. DSC 
measurements after recooling and tempering of the triglycerides for 1 day at 43 °C (H12) and 
47 °C (E85) did not show the formation of unstable modifications or a melting point 
depression. X-ray measurements showed identical crystalline structure of H12 before and 
after mixing with DiR. 
The fluorescent dye was used to allow location of the implants in-vivo and to follow the 
progress of biodegradation. DiR is a nontoxic lipophilic fluorescent dye with an excitation 
maximum of 750 nm and an emission maximum of 782 nm in the near infrared (NIR) region. 
Within this region, the auto-fluorescence of tissue is minimal and thus an accurate location of 
the implants should possible by use of the IVIS Lumina System and the Li-Cor gel scanner 
after explantation. DiR has been used in a variety of cell based in-vitro and as well in-vivo 
studies and was shown to be safe. For example, DiR was nontoxic and did not affect cell 
viability or cell functions in macrophages [241] and allowed the non-invasive in-vivo tracking 
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of e.g. inflammatory cells [241], low-density lipoprotein nanoparticles [242] and hematopoietic 
cells [243].  
 
 
Figure 62: Excitation and emission spectra of DiR. 
 
Figure 63: Molecular structure of DiR (1,1´-dioctadecyl-3,3,3´,3´-tetramethylindotricarbocyanine iodide, 
DiOC18(7)) 
 
2.3. Preliminary testing  
Detection of tsc-extrudates (marked with DiR) in tissue was tested in an in-vitro experiment 
prior to application in rabbits. Therefore tsc-extrudates were incubated in PBS buffer pH 7.4 
at 37 °C for 4 weeks and subsequently placed underneath the hypodermis of a pig´s ear 
(Figure 64). Additionally, fresh tsc-extrudates were also inserted into the pig´s ear and the 
feasibility to detect these extrudates was tested with a Li-Cor Odyssey gel scanner 
(Bioscience GmbH, Bad Homburg) and the IVIS Lumina system (Caliper Life Science, 
Hopkinton, USA). A pig´s ear was chosen for the experiment because it is denser and harder 
than rabbit tissue and thus forms a litmus test for our detection system. 
 
nm 
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2.4. Differential scanning calorimetry (DSC) 
Twin-screw extrudates were ground in an agate mortar and approximately 10 mg per sample 
was analyzed in sealed Al-crucibles. Measurements were performed with DSC 204 Phoenix 
(Netzsch, Selb, Germany) with heating and cooling rates of 10 K/min in a temperature range 
from 5 °C to 90 °C. The area under the curve (AUC) of melting endotherms was used to 
calculate the ratios of low melting and high melting triglycerides. 
 
2.5. Scanning electron microscopy (SEM) 
Lipid implants were assessed with a scanning electron microscope 6500F (Jeol GmbH, 
Eching, Germany) without applying any coating procedure.  
 
2.6. Selection of test animals 
Rabbits were selected as test animals because they show a lipidic hypodermis with fat tissue 
which is similar to the human one. For an in-vivo rhIFNα release study, Schwab et al. also 
used rabbits for the implantation of compressed lipid implants [31]. In addition to that, smaller 
animals like rats or mice do not develop a fat tissue and are quite musculous and active 
animals which would not allow our implants system to rest silent at the site of implantation. 
Therefore rabbits were chosen as test animals. 
 
2.7. Animal treatment and in-vivo degradation study 
Rabbits were housed in pairs in standard cages, fed ad libitum with hay and commercial 
rabbit food. The tsc-extrudates were injected subcutaneously by a microchip applicator 
(Backhome BioTec ®, Virbac, Bad Oldesloe, Germany) at t = 0 month, t = 3 months and t = 5 
months. 6 months after the first application, animals were euthanized by intravenous 
administration of 0.4 mL xylazine (Xylazin, Serumwerk Bernburg, Germany) and 0.6 mL 
ketamine (Ursotamin, Serumwerk Bernburg, Germany), followed by 1.0 mL T61® (Intervet, 
VII. – IN-VIVO BIODEGRADABILITY OF TWIN-SCREW EXTRUDED IMPLANTS IN RABBITS 
137 
Unterschleissheim, Germany), thus resulting in incubation times of the implants of 1, 3 and 6 
months (Table 14). 
Control formulation A was implanted into each animal in order to increase statistical power 
(n = 9) and to gain an internal standard throughout all animals. All other formulations were 
implanted in triplicate (n = 3) for each point of time.  
All experiments were approved by the responsible regulatory body (Regierung von 
Oberbayern, Aktenzeichen 55.2-1-54-2531-153-09). 
 
Table 14: Schedule for the implantation of tsc-extrudates into rabbits. Formulations A, B, C and D as 
described in Figure 61. 
animal no. / time t0 t3 month t5 month t6 month 
1 A + B A + B A + B end of study 
2 A + B A + B A + B end of study 
3 A + B A + B A + B end of study 
4 A + C A + C A + C end of study 
5 A + C A + C A + C end of study 
6 A + C A + C A + C end of study 
7 A + D A + D A + D end of study 
8 A + D A + D A + D end of study 
9 A + D A + D A + D end of study 
 
2.8. Recovery of implants and assessment of implant weights after 
in-vivo study 
Six months after implantation the animals were sacrificed, tissue samples were excised and 
placed on an infrared scanner (Li-Cor Odyssey, Bioscience GmbH, Bad Homburg) and each 
sample was scanned at 700 nm and 800 nm. After removal of the implants from the samples, 
the remaining tissue was scanned again to ensure complete recovery of the tsc-extrudates. 
The remaining implant material was washed three times with distilled water and vacuum 
dried to constant weight in a vacuum dryer (Memmert, Schwabach, Germany) at 25 °C and 
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11 mbar. Afterwards the implants were weighed on an analytical balance (d = 0.001mg) and 
the recovery was calculated as a percentage of the initial implant mass. 
 
2.9. In-vitro degradation study 
Freshly prepared implants were weighed, placed into 2.0 mL safe lock reaction tubes 
(Eppendorf AG, Hamburg, Germany) and incubated in 1.9 mL 0.01 M isotonic phosphate 
buffered saline (PBS) pH 7.4 containing 0.05% NaN3 as preservative. The samples 
(formulation A: n = 27; formulations B, C and D: n = 9) were placed in a water bath at 39 °C 
to mimic the body temperature in rabbits (Julabo SW-20C, Julabo Labortechnik GmbH, Bad 
Seelbach, Germany). After 1 day, 1 week and 2 weeks the buffer medium was completely 
exchanged to remove the dissolved PEG 6000 from the samples. After 1 month, 3 months 
and 6 months samples were drawn (formulation A: n = 9; formulations B, C and D: n = 3), 
treated as described for the in-vivo samples and the recovery was calculated as a 
percentage of the initial implant mass.  
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3. Results and discussion 
3.1. Preliminary studies 
3.1.1. Detection of fluorescent dyes within tissue 
As DiR is a lipophilic dye it remained within the lipid tsc-extrudate over the period of in-vitro 
incubation (4 weeks, 37 °C). By use of the IVIS Lumina System and the gel scanner, the 
fresh implants as well as the incubated implants could be detected after insertion in the 
hypodermis of the pig´s ear. In all cases the tsc-extrudate was clearly visible. However, the 
non-incubated implants showed stronger fluorescence than the incubated samples which 
means that the fluorescent dye was washed out to a small extent over time. Nevertheless, 
we were able to detect the implant by two different detection systems (Figure 65) within a 
real tissue. 
 
  
Figure 64: Fluorescently labeled tsc-extrudate are inserted under the hypodermis of a pig’s ear. 
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Figure 65:Detection of fluorescently marked lipid implants inserted under the hypodermis of a pig’s ear 
by the IVIS Lumina System. A: Implant after 4 weeks of incubation in PBS buffer at 37 °C; B: fresh 
implant; C: control area. 
 
 
Figure 66: Image of tsc-extrudates which were inserted under the hypodermis of a pig´s ear by Li-Cor gel 
scan (800 nm). Left side: freshly prepared implant. Right side: Implant after 4 weeks of incubation in PBS 
at 37 °C (still visible).  
 
3.2. Animal treatment and recovery of implants 
After euthanasia, rabbit hair was clipped on both sides of the abdomen, and implants were 
localized by digital palpation. Lipid implants were excised and adhering tissue was removed 
after localization of the implant fragments within the tissue with a Li-Cor gel scanner (Figure 
68). Due to the fluorescent marker dye DiR the implants were easily located and completely 
excised from the surrounding tissue. The IVIS Lumina scanner, which was tested as a 
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backup system, was not used, because the remaining implant rods were easily detected after 
long-term incubation with the LiCor gel scanner and handling was easier with this system. 
All implants were encapsulated by a fibrous capsule (Figure 67) which could be easily 
removed. Besides the fibrous capsule no further foreign body reactions were observed 
during the in-vivo study. Fibrous encapsulation is described in literature as the end-step 
healing process to biomaterials and was observed for various other materials including lipids, 
collagen and PLGA [23, 244-246].  
During the in-vivo degradation study, one animal had to be euthanized after 4 months due to 
a fractured spinal column. However, the exitus was no related to the degradation study but 
happened by accident. Extrudates which were implanted in this animal for 1 month and 4 
months (formulations A and B) were included into the 1 month and 3 months groups for 
analysis respectively. 
 
3.1. In-vitro degradation study of lipid implants 
Weight assessment of implants of formulation A (n = 9) after the in-vitro degradation study 
showed remaining implant masses of 80% (± 2%), 79% (± 2%) and 77% (± 1%) after 1, 3 
and 6 months respectively (Table 1). This was not surprising as 20% of the implant 
formulation consisted of water soluble PEG 6000 which was quickly released from the 
implant. Thus, we obtained recoveries of 100% (± 3%), 100% (± 3%) and 96% (± 2%) of 
triglyceride material after 1, 3 and 6 months respectively and only minimal matrix degradation 
was detected in a lipase free in-vitro model. Implants of formulations B, C and D (n = 3) 
showed mass losses which also derived from PEG 6000 dissolution (Table 1). However, 
after 6 months of incubation weight assessment of formulations A-C showed a minimal 
degradation (3%) of the triglyceride matrix material which was in contrast to implants of 
formulation D which remained constant throughout the experiment (Table 15).  
 
VII. – IN-VIVO BIODEGRADABILITY OF TWIN-SCREW EXTRUDED IMPLANTS IN RABBITS 
142 
 
Figure 67: (A) Lipid implant surrounded by fibrous capsule and attached tissue. (B) Lipid implant after 
removal of tissue and the fibrous capsule. 
 
Figure 68: (a) – lipid implant embedded in rabbit tissue directly after excision, (b) – 800 nm scan of rabbit 
tissue before removal of the implant, (c) – implant after complete removal from rabbit tissue, (d) – 800 nm 
scan of the tissue after removal of the implant (grey staining derives from auto-fluorescence of the 
tissue). 
 
DSC measurements of tsc-extrudates revealed endotherms for H12 melting at 36 °C and for 
D118 melting at 72 °C after incubation (Figure 69). The melting endotherms of D118 and 
H12 in tsc-extrudates were more distinct after incubation compared to samples before 
incubation and the endotherm of H12 split into two maxima (36 °C and 42 °C, formulations 
A-C). Formulation D (E85 instead of H12) also exhibited a split melting endotherm for the low 
melting lipid E85 after long-term incubation (Figure 69). This changed melting profile derived 
from a tempering step during long-term incubation at 39 °C. The PEG melting endotherm 
1 cm1 cm
A B
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(60 °C), which was observed as a prominent endothermic event in samples prior to the 
degradation study disappeared as the polymer was released from the implant during 
incubation (Figure 69).  
Assessment of the triglyceride composition of all implants was carried out by comparison of 
the AUCs of the melting endotherms, since the AUCs of the melting endotherms correlate 
directly with the amount of triglyceride [221]. The analysis of the samples revealed a slight 
decrease of the mass of H12 (formulation A-C) after in-vitro incubation but no decrease of 
E85 (formulation D) (Table 15). H12 melts below and E85 melts above the incubation 
temperature. Thus the loss of triglyceride material from H12 containing implant derived from 
H12 melting during incubation and implants of formulation D were better preserved due to 
the higher melting point of E85 compared to H12. 
For formulations A-C SEM measurements after 1 month of incubation revealed smooth 
implant surfaces with well defined pores which formed upon release of PEG 6000 (Figure 72 
– lower part). The implant surfaces changed during incubation for 3 months (data not shown) 
and 6 months (Figure 72 – lower part) and the implants became more fissured and jagged 
with increasing incubation time. Additionally, implants became more fragile after long term in-
vitro incubation. However, they all could still be recovered as intact rods. 
Implants of formulation D were better preserved during the incubation period compared to 
formulation A which was explained by the different melting profiles of H12 and E85. 
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Figure 69: DSC thermograms of tsc-extrudates. From bottom to top: before the degradation study, after 1 
month in-vivo degradation, after 3 month in-vivo degradation, after 6 month in-vivo degradation and after 
6 month in-vitro degradation study (39 °C). A, B, C and D depict formulation A (D118/H12 + 20% PEG 
6000), formulation B (D118/H12 + 0% PEG 6000), formulation C (D118/H12 + 40% PEG 6000) and 
formulation D (D118/E85 + 20% PEG 6000). Melting endotherms: D118 = 70-78 °C, PEG 6000 = 57-65 °C, 
E85 = 37-45 °C, H12 = 32-40 °C. 
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Table 15: Results of weight assessments and DSC measurements of lipid tsc-extrudates after in-vitro 
incubation; * starting point: 100%; ** theoretical value (weighed in amount of H12), determination not 
feasible due to the presence of PEG 6000. 
formulation incubation time total recovery [%] 
recovery of 
triglycerides [%] 
AUCs of H12/E85 
[%] 
A 
(D118/H12, 
20% PEG) 
before incubation 100%* 100%* 24% **
 
1 month 80% ± 2% 100% ± 3% 23.9% ± 1.2% 
3 months 79% ± 2% 100% ± 3% 24.6% ± 0.7% 
6 months 77% ± 1% 96% ± 2% 21.0% ± 0.7% 
B 
(D118/H12, 
0% PEG) 
before incubation 100% 100% 25.3% ± 0.4% 
1 month 100% ± 0% 100% ± 0% 24.7% ± 0.5% 
3 months 100% ± 0% 100% ± 0% 24.0% ±0.5% 
6 months 98% ± 0% 98% ± 0% 21.2% ± 0.7% 
C 
(D118/H12, 
40% PEG) 
before incubation 100%* 100%* 24% ** 
1 month 60% ± 1% 100% ± 2% 26.3% ± 0.5% 
3 months 60% ± 1% 100% ± 2% 24.2% ± 0.5% 
6 months 58% ± 1% 96% ± 2% 21.0% ±0.6% 
D 
(D118/E85, 
20% PEG) 
before incubation 100%* 100%* 24% ** 
1 month 79% ± 1% 98% ± 2% 25.6% ± 0.5% 
3 months 79% ± 1% 98% ± 1% 26:4% ± 0.6% 
6 months 79% ± 1% 98% ± 2% 24.0% ± 0.5% 
 
3.2. In-vivo degradation of formulation A 
After the in-vivo degradation study the total recoveries of the explanted lipid tsc-extrudates of 
formulation A decreased to 62% (± 11%), 44% (± 11%) and 19% (± 14%) after 1, 3 and 6 
months respectively (Figure 70). DSC data showed the total absence of PEG within eight of 
nine samples after 1 month of incubation which is in accordance with the in-vitro data were a 
total depletion was detected after 1 month (Figure 71). Thus the remaining implant masses 
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consisted only of triglycerides, and recoveries of 77% (±14%), 55% (±14%) and 25% (±17%) 
of the lipidic material after 1, 3 and 6 months (Figure 70) were obtained.  
 
 
Figure 70: Comparison between remaining masses after in-vitro (white bars) and in-vivo (grey bars) 
degradation studies of tsc-extrudates of formulation A. I: Remaining implant mass after 1, 3 and 6 months 
(n = 9; except in-vivo (6 months): n = 8). II: Remaining triglyceride matrix material after 1, 3 and 6 months 
(n = 9; except in-vivo (6 months): n = 8). Dotted line = extrapolation of the assumed slope of the in-vivo 
degradation. 
 
The results for different incubation times (1 month versus 3 months, 1 month versus 6 month 
and 3 months versus 6 months) showed statistically significant differences (P < 0.01). An 
approximated linear extrapolation of the degradation rate indicated that all implants will be 
totally degraded within 8-9 months (Figure 70 – I, II). The comparison between in-vivo and in-
vitro incubation data showed that in-vivo degradation was significantly faster compared to 
in-vitro degradation (P < 0.001). 
Visual inspection of the remaining implant rods showed fragmentation and deformation of the 
implants with increasing incubation time. SEM micrographs and visual inspection of the 
remaining implants revealed a porous and rod-shaped structure after 1 month of in-vivo 
incubation. This structure was lost after 3 months (data not shown) and 6 months (Figure 72) 
and only dense implant fragments could be recovered from animal tissue. This is in contrast 
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to the in-vitro incubation data where the rod-shaped form of the implant and the porous 
implant structure were conserved during 6 months of incubation (Figure 72).  
DSC data after 3 and 6 months of incubation showed a total depletion of PEG from the 
implant matrices whereas small amounts PEG could still be found within the implants after an 
incubation time of only 1 month (Figure 71). Deviations between remaining implant masses 
can be explained by different ratios of released H12 during in-vivo incubation (Table 16). 
 
 
 
Figure 71: DSC thermograms of three tsc-extruded lipid implants (formulation A) after in-vivo incubation 
for 1 month. In sample 1 residues of PEG 6000 are observable. Melting endotherms: H12 =35 °C, PEG 6000 
= 55 °C and D118 =72 °C. 
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Table 16: Results of DSC measurements of tsc-extrudates after 1 month in-vivo implantation in rabbits. 
Displayed are the area under the curve (AUC) of the low melting lipid (H12) and high melting lipid (D118) 
as percentage of the total AUC. 
*)
 sample contained residues of PEG 6000 
formulation sample number 
remaining 
implant 
mass 
remaining lipid 
material 
AUC of H12 
[%] 
AUC of D118 
[%] 
A 
1 82% 100% 
*)
 12.6% 87.4% 
*)
  
2 59% 74% 7.2% 92.8% 
3 51% 64% 4.3% 95.7% 
 
We conclude that the initial 20% of the weight loss during in-vivo degradation was mainly 
related to PEG dissolution and release. Subsequently, H12 was depleted from the implant 
and after 3 and 6 months only marginal amounts of H12 were present in the implants. 
H12 depletion from the implant matrix was explained by two factors: (A) simple transportation 
phenomena of molten H12 at body temperature (39 °C) or (B) fast cleavage of the low 
melting triglycerides by lipases which are omnipresent in the body fluids.  
Schwab et al. [33] have already shown that the application of lipases induced faster in-vitro 
degradation of tsc-extrudates than of compressed implants. This was found to be a 
consequence of the manufacturing process and the presence of the low melting triglycerides 
which were more prone to the lipolytic activity of lipases. The triglyceride material of tsc-
extrudates had been rapidly degraded in-vitro and the implants completely lost their shape 
after a few days of incubation, resulting in fine particles in the range of 40-90 µm. In contrast 
to tsc-extruded implants, only small amounts of triglyceride had been cleaved from 
compressed implants consisting of pure D118 and these implants had kept their shape 
throughout the experiment [33]. In our experiment, however, the implant erosion of tsc-
extrudates took months instead of days and this was explained by lower lipase 
concentrations in the body fluids compared to the concentrations applied for the in-vitro 
studies of Schwab et al. [33].  
DSC measurement after in-vivo implantation showed a depletion of H12 from the implants 
which can result in a fragmentation of the matrix and the formation of fine D118 particles, 
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comparable to the resulting particles found by Schwab et al. [33]. The low melting lipid is 
thought to act as ´glue` during manufacturing which fixes the fine D118 particles together 
during preparation. After depletion of the ´glue` these small particles can easily erode from 
the matrix and are of course more prone to degradation than compact D118 implants. For 
examples they can be washed away by body fluids, undergo degradation by lipases or are 
eliminated by phagocytosis. 
Thus the fragmentation and the matrix breakdown of lipid tsc-extrudates were explained 
mainly by the depletion of H12 from the triglyceride matrix. But H12 did not only ´glue` D118 
particles together, it also worked as softening agent during manufacturing which enabled 
extrusion of the solid powder formulation and led to the creation of a dense implant matrix. 
Consequently, melting of H12 during the in-vivo study within the solid triglyceride implant at 
body temperature also led to a softening of the extrudates in-vivo which became formable 
again. SEM measurements after the in-vivo study showed that the void spaces and the 
porous implant structure which were created upon PEG dissolution were lost due to 
deformation of the implants. This phenomenon was not observed to the same extent after in-
vitro studies where no mechanical stress was applied to the implants (Figure 72).  
In our study we observed an erosion of 23% of the lipidic matrix components after only 1 
months of incubation and after 6 months an average erosion of 75% was detected. One 
implant even eroded to 95%. This was in strong contrast to the in-vivo degradation data of 
compressed implants of pure D118 which did not showed any sign of erosion after 4 weeks 
of subcutaneous implantation in rabbits [31]. Thus tsc-extrudates showed excellent 
biodegradability in rabbits and this can be explained by the implant composition and the 
characteristics of tsc-extrudates.  
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Figure 72: SEM measurements and digital photographs of implants after degradation studies. Upper part 
– SEM micrographs after in-vivo incubation of formulations A-D for 1 and 6 months (A1-D6); middle part – 
digital photographs after in-vivo incubation of formulations A-D for 1 and 6 months (A1-D6); bottom part – 
SEM micrographs after in-vitro incubation of formulations A-D for 1 and 6 months (A1-D6). 
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3.3. Influence of the amount of pore-former on the degradability of 
lipid tsc-extudates 
To study an influence of the amount of pore forming agent on the in-vivo degradation of 
tsc-extrudates, the ratios between H12 and D118 were kept constant but the amount of pore 
forming agent PEG 6000 was varied between 0% (formulation B) and 40% (formulation C). 
Implants of formulation B showed a time dependent biodegradation with recoveries of 81% 
(± 11%, n = 3), 69% (± 2%, n = 3) and 48% (± 5%, n = 2) of the implant mass (Figure 73). 
Implants consisting of formulation C (n = 3) eroded faster and recoveries of 44% (± 5%), 31% 
(± 6%) and 21% (± 7%) were measured (Figure 73). This higher degradation rate was not 
surprising as 40% of the implants of formulation C consisted of water soluble PEG 6000 
whereas formulation B did not comprise PEG 6000. A calculation of the recovery of the lipidic 
material of formulation C resulted in 74% (± 9%), 52% (± 11%) and 35% (± 12%) recovery 
after 1, 3 and 6 months compared to 77%(± 14%), 55% (± 14%) and 25% (± 17%) for 
formulation A respectively. DSC data showed an identical depletion of H12 from all 
formulations independent of the implantation period (Figure 69). Comparison between 
formulations A, B and C showed no statistical significant difference in the degradation of the 
triglyceride matrix material (Figure 74). However, mass recoveries from formulation B (0% 
PEG 6000) were higher compared to formulations A and C and visual assessment as well as 
SEM measurements indicated that implants of formulation B were better preserved than the 
more porous and fragile implants of formulations A and C (Figure 72). We conclude that 
increasing amounts of pore former led to an enhanced in-vivo degradability of triglyceride 
matrices due to higher matrix porosities after release of the pore former. 
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Figure 73: Comparison between in-vitro (white bars) and in-vivo (grey bars) degradation data of tsc-
extrudates of formulations B and C. Left: Remaining implant mass of formulation B after 1, 3 and 6 
months. Right: Remaining implant mass of formulation C after 1, 3 and 6 months (n = 3 except for 
formulation B, 6 months, in-vivo: * n = 2) 
 
 
Figure 74: Remaining triglyceride matrix material after in-vivo degradation study in rabbits for 1, 3 and 6 
months: black bars = D118/H12 implants containing 0% PEG (formulation B), grey bars = D118/H12 
implants containing 20% PEG (formulation A) and white bars = D118/H12 implants containing 40% PEG 
(formulation C). 
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3.4. Influence of the type of low-melting lipid 
In formulation D the triglyceride H12 was replaced by the triglyceride E85 because this 
formulation was shown to be less degradable in an in-vitro degradation study where lipases 
were used to cleave the lipid material [33]. 
The biodegradation study in rabbits showed that 62% (± 9%), 55% (± 5%) and 29% (± 9%) of 
the total implant mass was recovered from implants of formulation D which was equal to 78% 
(± 12%), 69% (± 6%) and 37 (± 14%) of triglyceride material  after 1, 3 and 6 months of 
incubation, respectively. The degradability of the lipid implants was dependent on incubation 
time and differences between the mass losses after 1 month and 6 months and after 3 
months and 6 months of incubation were statistically significant (P<0.01).  
Visual inspections and SEM measurements indicated that implants of formulation D better 
preserved their shape and form compared to implants of formulation A (Figure 72). 
Additionally, higher mass recoveries were measured from implants of formulation D 
compared to standard formulation A (Figure 75). However, the differences in recovery 
between formulations A and D were not statistically significant. DSC measurements of 
formulation D showed only marginal amount of E85 within the lipid matrix after 1 month of in-
vivo incubation and almost total depletion of the low-melting lipid from the implant after 3 and 
6 month of in-vivo incubation which was similar to the standard formulation A (Figure 69). 
Thus no significant difference between formulation A and D was detectable although a 
tendency (mass loss and SEM micrographs) indicated that implants comprising D118/E85 
degraded to a smaller extent than implant consisting of D118/H12. Our findings of the in-vivo 
study correlate well with the in-vitro data and the data from the in-vitro lipase assay were the 
D118/E85 extrudates were also less degradable. Thus we conclude that by choosing a 
suitable low melting lipid (melting temperature, cleavage rate) the in-vivo degradation rate of 
tsc-extrudates can be prolonged or shortened. However, the rate of biodegradation is quite 
robust regarding small variations in lipid compositions which would allow for a reliable long-
term biodegradation in patients. 
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Figure 75: Remaining masses of triglyceride matrix material of tsc-extrudates after in-vivo degradation 
study in rabbits for 1, 3 and 6 months: black bars = D118/H12 implants containing 20% PEG 6000 (n = 9, 
formulation A), white bars = D118/E85 implants containing 20% PEG (n = 3, formulation D). 
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4. Conclusion 
Tsc-extrudates showed excellent in-vivo biodegradability in rabbits. The implants degraded 
continouslyover a time period of 6 months and only 25% of the lipid matrix material was 
recovered. In contrast to in-vitro degradation (= incubation in lipase free buffer) a significant 
mass loss and a breakdown of the porous implant matrix structure was detected. The 
degradation rate allows a linear extrapolation indicating total implant degradation within 9 
months. DSC measurements and comparison between in-vitro and in-vivo data indicated that 
in the beginning of implant erosion the water soluble amount of the implant (PEG 6000) was 
dissolved and released. Afterwards the low melting lipid was degraded in-vivo or was simply 
cleared from the implant as a melt and the remaining implant matrix broke to pieces and 
eroded over time. 
Increasing amounts of pore-forming agent resulted in faster degradation rates of the total 
implant mass. However, this effect was mainly dominated by the dissolution of PEG 6000. 
Data indicate a better degradability of tsc-extrudates with increasing amounts of pore-forming 
agent. However due to the limited sample numbers in this orientation study the differences 
between the formulations were not statistically significant. Application of a different low 
melting lipid (E85) with a higher melting point resulted in a higher recovery of the implant 
mass and a better preservation of the implant structure. We conclude that the degradation 
rate can be controlled by variation of the triglyceride components and the amount of 
hydrophilic excipients.  
In order to achieve appropriate biodegradation rates of tsc-extrudates the choice of the low 
melting lipid as well as the amount of incorporated hydrophilic components is of importance. 
For the preparation of biodegradable tsc-extrudates the use of low melting lipids with melting 
endotherms below the body temperature is recommended. Total degradation of implants of a 
typical size of 2 cm length and 1.9 mm diameter can be expected after 9 months. 
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VIII. Lipase induced in-vitro degradation study with tsc-
extrudates 
1. Introduction 
For a long time one of the major drawbacks of triglyceride based implant systems was their 
low ´bio`-degradability in-vivo. Although lipids per se are natural substances, the 
concentration of lipases in the subcutaneous tissue is too low to allow rapid degradation of 
compressed implant [31, 33]. Tsc-extrudates show partial implant melting during in-vitro and 
in-vivo incubation and were therefore shown to be degradable over a period of several 
months (see chapter 0). However, often shorter periods for drug release are desired (2 
weeks to 3 months) and therefore it seems to be a very promising attempt to control or even 
tailor the rate of implant degradation. As it was shown by Schwab et al. lipases can be used 
to enhance the rate of implant degradation [33]. Therefore we tried to incorporated lipases 
into tsc-extrudates and analyze the rate of implant degradation. In further studies we 
investigated whether faster implant degradation can be used for controlled protein release.  
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2. Materials and methods 
2.1. Materials 
2.1.1. Lipase 
Lipase from Rhizopus oryzae (> 30 U/mg) was purchase from Sigma-Aldrich (Germany). It 
consists of a light brown powder and its activity optimum is at pH 7.2 but the enzyme is 
highly active between pH 6.4 and 7.5. Therefore degradation studies were performed in 
isotonic PBS pH 7.4. 
2.1.2. Triglycerides 
D118, H12 and E85 were donated from Sasol (Witten, Germany) and their composition is 
described in VI.2.1 (Table 11).  
 
2.2. Methods 
2.2.1. Preparation of tsc-extrudates 
Tsc-extrudates were prepared as described above (III.2.9). Lipid powder blends (Table 17 +  
Table 18) comprising D118 as high melting lipid and either H12 or E85 as low melting lipid 
were prepared and mixed with various amounts of lipase or lipase + lysozyme. Mixing was 
performed in a mortar which was lined with the low-melting lipid to seal the mortar’s porous 
surface. Lipase and/or lysozyme were added to the mortar and mixed with the same volume 
of H12. Afterwards H12 was added to double the volume again and in continuative steps the 
extrusion-mixture was built up by addition of H12 and D118. 
Extrusion of rod-shaped implants was performed through a 1.9 mm outlet die in steady-state 
mode with closed bypass. 
The resulting rod-shape (light brownish) implants (Figure 76) were cut at length (~ 3.0 cm), 
accurately weighed and used for degradation and release studies. 
VIII. – LIPASE INDUCED IN-VITRO DEGRADATIO STUDY WITH TWIN-SCREW EXTRUDATES 
160 
 
Figure 76: Twin-screw extrudates directly after preparation (~ 3 cm length). A: implant comprises 10% 
lipase (formulation 4, Table 17), B: implant comprises 0.1% lipase (formulation 2, Table 17). 
 
Table 17: Composition of tsc-extrudates for degradation studies 
No. 
D118 
high melting lipid 
H12 
low melting lipid 
ratio between 
D118:H12 
lipase 
1 80.0% 20.0% H12 80:20 0% 
2 79.9% 20.0% H12 80:20 0.1% 
3 79.2% 19.8% H12 80:20 1.0% 
4 72% 18% H12 80:20 10.0% 
 
Table 18: Composition of tsc-extrudates for lysozyme release studies 
No. 
D118 
high melting lipid 
H12 
low melting lipid 
ratio between 
D118:H12 
lysozyme lipase 
11 68.3% 29.2% 70:30 2.5% - 
12 66.5% 28.5% 70:30 5.0% - 
13 63.0% 27.0% 70:30 10.0% - 
14 68.2% 29.2% 70:30 2.5% 0.1% 
15 68.0% 29.2% 70:30 2.5% 0.3% 
16 67.9% 29.1% 70:30 2.5% 0.5% 
17 67.8% 29.0% 70:30 2.5% 0.7% 
18 67.6% 28.9% 70:30 2.5% 1.0% 
19 66.2% 28.3% 70:30 5.0% 0.5% 
20 62.7% 26.8% 70:30 10.0% 0.5% 
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2.2.2. Degradation study 
For tsc-extrudate degradation studies a similar setup was chosen as it was used by Schwab 
et al. [33]. In brief, implants were incubated in 1.9 mL isotonic PBS pH 7.4 in low bind protein 
tubes (2 mL, Eppendorf AG, Hamburg) at 37 °C in a water-bath. At predetermined points of 
time the incubation medium was completely exchanged and free fatty acids were extracted 
from the incubation medium according to a method proposed by Schwab et al. and Dole et 
al. [33, 247]. In brief, 1 mL of sample solution was admixed with 2.5 mL of extraction medium 
(propan-2-ol : heptan : phosphoric acid (2 M) 40 : 10 : 1 (v/v)), vortexed for 15 sec and 
placed in a ultrasonic bath (Sonorex Super RK 510, Bandelin Electronic GmbH & Co KG, 
Berlin, Germany) for 2 min. Afterwards the samples were vortexed again (15 sec) and 
incubated at room temperature for 10 minutes. After addition of 1 mL heptan and 1.5 mL 
water the samples were vortexed (15 sec) and ultrasonicated (2 min) again und finally 
centrifuged at 1000 g at 4 °C for 10 min. 1 mL of the organic phase which separated on top 
of the sample was transferred to a HPLC vial (VWR, Germany) and dried in a stream of dry 
nitrogen (in-house supply line). Standard solutions of lauric, myristic, palmitic and stearic acid 
were prepared in dichloromethanol (0.2 mg/mL) and treated like sample material in order to 
prepare calibration curves 
 
2.2.3. Assessment of free fatty acids 
Free fatty acids were quantified by RP-HPLC after derivatization according to Schwab et al. 
[33] and Wood et al. [248]. Dried samples (free from heptan) were dissolved in aceton (1 mL) 
and admixed with 70 µL of phenacyl bromide solution (10 mg/mL in aceton) and 70 mL of 
triethylamine solution (10 mg/mL in aceton). The vials were sealed and incubated for 20 min 
at 70 °C in a drying oven (Memmert, Schwabach, Germany). After cooling to room 
temperature 112 µL of a solution of acetic acid in aceton (2 mg/mL) was added to react with 
the excess of derivatization reagents and incubated for additional 10 minutes at 70 °C. 
Samples were again dried under a stream of dry nitrogen and reconstituted in 1 mL methanol 
for RP-HPLC analysis 
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2.2.4. Quantification of free fatty acids by RP-HPLC 
Reconstituted samples were analyzed by RP-HPLC and peak areas were used to quantify 
the amount of free fatty acids. Calibration curves were prepared from 5-200 µg/mL of each 
fatty acid and showed linear correlation between peak area and fatty acid concentration 
(Figure 78). RP-HPLC settings are described below: 
HPLC:     Dionex Ultimate 3000 (Dionex Softron GmbH, Germany) 
Pre-column:    LiChroCART®250-4, Merck Darmstadt 
RP-column:    LiChrosper®100 RP-18 (5 µm), Merck Darmstadt 
Mobile phase:  methanol : acetonitrile : water (80 : 10 : 10) 
Flowrate:    2 mL/min, isocratic 
Run time:    30 min 
Detection:    254 nm (U timate 3000, Variable Wavelenght Detector, Dionex Softron) 
Injection volume:   100 µL 
Baseline separation for free fatty acids was achieved (see Figure 77). 
 
 
Figure 77: RP-HPLC chromatogram of 5 fatty acids (capric (C-10), lauric (C-12), myristic (C-14), palmitic 
(C-16) and stearic acid (C-18)) after derivatization according to 2.2.3. Fatty acid concentration was 
40 µg/mL of each acid. Fatty acids were baseline separated. 
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Figure 78: Calibration curves for free fatty acid determination. 
 
2.2.5. Quantification of lysozyme and lipase release from tsc-
extrudates 
Implants comprising lysozyme and lipase were incubated in protein low bind Eppendorf tubes 
with 1.9 mL isotonic PBS pH 7.4 (+ 0.05% sodium azide) at 37 °C and placed in water baths. 
At predetermined points of time, samples were drawn by complete exchange of the 
incubation medium and samples were analyzed by SE-HPLC as described below: 
HPLC:   Dionex Ultimate 3000 (Dionex Softron GmbH, Germany) 
SEC-column:   Superose 12, 10/300 GL (GE Healthcare, Uppsala, Sweden) 
Mobile phase:  0.2 M potassium phosphate + 0.15 M potassium chloride, adjusted to 
pH 6.8 
Flowrate:   0.65 mL/min 
Run time:   33 min 
Detection:   215 nm (Ultimate 3000, Variable Wavelenght Detector, Dionex Softron) 
Injection volume:  100 µL 
Lysozyme (25 min) and lipase (20 min) were baseline separated and quantification was 
possible in a range from 0.01 mg/mL to 1 mg/mL. Separation and quantification of lysozyme 
and lipase was possible from solutions containing both proteins (Figure 79). 
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Figure 79: Calibration curves for lipase and lysozyme after SE-HPLC separation and UV detection at 
215 nm. Calibration curves were generated from mixed solutions of lysozyme and lipase as well as from 
solution of pure lysozyme or lipase and yielded identical results. 
 
2.2.6. SEM measurements 
SEM measurements were performed with a 6500F (Jeol GmbH, Eching, Germany). Samples 
were dried in a vacuum chamber (VO 200, Mammert, Schwabach, Germany) at 25 °C and 
20 mbar for 6 days and analyzed without coating. 
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3. Results 
3.1. Implant degradation after embedding of lipase 
After embedding of various amounts of lipase (0.1% - 10.0%, formulations Table 17) and 
incubation of implants in PBS pH 7.4, implants degraded to a different extent depending on 
the applied amount of the enzyme. Visual observations showed that the embedding of 10% 
lipase resulted in a rapid degradation and total matrix breakdown of the implant within 
24 hours. The usage of less lipase (1.0% and 0.1%) did not result in a breakdown of the 
matrix within 14 days of observation (Table 19 + Figure 80). 
Table 19: Visual assessment of degradation rate of lipase containing lipid tsc-extrudates 
no. 
type of  
low melting lipid 
amount of lipase degradation 
1 H12 0% no degradation 
2 H12 0.1% 
no matrix breakdown, lipid particles cleaved 
from matrix 
3 H12 1.0% 
no complete matrix breakdown, lipid particles 
cleaved from matrix 
4 H12 10.0% total matrix breakdown within 1 day 
 
 
 
  
Figure 80: Lipid tsc-extrudates after incubation in PBS pH 7.4. A: 10% lipase (1 day), B: 1.0% lipase 
(1 day), C: 1.0% lipase (14 days), D: no lipase (14 days). 
A B 
C D 
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SEM measurements of samples which were incubated for 24 h showed increasing 
roughness of the implant surface if increasing amounts of lipase were used (Figure 81). 
Samples which comprised 10% lipase were assessed by SEM measurements after 1 hour of 
incubation only and showed a broken implant surface compared to the control formulation 
(no lipase) (Figure 82). Thus lipase lead to matrix breakdown and changed the implant 
surface although it was embedded into the matrix of the implant. It is highly likely, that lipase 
was release from the implant during incubation and affected the implant not only from the 
matrix core but also at the surface. 
 
 
Figure 81: SEM measurements with 1000-fold magnification of surfaces of lipid tsc-extrudates comprising 
no lipase (A), 0.1% lipase (B) and 1.0% lipase (C) after 24 hours of incubation in PBS pH 7.4 
 
 
Figure 82: SEM measurements with 35-fold magnification of lipid tsc-extrudates comprising no lipase (A) 
and 10% lipase (B) after 1 hour incubation in PBS pH 7.4. 
A B 
A B C 
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Quantification of free fatty acid release was not performed for samples comprising 10% 
lipase as total matrix breakdown was achieved within 24 hours. Free fatty acid release from 
samples comprising 0%, 0.1% and 1.0% lipase is depicted in Figure 83.  
For control implants with 0% lipase a release 0.4% free fatty acid was detected after seven 
days of incubation. At every point of time, the released amount of free fatty acids from 
implants without lipase accounted for approximately 0.08% of the total implant mass and it 
was mainly lauric acid which was detected after derivatization. This marginal ´release` of free 
fatty acid can be explained by two factors. Firstly free fatty acids might still be present within 
the triglyceride bulk material and can be slowly released into the incubation medium like any 
other molecule. Secondly, partial implant melting might result in a very fine dispersion or 
even solution of triglyceride material in incubation buffer. Due to the extraction procedure the 
fatty acids might thus be accessible for the derivatization reaction. Lauric acid was the main 
component which was detected by RP-HPLC and this acid derives from the low melting H12 
but not from D118 (stearic acid).  
Calculation of the amount of free fatty acids showed erosion of 2.2% of implant matrix 
material after approximately two days if 0.1% lipase was used and 2.5% of implant matrix 
material if 1.0% lipase was used. These values are in the same region as reported by 
Schwab et al. [33] who found about 4% free fatty acids after incubation in lipase solution for 
30 days based on the initial mass of the implant matrix material. However, in contrast to 
Schwab et al. we detected a high degradation rate at the beginning of the experiment and 
slow implant degradation or no degradation of the implant towards the end of the experiment.  
Schwab et al. replenished the incubation medium with fresh lipase buffer after sampling and 
did not completely exchanged the incubation buffer like we did. Thus our approach resulted 
in a depletion of lipase from the implants and from the incubation medium. 
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Figure 83: Degradation of lipid tsc-extrudates. Calculation based on the mass of free fatty acids in the 
incubation buffer  
 
3.2. Simultaneous release of lipase and lysozyme from lipid 
tsc-extrudates 
In order to investigate the effect of embedding of lipase into triglyceride matrices on the 
lysozyme release kinetics from tsc-extrudates, implants comprising lysozyme and lipase 
were prepared according to  
Table 18 and release of both proteins was quantified simultaneously by SE-HPLC 
assessment.  
Preliminary studies were performed to ensure that incubation of mixtures of lipase and 
lysozyme did not cause problems regarding protein stability. Therefore lysozyme and lipase 
were dissolved in PBS pH 7.4, mixed to give final concentrations of 0.01 mg/mL to 
1.0 mg/mL and incubated at 37 °C for seven days. Total recovery of lipase and lysozyme 
was achieved for all mixing ratios and no increase in aggregated species was detected by 
SE-HPLC detection. 
Within tsc-extrudates the maximum loading of lipase was 1.0%, as higher loadings (10%) 
resulted in immediate breakdown of the implant matrix (within 24 h) as observed in former 
experiments. 
0
0.5
1
1.5
2
2.5
3
0 2 4 6 8
m
a
s
s
 o
f 
fr
e
e
 f
a
tt
y
 a
c
id
s
 c
a
lc
u
la
te
d
 f
ro
m
 t
o
ta
l 
im
p
la
n
t 
m
a
tr
ix
 m
a
s
s
 [
%
]
incubation time [days]
0%
0.10%
1.00%
VIII. – LIPASE INDUCED IN-VITRO DEGRADATIO STUDY WITH TWIN-SCREW EXTRUDATES 
169 
Release studies showed immediate release of lipase from all tsc-extrudates independent of 
the amount of lipase applied (Figure 84 + Figure 86). Interestingly, total release of lipase was 
achieved for all formulations although only relatively small amounts of the enzyme were 
embedded into the implant matrices which - from theory - would be insufficient to allow 
complete and rapid protein release. We conclude that lipase frees itself by implant matrix 
degradation upon incubation in PBS at 37 °C and rapidly cuts its way through the matrix by 
cleavage of matrix material. This rapid release of lipase also explains the high initial ´release` 
of free fatty acids from triglyceride matrices. Subsequently no free fatty acids are generated 
at longer incubation times due to depletion of lipase from the incubation medium by 
exchange of the incubation buffer (Figure 83).  
Release of lysozyme was strongly influence by the presence of lipase. As can be seen in 
Figure 85 and Figure 87 the application of lipase resulted in a ´non-release` of lysozyme from 
tsc-extrudates. ´Normal` release rates were obtained if only 2.5%, 5.0% or 10% lysozyme but 
no lipase were used to prepare tsc-extrudates. The embedding of only 2.5% lysozyme 
resulted in a slow but measurable release and higher release rates were obtained for higher 
loadings (Figure 85). The application of only 0.5% lipase to the implant matrix completely 
changed the release rate and a non-release of lysozyme was observed even if at high 
lysozyme loadings (10%) (Figure 85). This was completely contrary to our expectations as 
we expected faster lysozyme release in the presence of lipases due to higher implant 
porosity and faster implant matrix breakdown. After a burst release of approximately 1% 
lysozyme no liberating of further lysozyme was detected although lipase had already been 
completely released after 24 h. Figure 87 shows lysozyme release from implants comprising 
2.5% lysozyme and increasing amounts of lipase. The application of only 0.1% lipase led to a 
decrease of lysozyme release and even the burst release was reduced from 14% to 3%. 
Application of higher lipase concentrations led to ´non-release` of lysozyme with only 1% 
burst release. 
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Figure 84: Release of lipase from tsc-extrudates comprising 0.5% lipase (m/m) and 2.5, 5.0 and 10.0% 
lysozyme respectively. 
 
 
Figure 85: Release of lysozyme from tsc-extrudates comprising no lipase (closed symbols) or 0.5% lipase 
(m/m) (open symbol) and 2.5, 5.0 and 10.0% lysozyme respectively. 
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Figure 86: Release of lipase from tsc-extrudates comprising 2.5% lysozyme and 0.1%, 0.3%, 0.5%, 0.7% or 
1.0% lipase (m/m).  
 
 
Figure 87: Release of lysozyme from tsc-extrudates comprising 2.5% lysozyme and 0%, 0.1%, 0.3%, 0.5%, 
0.7% or 1.0% lipase (m/m). 
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After incubation for 17, 24 and 38 days a gel-like substance was detected on top of the 
release medium. We concluded that this substance might be aggregated lysozyme. 
However, no direct proof was shown besides the fact, that a non-release of lysozyme was 
detected and the substance looked like acid denaturized lysozyme (100 mg/mL lysozyme + 
acetic acid). Preliminary experiments have already shown that lysozyme stability was not 
affected by the presence of lipase in PBS. However, lipases cleave triglycerides into free 
fatty acids and di-glycerides besides mono-glycerides and glycerol. Thus lipase within tsc-
extrudates creates free fatty acids and glycerides which can increase the osmotic pressure 
and can act as surface active substances within the implant matrix. 
Figure 83 shows the amount of degraded matrix material upon incubation of tsc-extrudates 
comprising 1.0% lipase. As free fatty acids were mainly lauric acid a rough calculation of the 
lauric acid concentration in the release medium can be made. Hereby a concentration of 
0.94 mg/mL lauric acid (0.0047 M) was calculated (Equation 4).  
 
Equation 4    )/(
deg
mLmg
V
fm
conc
buffer
radedimplant
lauric

  
conclauric = concentration of lauric acid in incubation buffer  
mimplant = mass of tsc-extrudate before incubation – 90 mg  
fdegraded = relative mass of free fatty acids calculated from total implant mass [%] – 2.0%   
Vbuffer = volume of incubation buffer PBS – 1.9 mL 
 
Within the implant matrix the concentration of this free fatty acid may be even much higher. 
Interestingly, the stability of IFNα and G-CSF has been shown to be dramatically negatively 
affected in matrices of stearic acid [223].  
In general, four main effects may result from triglyceride cleavage within lipid tsc-extrudates. 
First, free fatty acids can lead to an acidification within the implant matrix similarly to the 
effect which was observed during PLGA erosion. Although free fatty acids are less acidic 
(pKa ~ 5-6) than acetic acid (pKa ~ 4.8) and glycolic acid (pKa ~ 3.8) a high concentration of 
acidic substances is generated in a short period of time. [69, 78]. Second, the osmotic 
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pressure within the implant can increases and this can cause protein aggregation [69]. Third, 
triglyceride cleavage by lipase activity generates mono- and di-glycerides which can act as 
glue, leading to pore-closure within tsc-extrudates. Although SEM picture indicate that tsc-
extrudates became more porous upon lipase incubation, no investigations on the microscale 
were conducted so far to clarify this. Fourth, the generation of surface active substances like 
mono- and di-glycerides as well as free fatty acids and their deprotonated forms can result in 
decreased protein stability. The last factor seems to be the most critical one as high osmotic 
pressure can be assumed to be present in the implant core anyway and a pH drop from 7.4 
to 5 should not result in a massive loss of lysozyme which is very stable protein with respect 
to pH. Surface active substance on the contrary can ease protein unfolding and thereby 
destabilize the protein and promote aggregation. 
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4. Conclusion 
The embedding of lipase into tsc-extrudates led to accelerated matrix degradation and 
release of free fatty acids. Although lipase did not directly degrade the model protein 
lysozyme, co-embedding of lipase and lysozyme into tsc-extrudates led to a non-release of 
lysozyme. Various factors might account for this non-release, however, no final conclusion 
could be drawn from the data so far. Further investigations should focus on the effect of 
triglyceride cleavage on protein stability and the implant (micro-)structure. 
It is yet unclear to which extent the observe effect may influence the applicability of 
triglyceride based implant systems in-vivo. Tsc-extrudate erosion in-vivo has been proven 
(chapter 0) and it is highly likely that lipases (besides implant melting) have an influence on 
the degradation of the implants. However, low lipase concentrations in the human body, as 
well as a surface erosion of the implants in-vivo render it highly unlikely that matrix erosion 
might lead to protein degradation within the implant. However, concerns during long-term 
release might arise and thus further investigations about protein stability in triglyceride 
implants during in-vivo release need to be carried out.  
From our data, the embedding of lipases into triglyceride formulations to increase the 
degradation rate of implants should however be avoided as in-vitro experiment clearly 
showed the detrimental effect of this approach. However, if lipases get in contact with the 
implant from the outer medium (e.g. in-vivo), lipase activity even might positively affect the 
release kinetics by reduction of the burst effect due to pore-closure. 
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IX. Single molecule fluorescence microscopy studies and 
release pathways of protein drug molecules from triglyceride 
based implants 
1. Introduction 
The general mechanisms of sustained protein release from inert matrices were already 
extensively reviewed [17, 222, 249]. Various factors including drug/compound particle sizes, 
drug load, implant geometry and preparation technique have been identified to influence 
protein release kinetics [187]. Furthermore it was found that macromolecular drug release 
from such devices was much more sustained than mathematical models predicted even if 
varying porosity values of the devices and smaller diffusion coefficients of the incorporated 
drugs were taken into account [222]. Multiple factors were identified to account for the 
sustained release: concentration dependent diffusion, random pore topology, sealing effects 
and a constricted pore geometry [17, 249]. Based on the groundbreaking work of Langer et 
al. [16, 17, 222, 249] it is common sense that the ´constricted pore-geometry` leads to a so-
called ´random walk` of the protein within the inert implant matrix and is the major contributor 
to the sustained release behavior. Hereby, the protein diffuses upon hydration within water-
filled pores inside the implant and is trapped within each pore until it finds its way out through 
a narrow connecting channel [222]. Due to this retention within individual pores, the release 
becomes sustained and very slow release rates can be achieved. However, this ´random-
walk` could never be visualized or proven by any other technique than mathematical 
modeling [30].  
Today, new techniques are available which allow the tracking of single molecules, e.g. within 
mesoporous matrices by wide-field fluorescence microscopy [250]. This technique was 
successfully used to elucidate the three-dimensional structure of nano-channels in 
mesostructured silica by tracking of individual dye molecules [251]. We used this technique 
to track individual fluorescent labeled recombinant human IFNα protein molecules within lipid 
tsc-extrudates and determined the diffusion coefficients of these molecules. Hereby we were 
able to elucidate the major contributors to the sustained release mechanism from tsc-
IX. - SINGLE MOLECULE MICROSCOPY STUDIES AND RELEASE PATHWAYS OF PROTEIN DRUG MOLECULES 
178 
extrudates and to visualize the ´random walk` of single IFNα molecules in micro-pores of the 
triglyceride based device. 
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2. Materials and methods 
2.1. Materials 
Triglycerides (H12, Dynasan D118) were a gift from Sasol (Witten, Germany). PEG 6000 
was donated from Clariant (Wiesbaden, Germany). Hydroxypropyl-β-cyclodextrin (HP-β-CD) 
was provided from Wacker (Burghausen, Germany). For dye labeling ATTO647N NHS-ester 
was purchased from ATTO-TEC (Siegen, Germany). The µ-Stick 8-well microscopy slides 
and hydrophobic uncoated 0.2 mm µ-Slide Luer® ibiTreat microscopy slides were purchased 
from IBIDI (Martinsried, Germany). Buffer salts were of analytical grade and bought from 
Merck (Darmstadt, Germany).  
IFNα was a gift from Roche Diagnostics, Penzberg, Germany. It is formulated in 25 mM 
acetate buffer of pH 5.0 containing 120 mM sodium chloride. The protein concentration was 
1.53 mg/mL. IFNα contains 165 amino acids (AA) with 4 cysteines and 2 disulfide linkages 
(AA 1-AA 98 and AA 29-AA 138) and has a molecular weight of 19.225 kDa. In contrast to 
native IFNα2a it is not glycosylated and contains an extra N-terminal methionine. The 
secondary structure consists of a total of 6 α-helices (65% alpha helical) which arrange in the 
typical tertiary structure [252, 253]. The isoelectric point (IP) of the protein is between pH 6.0 
and pH 7.0 [254]. 
 
2.2. Fluorescence labeling of IFNα 
30 µl of an IFNα solution (1.56 mg/mL, MW = 19.2 kDa, n = 2.44∙10-9 mol) were mixed with 
70 µl of a PBS solution of pH 8.0. Then approximately 0.1 mg of ATTO647N NHS-ester (M = 
843 g/mol, n = 1.18∙10-7 mol) were added. The mixture was heated at 30 °C for 1.5 h and 
vortexed shortly every 10 minutes. Excess unlabeled dye was removed afterwards from the 
fluorescent labeled proteins (fluo-IFNα) by centrifugation at 2000 rcf for 1 min in a Micro Bio-
Spin 6 Chromatography Column (Bio-Rad Laboratories) where the free dye was bound to the 
column, but the labeled protein remained in solution. 
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2.3. Protein analysis 
IFNα was quantified by SE-HPLC in analogy to the method described by Mohl et al. (Dionex 
Ultimate 3000, flow rate: 0.5 mL/min, UV: 215 nm + 280 nm, Tosoh TSKgel 3000SWXL) [27]. 
Samples were additionally assessed by a fluorescence detector (excitation 644 nm; emission 
669 nm) after separation by SE-HPLC. 
 
2.4. Preparation of IFNα lyophilisates 
IFNα was lyophilized as described by Herrmann and Mohl [24, 223]. In brief IFNα stock 
solution was concentrated to 20 mg/mL with Vivaspin 20 tubes (MWCO 5,000 – VS 2011) 
and admixed with a solution containing 240 mg/mL HP-β-CD giving a final concentration of 
16 mg/mL IFNα and 48 mg/mL HP-β-CD (1:3 (m/m)). The solution was spiked with a dilution 
of freshly labeled fluo-IFNα and was adjusted to pH 4.2 (with acetic acid). After freeze-drying 
of 1 mL aliquots in 2R glass vials with an ε12G apparatus (Christ, Osterode, Germany) 
samples containing 64 mg of lyophilized cake were obtained. Freeze drying was performed 
using the following program (Table 20). The resulting cake comprised 10-9 (m/m) fluo-IFN 
calculated from total solid mass. 
 
2.1. Preparation of lipid twin-screw extrudates and protein-lipid 
dispersions for wide-field fluorescence spectroscopy 
Lipid tsc-extrudates were prepared as described by Schulze et al. [32] with a Haake MiniLab® 
Micro Rheology Compounder (Thermo Haake GmbH, Karlsruhe, Germany). In brief, a lipid 
powder blend comprising D118 as high melting lipid and H12 as low melting lipid was mixed 
with 10% of lyophilized PEG 6000 and 10% of lyophilized IFNα (1:3 with HP-β-CD [32]). 
Extrusion of rod-shaped implants was performed through a 1.9 mm outlet die in steady-state 
mode with closed bypass. Rod shaped implants were forged into a flatter cylinder by the 
application of pressure on the warm and formable implant after tsc-extrusion. The flat 
cylinder was placed into a µ-Stick 8-well microscopy slide (ibidi GmbH, Martinsried, 
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Germany) and incubated in PBS pH 4.0 for wide-field fluorescence microscopy (Figure 88, 
left). Additionally lyophilized IFNα was mixed with pure H12 in a ratio of 1:10 (m/m) and 
heated in a beaker until the lipid became creamy. The melt was casted into µ-Stick 8-well 
microscopy slides (Figure 88, right). The protein-lipid dispersion was also analyzed by wide-
field fluorescence microscopy. 
Table 20: Lyophilization program for IFNα 
 temp. [°C] time or temperature rise pressure [mbar] 
cooling step 
to - 45 °C 1.6 °C/min atmospheric pressure 
- 45 °C 90 min atmospheric pressure 
primary drying 
to -20 °C 0.1 °C/min to 10
-2
 [mbar] 
- 20 °C 30 hours 10
-2
 [mbar] 
secondary drying 
to + 20 °C 0.1 °C/min to 10
-3
 [mbar]
 
+ 20 °C 15 hours 10
-3
 [mbar] 
sealing of vials 
The pressure chamber was filled with nitrogen to a pressure of 800mbar and 
the vials were sealed with rubber stoppers. 
 
 
 
Figure 88: Experimental setup for wide-field fluorescence spectroscopy studies of tsc-extrudates (left) 
and protein-lipid dispersions (right). 
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2.2. Preparation of PEG samples for fluorescence microscopy 
PEG 6000 was dissolved in PBS pH 4.0 to give final concentrations of 30%, 40% and 53% 
(w/w). 15 mL of these solutions were spiked with 15 µL of a solution of IFNα (conc. 
1.56 mg/mL) which comprised 1.0 x 10-9 mg/mL of fluo-IFNα. Thus the theoretical 
concentration of fluo-IFNα was 1.0 x 10-12 mg/mL in the PEG solutions. The solution was 
injected into a 0.2 mm µ-Slide Luer® ibiTreat (ibidi GmbH, Martinsried, Germany) and single 
fluorescence wide-field fluorescence microscopy was performed. 
 
2.3. Scanning electron microscopy (SEM) 
SEM was performed with a 6500F (Jeol GmbH, Eching, Germany). Samples were dried in a 
vacuum chamber (VO 200, Mammert, Schwabach, Germany) at 25 °C and 20 mbar for 6 
days and analyzed without coating. 
 
2.4. Wide-field fluorescence microscopy 
Fluorescence images were acquired with a wide-field setup, using a Nikon Eclipse TE200 
epifluorescence microscope and an oil-immersion objective with high numerical aperture 
(Nikon Plan Apo 100x/1.40 N.A. Oil). The Atto647N dye molecules were excited at 633 nm 
with a Coherent He-Ne gas laser (75 mW max. at 632.8 nm) with an intensity of 0.1-
0.7 kW cm-2. The fluorescence was detected with an Andor iXion DV897 back-illuminated 
EM-CCD camera in frame transfer mode (512 px x 512 px). Incident laser light was blocked 
by a dichroic mirror (640 nm cutoff, AHF) and a band-pass filter (730/140, AHF) [251]. 
 
2.5. Tracking of the proteins, visualization of the random walk and 
calculation of diffusion coefficients 
Single particle tracking (SPT) was employed to obtain the trajectories of individual protein 
molecules by fitting frame by frame theoretical diffraction patterns to the spots (described in 
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detail by Kirschstein et al. [251]). With this method the positions of the fluorophores can be 
obtained with an accuracy of down to 10 nm. 
The diffusion coefficients for each individual trajectory can be extracted from the linear part of 
the mean square displacement (MSD) plots according to the Einstein-Smoluchowski relation 
(Equation 5), assuming an isotropic Brownian diffusion in all three dimensions while only 
using the two-dimensional projection of the recorded images. 
 
Equation 5   DtMSD  4  
MDS = mean square displacement [nm
2
]  
D = diffusion coefficient [nm/s]  
t = time [s] 
 
2.6. Protein release studies 
Tsc-extrudates were cut into rod-shaped implants with 2.5 cm length and incubated in protein 
low-bind tubes (Eppendorf AG, Hamburg, Germany). For release studies from protein-lipid 
dispersions, the triglyceride H12 was molten at 40 °C and admixed with 10% of IFNα 
lyophilisate. Afterwards the dispersion was cast into protein low-bind Eppendorf tubes.  
Protein release studies were performed in 1.9 mL isotonic PBS buffer pH 4.0 (+ 0.05% 
sodium acid) to avoid protein precipitation in the presence of PEG 6000 [29]. At 
predetermined time points the incubation buffer was completely exchanged and the samples 
were assessed for protein content by SE-HPLC as described above. Tsc-extrudates were 
incubated at 37 °C in a water bath without agitation. Protein release from lipid-protein 
dispersions was assessed at 20 °C, 29 °C, 33 °C and 37 °C. 
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3. Results and discussion 
3.1. Scanning electron microscopy  
Scanning electron microscopy of tsc-extrudates before release tests showed a smooth and 
compact surface and a compact matrix with no porous structure in the core (Figure 89 A). 
After the release test (27 days) the matrix of the implant changed and pores and channels 
became visible which ranged between 1-100 µm (Figure 89 B). The creation of large pores 
and an interconnected pore network was explained by dissolution and release of lyophilized 
PEG and protein powder from the matrix. Various authors described the formation of such a 
pore network to be the major driving force for total drug release from inert matrices [17, 27, 
222] and the formation of pores and channels within tsc-extrudates was already described in 
previous chapters (IV.3.2, VI.3.5, 3.1). 
 
3.2. Quantification of fluo-IFNα 
Determination of total protein concentration after fluorescence labeling by SE-HPLC (UV 
detection 215 nm + 280 nm) showed a decrease of the protein concentration from 1.6 mg/mL 
to 1.0 mg/mL which can be attributed to the labeling process and the subsequent protein 
purification step. Calculation was based on total peak area of fluorescently labeled IFNα 
monomer compared to non-labeled protein of known concentration. The UV chromatograms 
and the fluorescence chromatogram did not show the presence of dimers or soluble 
oligomers after the labeling process and thus all labeled protein was ascertained to be 
monomeric. The slight shift between the retention times of the UV and the fluorescence 
signal results from the in-line connection of the fluorescence detector after the UV detector 
(Figure 90).  
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Figure 89: Scanning electron microscopy images of tsc-extrudates before (A) and after (B) in-vitro release 
tests. A 1 + B 1: Implant surface; A 2 + B 2: longitudinal cross-section; A 3: close-up of implant surface; 
A 4 + B 3: upright cross section; B 4: close-up of upright cross section 
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Figure 90: (A)SEC chromatograms with UV (215 nm + 280 nm) and fluorescence (excitation 644 nm, 
emission 669 nm) detection of Atto647N dye labeled IFNα (fluo-IFNα). (B) zoom-in of chromatogram (A) 
 
3.3. IFNα release studies from tsc-extrudates 
The protein was released from tsc-extrudates at pH 4.0 and 37 °C in a diffusion controlled 
way over a period of 27 days liberating up to 96% of the incorporated protein mass. 
Incubation pH was set to 4.0 to prevent IFNα precipitation in the presence of PEG 6000 as 
reported by Schulze et al. [24, 29]. They studied IFNα release in the presence of PEG at two 
pHs (4.0 + 7.4) and showed, that PEG can be used to achieve a triphasic IFNα release 
profile from tsc-extrudates at pH 7.4 which was induced by a protein precipitation step. 
However, a change to pH 4.0 revealed ‘normal’ diffusion controlled IFNα release, which was 
also observed in our study. A linear relation between the square-root of time (t1/2) and the 
released amount of IFNα could be established (Figure 91) which is typical for a diffusion 
controlled release from inert matrixes according to Higuchi´s square root of time kinetics [40]. 
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Figure 91: IFNα release from tsc-extrudates (n = 6) at 37 °C in PBS buffer pH 4.0. A linear correlation 
between the square root of time and the released amount of protein is shown in the insert. 
 
3.4. IFNα release from protein-lipid dispersions 
In order to mimic the behavior of IFNα within the H12 phase of tsc-extrudates, release 
experiments from H12-protein dispersion were performed. Release kinetics of IFNα from 
such dispersions were strongly dependent on incubation temperature. At 20 °C and 29 °C an 
initial burst release of about 4% was detected and afterwards a linear release phase started 
which lasted to day 14 and leveled into a plateau phase liberating a maximum of only 25% 
IFNα. DSC thermograms showed that the triglyceride was solid at these temperatures and 
thus only a small fraction of the protein was released whereas the main fraction remained 
trapped in the triglyceride matrix. At 33 °C, the release kinetics accelerated and 91% of the 
protein were released within 14 days. Only a part of the lipid was molten at 33 °C and the 
lipid-protein dispersion became ´waxy` but stayed at the bottom of the Eppendorf tube during 
the release test. Immediate and complete release of IFNα (99% within 1 day) was achieved if 
the incubation temperature was increased to 37 °C (Figure 92). Hereby the lipid was 
completely molten separated on top of the aqueous phase. Thus a strong influence of the 
physical properties of the lipid on the release behavior of IFNα was found which was identical 
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to our observations regarding long-term lysozyme release from tsc-extrudates without pore-
forming agent (chapter VI.4.3). 
 
Figure 92: IFNα release from lipid-protein dispersions at different temperatures (19 °C, 29 °C, 33 °C, 
37 °C). 
 
3.5. Wide-field fluorescence microscopy of tsc-extrudates 
Fluorescence microscopy of lipid tsc-extrudates at room temperature and before incubation 
in PBS buffer revealed a heterogeneous structure of the implant matrix. Large areas with 
strong fluorescence signals were detected, which had dimensions of about 1-100 µm in 
diameter and were attributed to fluorescently marked protein particles (Figure 93a), as they 
correlated well in size and shape with the previously shown SEM images (Figure 89). 
Surprisingly, all other areas were not completely dark as it was expected for an inert matrix 
system. Instead, fluorescence signals of immobile single protein molecules were detected 
indicating finely distributed protein all over the implant (Figure 93b).  
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Figure 93: Fluorescence microscopy images of tsc-extrudates. a) Dye-labeled protein particle reservoirs. 
b) Finely distributed single protein molecules. c) ´Empty pore` = area without fluorescent molecules 
which is created upon incubation in release medium. 
 
Upon incubation in PBS buffer (37 °C, pH 4.0) the situation within the implant changed and 
areas with strong fluorescence vanished over time (within days). In return, ´black areas` (10-
100 µm) were detected with the microscope, which had the same size as the former protein 
particles and were identified as void spaces or ´pores` (Fig. 6c). Within these ´pores` in most 
cases more no fluorescent molecules could be detected which was surprising as not all of 
the protein was yet released from the implant (Figure 91). This finding was explained by the 
high velocity of the diffusing fluo-IFNα molecules above the resolution of the microscope and 
the low penetration depth of the microscope (100 µm). Thus it is possible that larger protein 
reservoirs were still present within the core of the implant without being visualized but still 
enabling IFNα release. Despite these limitations, we were able to track some fluo-IFNα 
molecules inside the cavities in the outer section of the implant. The mean square 
displacement (MSD) of the molecular movement was linear (Figure 94) and thus the 
movement of the proteins inside these pores was clearly diffusion controlled with an apparent 
mean diffusion coefficient of <D> = 8.5±2.5x106 [nm/s].  
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Figure 94: Mean square displacements (MSDs) of single IFNα molecules (green) diffusing in a pore of a 
tsc-extrudate. The black line shows the mean value all single tracking experiments.  
Fluo-IFNα molecules which were finely dispersed in the matrix also started to move upon 
incubation. These molecules wandered more slowly than the ones found in the ´pores` and 
the mean diffusion coefficient was determined to be <D> = 1.6±0.9x106 [nm2/s], which was 
about 10-fold lower than for proteins in the ´pores`. The motion of this second species of fluo-
IFNα was also only controlled by diffusion and no directed flow was found as the MSD was 
linearly correlated to time (Figure 95). Thus diffusion was found to be the main driving force 
for protein release from tsc-extrudates. However, we could clearly distinguish between two 
populations of diffusing proteins. 
 
Figure 95: MSDs of ´fast` (red) and ´slow` (blue) IFNα molecules diffusing in tsc-extrudates and respective 
molecules in PEG solution (black) or dispersions with H12 (green). The linear correlation indicates normal 
diffusion of the molecules. All MSDs are displayed as mean values from individual tracking experiments. 
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3.6. Diffusion pathways of fluo-IFNα molecules in tsc-extrudates 
So far we were able to distinguish between two different populations of fluo-IFNα molecules 
inside the implant regarding to their diffusion coefficients. We assumed that the two 
populations might reside in different phases of the host matrix. Theoretically, one would 
expect all protein to be present in the water-soluble parts of the implant, the ´pores`, which 
are filled with solid PEG 6000 and lyophilized protein powder after preparation and later 
contain an aqueous solution/suspension of these compounds upon incubation in buffer. The 
second population of fluo-IFNα molecules however was thought to diffuse within the matrix of 
the implant in phases of molten H12. In order to proof our theory, we investigated the 
diffusion of IFNα molecules in solutions of PEG 6000 in isotonic PBS (pH 4.0, 37 °C), and 
also the diffusion of IFNα in molten H12 for comparison with the two populations found in the 
implant after incubation. 
As already described before, highly fluorescent areas were identified in the implants before 
incubation in buffer and were ascribed to lyophilized protein particles. Upon incubation in 
buffer, protein and PEG particles dissolved and these highly fluorescent areas vanished. 
Only a few molecules were detected within the newly formed ´void` pores. The fact that so 
few molecules were found was explained by the fast diffusion of the molecules in diluted 
solutions of PEG. In our control experiments, a minimum concentration of 53% (w/v) PEG 
was necessary to allow the visualization of diffusing fluo-IFNα molecules. If the concentration 
of PEG was lower, the diffusion coefficient of the protein was too high to allow the detection 
and tracking of fluo-IFNα. Within a 53% PEG solution we tracked individual fluo-IFNα 
molecules and calculated the mean diffusion coefficient to be <D>= 14.1 ± 6.5 x 106 [nm2/s] 
which was in good correlation to the ´fast` fluo-IFNα population in the implant pores (<D> = 
8.5±2.5x106 [nm/s]). For comparison, Herrmann et al. measured the diffusion coefficient of 
IFNα molecules in solutions of PBS by a modified open-end capillary technique proposed by 
Anderson and Saddington [29, 255]. They calculated a diffusion coefficient of IFNα in PBS of 
1.8 x 108 [nm2/s] which is about 17-times faster than the molecules which were detected by 
wide-field fluorescence spectroscopy. According to the data from Schulze et al. and our 
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control measurement with 30% and 40% PEG 6000 (in which we were not able to detect 
diffusing fluo-IFNα molecules) we concluded that IFNα might have been still present in the 
´black areas` of our tsc-extrudate, however we were not able to detect it as the velocity of the 
IFNα molecules was too high upon rapid dissolution of PEG within the release buffer. 
Release data from tsc-extrudates strengthened this conclusion as release was going on for 
27 days and protein must still have been present in the pores of the implants while the 
measurement were performed. 
The second population of molecules was attributed to diffusion of IFNα in the molten 
triglyceride phase (H12) of the implant. DSC thermograms of tsc-extruded implants indicated 
that the low-melting lipid H12 was mostly molten at the incubation temperature of 37 °C 
within the implant while the other compounds (PEG 6000 and D118) were still solid or 
dissolved in PBS buffer (Figure 96). As already shown in release experiments, IFNα was 
rapidly released from molten protein-lipid dispersions (37 °C) and from softened lipid at 
33 °C. Single-molecule tracking experiments with the lipid-protein dispersion showed that the 
dispersions were very heterogeneous at room temperature and large areas with strong 
fluorescence could be detected besides finely dispersed single protein molecules. Thus the 
system resembled well the situation in a tsc-extrudate before incubation. Diffusion of the 
finely dispersed protein molecules was observable in the lipid dispersion at 37 °C and 
tracking of the single molecules allowed to calculate a mean diffusion coefficient of <D> = 0.9 
± 0.4 x 106 [nm2/s] (<D> (implant) = 1.6 ± 0.9 x 10
6 [nm2/s]).  
A comparison of the mean diffusion coefficients of fluoIFNα in either the 53% PEG solution or 
the lipid-protein dispersion with the diffusion coefficients of the two populations of proteins in 
the implant showed a striking match (Figure 97, Figure 95, Table 21). A plot of the 
cumulative probability (P (D ≤D0) against the diffusion coefficient (D) – which depicts the 
probability of D to be smaller than D0 within the chosen setup – showed a very good 
correlation between the ´fast` population and fluoIFNα in 53% PEG solution and between 
´slow` population and fluoIFNα molecules diffusing in molten H12. 60% of proteins diffusing 
in 53% PEG solution had the same diffusion velocity as ´fast` molecules which were detected 
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within the implant and 90% of IFNα molecules in molten H12 diffused with the same velocity 
as the ´slow` population. Additionally, no overlap between the two populations was detected 
(Figure 97) strengthening the assumption that the populations were indeed independent from 
each other. We suppose, that the higher diffusion coefficient of IFNα in 53% PEG resulted 
higher concentrated PEG solution in the implant pores at a moment when the water front just 
reached this area. When dilution in the pores by more water took place, single molecules 
diffused too fast, and we could not detect them anymore. This also explains why only so few 
of the fast diffusing molecules could be tracked within the system. 
 
Figure 96: DSC thermogram of a tsc-extrudate comprising the triglycerides H12, D118 and the water-
soluble excipient PEG 6000. 
The diffusion of the 10-fold ´slower` protein population in the host matrix closely resembles 
the diffusion of IFNα in the protein-lipid dispersion (Figure 97, Figure 95, Table 21). This 
proved that IFNα proteins can indeed diffuse within H12 melts and explains the existence of 
the slow diffusing protein population in the tsc-extrudate. Diffusion of IFNα molecules in 
partially molten triglycerides also explains the IFNα release profiles from protein lipid 
dispersions. It also explains lysozyme release profiles from tsc-extrudates where total protein 
release was only achieved if parts of the implants were incubated above the onset of melting 
of the low-melting lipid (chapter 0). Thus a novel release mechanism is described here via a 
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non-aqueous diffusion pathway. Sustained protein release from a tsc-extruded implant 
system is possible by partial implant melting from a phase of molten triglycerides. 
Table 21: Diffusion coefficients of fluoIFNα molecules as calculated from wide-field microscopy 
measurements in different environments: tsc-extrudates (fast and slow species), 53% PEG solution and 
molten H12. 
 <D> [nm
2
/s] 
tsc-extrudate – fast species 8.5 ± 2.5 x 10
6
 
53% PEG solution 14.1 ± 6.5 x 10
6 
tsc-extrudate – slow species 1.6 ± 0.9 x 10
6
 
H12 melt at 37 °C 0.9 ± 0.4 x 10
6
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Figure 97: Cumulative probability P (D≤D0) of the diffusion coefficient of fluoIFNα measured in control 
experiments to be smaller than the highest measured value found in tsc-extrudates. Blue dots: Slow 
diffusing protein species in tsc-extrudates. Green dots: IFNα molecules in molten H12. Red triangles: Fast 
diffusion IFNα proteins in pores of tsc-extrudates. Black triangles: Protein molecules diffusing in 53% 
PEG solution in PBS. 
 
3.7. Random walk of IFNα molecules 
At 37 °C two different populations of diffusing proteins were detected within tsc-extrudates 
and were attributed to diffusion in PEG-buffer solutions and molten H12. Assessment of 
MSDs clearly showed a linear correlation to ∆t which indicates free diffusion of the molecules 
(Figure 95) and no directed flow or ´random walk between neighboring pores could be 
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visualized. This was explained by the large 3-dimensional pore-cavities ranging up to 100 µm 
and the high diffusion velocities of the protein molecules. Thus the boundaries of the cavities 
were too far stretched to visualize a ´random walk` and only free diffusion within these pores 
was detected. Additionally, only a few molecules could be visualized within the implant pores, 
and this made it impossible to follow a molecule long enough to visualize it while it 
´randomly` diffused through a connecting channel between two neighboring pores. 
However, during incubation at 23 °C (below the melting temperature of H12) fast diffusing 
molecules were detected which wandered within micropores (0.5 x 0.5 µm) of the implants. 
As the diffusion coefficients were faster than those in H12 melts and no molten H12 was 
present at 23 °C the signals were attributed to protein diffusion in highly concentrated PEG-
buffer-solutions. The micropores were probably created upon cooling of the lipid matrix after 
the manufacturing process and ranged in the nanometer and low micrometer size. Upon 
incubation at 37 °C no such structures were detectable anymore which was explained by a 
sealing of these microcavities by partial implant melting. Molecules which were detected 
within these microstructures showed a defined movement and free diffusion was limited by 
the boundaries of the micropores (Figure 98). In agreement with the random walk theory, the 
protein molecules were trapped within microcavities until they randomly found their way out 
and diffused into the next cavity. Thus the observation of the random walk on a micro-scale 
was feasible with the chosen setup; however not within large implant pores in the range of 
100 µm. 
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Figure 98: Trajectories of single IFNα molecules diffusing in micropores within lipid tsc-extrudates with 
boxerrorbars. 
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4. Conclusion 
Various authors investigated protein release rates from inert matrices and found it being 
controlled by a plethora of factors including wettability of the implant [170], water entry 
velocity [26], particle sizes of the compounds [17, 177, 187], drug solubility [24, 29], and drug 
loading [17, 27, 249]. In order to achieve more sustained release profiles the use of smaller 
protein drug particles and a more homogeneous drug distribution within the implant matrix 
has been successfully used by various authors [17, 26, 177, 188, 249]. Our lipid tsc-
extrudates show a sustained protein release profile which can be explained by the dense 
implant matrix which prevents rapid water access to the implant core (chapter 0) and a very 
fine and homogeneous distribution of the protein particles [179]. Additionally, partial implant 
melting during production (chapter 0) and release (chapter 0) have been identified to strongly 
influence release kinetics. Besides all mentioned factors, protein diffusion velocity within the 
implant system is the most important factor controlling the rate of release [26] and therefore it 
is reasonable to calculate an apparent drug diffusion coefficient [24, 30] to allow 
mathematical modeling of drug release kinetics. This apparent diffusion coefficient takes into 
account drug solubility, the tortuosity of implant matrix, the constricted pore-geometry 
between neighboring pores and of course the absolute diffusion coefficient which can be 
influenced by temperature and viscosity [249].  
We prepared slowly releasing triglyceride based implants by tsc-extrusion and embedded 
fluorescent labeled IFNα into the matrix. Tracking of individual IFNα molecules within tsc-
extrudates by single-molecule wide-field fluorescence microscopy allowed for the first time to 
measure the absolute diffusion coefficient of IFNα in different phases of the implants and 
allowed a more accurate description of the processes involved in protein release from 
triglyceride based matrices. 
Two populations of diffusing protein molecules were detected within the implants. The first 
population was found to diffuse within PEG and buffer filled pores which were created upon 
incubation. This finding was in good agreement with theoretical considerations which explain 
protein release from lipid implants through an interconnected pore-network which was 
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created upon dissolution of hydrophilic excipients and the drug itself. Surprisingly, a second 
population was found to diffuse in a phase of molten lipid. We explained this by the partial 
melting of the implant matrix during release and concluded that implant melting during 
preparation led to a molecular distribution of IFNα in the implant matrix. Upon incubation at 
37 °C the implant matrix was not completely ‘inert’ but acted as protein reservoir. This finding 
was also in good agreement to previously reported results of incomplete protein release from 
tsc-extrudates at incubation temperatures below the melting range of the low melting 
component (chapter 0). Thus, tsc-extrusion created a ‘protein reservoir’ in the lipid matrix 
which was slowly depleted by protein diffusion in the triglyceride phase and this non-aqueous 
diffusion explained the very slow release kinetics from tsc-extrudates at incubation 
temperature above the melting point of the low-melting lipid.  
According to our results in chapter VI the portion of the protein which was embedded in the 
low melting part of the matrix accounted for approximately 20% of the total protein load. This 
value derived from the observation that after in-vitro release studies of lysozyme at 20/25 °C 
from highly porous implant (20% porogen) about 20% of the total protein loading had 
remained trapped in the matrix and had not been released. 
No ‘random-walk’ of fluo-IFNα between neighboring pores was observed which was 
explained by the rather large three-dimensional pore-cavities and the high diffusion 
coefficients of the proteins. Responsible for the large pores was the particle size distribution 
of PEG and protein lyophilisate mechanically mixed into the lipid during extrusion. The 
‘random walk’ between neighboring pores could only be shown in very small cavities of the 
implants at 20 °C which are sealed upon incubation at elevated temperatures. Although the 
random-walk was not directly visualized, the measurement of the real diffusion coefficient 
within pores of lipid tsc-extrudates strengthened the random-walk theory as the measured 
values were identical with theoretical assumptions used for modeling approaches. A 
mathematical modeling of the release conditions in tsc-extrudates might help to calculate the 
apparent diffusion coefficient from tsc-extrudates and clarify the contributions of diffusions in 
PEG/buffer and lipid to the sustained protein release. 
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X. Final Summary 
Triglyceride based lipid implants which were prepared by tsc-extrusion (tsc-extrudates) were 
investigated for their characteristics regarding protein release and biodegradation. Tsc-
extrudates consist of a low melting and a high melting lipid, a dry protein powder formulation 
(drug) and a pore-forming/precipitating agent. The mixture of low melting and high melting 
lipids facilitates extrusion at moderate temperature without affecting protein integrity and the 
porogen/precipitant is used to control the rate of protein release. 
We were able to establish a linear and sustained release of a monoclonal IgG1 antibody 
(mabB) from tsc-extrudates by utilizing a precipitation and re-dissolution mechanism (chapter 
III). PEG was used as porogen/precipitating agent and allowed complete release of mabB 
from tsc-extrudates. We were able to achieve a sustained release of the antibody over a 
period of 150 days with very little burst. Furthermore we could proof the influence of the 
protein precipitation step on the antibody release rate by changing the pH of the incubation 
medium from 7.4 to 4.0 and thereby preventing in-situ precipitation of mabB. Indeed, release 
rates at pH 4.0 were much faster than at 7.4. Interestingly, mabB was released from tsc-
extrudates mainly in its monomeric form, which was ascribed to the application of HP-β-CD 
which was used as cryo-/lyo-protectant and stabilizes the protein within the triglyceride 
material like it was already shown for IFNα [28]. 
In chapter IV we compared 4 different methods for the preparation of triglyceride based 
implants (RAM extrusion, tsc-extrusion, compression and compression of tsc-extruded 
material) and showed that tsc-extrusion led to a more sustained lysozyme release than 
compression or RAM extrusion. The production of ´compressed tsc-extrudates` by grinding 
and subsequent compression of tsc-extrudates resulted in a more sustained protein release 
profile than simple compression but exhibited a similar release rate than tsc-extrusion. We 
got a dear indication that partial melting of the triglyceride matrix materials during the 
manufacturing process plays a major role in controlling release kinetics from tsc-extrudates. 
Minor changes in triglyceride crystallinity and melting behavior were detected in tsc-
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extrudates by X-ray and DSC measurements. These changes derived from the melting 
process but were not negatively impacting implant stability. 
Further investigations to control the rate of protein release from tsc-extrudates were carried 
out with lysozyme as model protein (chapter V). Various types of PEG were used to study 
the influence of viscosity (within implant pores) on protein release kinetics. Additionally, 
lyophilized PEG was compared with crystalline PEG and three different PEG particle sizes 
were used to prepare tsc-extrudates. It turned out, that the system was quite robust towards 
these factors and no major influence was detected. A change of the low-melting or high-
melting lipid also had no effect on the release kinetics of lysozyme at 37 °C as long as the 
melting onset of the low-melting lipid was below the incubation temperature. 
In chapter VI the influence of partial implant melting at 37 °C on the release kinetics was 
studied. Lysozyme was released from tsc-extrudates (comprising 20% porogen) at various 
temperatures ranging from 20 °C to 40 °C. Increasing incubation temperature resulted in 
accelerated protein release and a borderline between fast + complete release and slow + 
incomplete release was detected at an incubation temperature of 29 °C. This temperature 
was also identified to be the onset of melting of the low-melting lipid which led to the 
conclusion that lipid melting accelerated protein release. A reduction of the amount of pore 
forming agent PEG from 20% to 0% resulted in slower release rate and altered release 
profiles. Even without pore-forming agent (and only 2.5% of lysozyme), the protein was 
almost completely released at 37 °C over a period of 200 days. Implant rods did not change 
their macroscopic shape or disintegrated but remained ´intact` throughout the experiment. 
DSC and SEM studies as well as assessment of implant weight after long-term incubation 
revealed that the low-melting lipid (H12) was depleted from the implant and the implant rods 
became more porous and fragile. Additionally, minor changes in triglyceride crystallinity were 
detected (increase of β-modification) which might also derive from a depletion of H12 which 
exhibited β´-modification. A control experiment at 20 °C showed that only 10% of lysozyme 
was released under this conditions but the rest remained trapped in the solid implant matrix. 
In summary, it turned out that tsc-extrudates do not consist of an impermeable matrix but a 
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triglyceride composition which softened and partially melted during in-vitro release studies. 
Thus we detected a novel, melting associated release mechanism from ´solid` triglyceride 
based implants which explains complete and sustained protein release at incubation 
temperature above the melting point of the low-melting lipid from porogen free matrices. 
Melting was identified to be a major driving force governing protein release and we found a 
depletion of the low-melting lipid (H12) from the implant matrix. In addition, an in-vitro lipase 
assay had already shown previously, that tsc-extrudates were more prone to lipase-induced 
degradation than e.g. compressed implants [33]. We assumed therefore that partial implant 
melting might also render tsc-extrudates more biodegradable. 
In chapter 0 an in-vivo biodegradation study with rabbits (n = 9) was performed over a period 
of 6 months by subcutaneous application of tsc-extrudates. Tsc-extrudates consisted of three 
ratios of PEG (0%, 20%, 40%), two different low-melting lipids (H12 or E85) and D118 as 
high melting lipid, and identical compositions were used in an in-vitro lipase-induced 
degradation study [33]. During in-vivo application, a time dependent erosion of tsc-extrudates 
(three timepoints: 1, 3 and 6 months) was observed and tsc-extrudates nearly completely 
eroded over the 6 months period (20% recovery of the triglyceride material from implants 
consisting of H12 + 20% PEG). Higher loadings of pore forming agent (PEG) resulted in a 
slightly increased mass loss and a change between low-melting lipids (E85 instead of H12) 
was found to slightly slow down the degradation rate. This was explained by a higher melting 
maximum of E85 (41 °C) than of H12 (37 °C) and thus E85-implant did not melt (and erode) 
to the same extent as H12-implants. Additionally, studies with lipase showed, that the 
enzyme preferentially cleaved lauric acid from triglycerides and this fatty acid is dominant in 
H12 (71%) but not in E85 (27%). Partial implant melting and triglyceride cleavage by lipases 
led to in-vivo implant erosion. 
In chapter 0 the application of lipases as degradation enhancer for lipid tsc-extrudates was 
investigated. It turned out that the embedding of only 1% lipase (m/m) into tsc-extrudates led 
to a rapid breakdown of the implant matrix. Lipase was rapidly released from tsc-extrudates 
within 24 h even if low concentrations of only 0.1% (m/m) were embedded into the tsc-
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extrudate matrix. The co-extrusion of lipase and lysozyme led to a non-release of lysozyme 
(model protein) from tsc-extrudates. As incubation of lipase together with lysozyme did not 
harm the protein, we concluded that the creation of free fatty acids, mono- and di-glycerides 
affected the release kinetics. Further work should focus on the influence of (bio-)degradation 
products on release kinetics and investigate the influence of drug diffusion and implant 
erosion on the overall release kinetics.  
In chapter 0 single molecule tracking experiments were conducted to elucidate the sustained 
release of proteins from tsc-extrudates and to visualize the ´random-walk` of proteins 
between neighboring pores. It turned out that a visualization of the random-walk between 
neighboring pores was only possible at 20 °C and in the low µm range (0.5 – 2 µm). Due to 
the high diffusion coefficient of the fluorescently labeled proteins and the large three-
dimensional structure of the implant pores (up to 100 µm), no long-term tracking of protein 
molecules was possible. Determination of the real diffusion coefficients of proteins in different 
phases of the implant was possible and two populations of proteins were detected. The first 
population diffused in PEG/water filled pores of the implant which was in accordance to 
theoretical expectations. The second population was much slower and diffused in a phase of 
molten lipid. Thus partial implant melting was confirmed to facilitate protein release and 
strongly contribute to the sustained release kinetics of tsc-extrudates. 
 
In conclusion, melting processes are the key to understand the properties of twin-screw 
extrudates. Melting processes during extrusion allows the preparation of rod-shaped and 
easily applicable implants at gentle temperatures without major changes in lipid modification 
or deterioration of dry protein powders. The extrusion process leads to a very homogeneous 
distribution of drug particles within the implants and generates a triglyceride matrix which 
acts as a ‘reservoir’ by incorporation of single protein molecules. Upon incubation, partial 
implant melting allows long-term release of proteins from this ´reservoir` without affecting 
protein integrity and without the use of an additional pore-forming agent. This novel release 
mechanism is driven by non-aqueous diffusion of protein molecules in phases of molten 
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triglyceride within solid implants. Melting also facilitates biodegradation of tsc-extrudates in-
vivo because it led to a depletion of the low-melting lipid from the implant matrix and 
increased the accessibility of tsc-extrudates for lipase induced degradation processes. 
Future work will therefore need to focus on the influence of melting-associated implant 
degradation (in-vitro and in-vivo) on protein release. The impact of diffusion and erosion 
processes on protein release from tsc-extrudates needs to be clarified in future work to allow 
tailoring of the release kinetics. 
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